**Studien zu Corona-Impfschäden**

**Corona vaccine injury studies**

1. Cerebral venous thrombosis after COVID-19 vaccination in the UK: a multicentre cohort study: <https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)01608-1/>
2. Vaccine-induced immune thrombotic thrombocytopenia with disseminated intravascular coagulation and death after ChAdOx1 nCoV-19 vaccination: https://www.sciencedirect.com/science/article/pii/S1052305721003414
3. Fatal cerebral hemorrhage after COVID-19 vaccine: <https://pubmed.ncbi.nlm.nih.gov/33928772/>
4. Myocarditis after mRNA vaccination against SARS-CoV-2, a case series: <https://www.sciencedirect.com/science/article/pii/S2666602221000409>
5. Three cases of acute venous thromboembolism in women after vaccination against COVID-19: <https://www.sciencedirect.com/science/article/pii/S2213333X21003929>
6. Acute thrombosis of the coronary tree after vaccination against COVID-19: <https://www.sciencedirect.com/science/article/abs/pii/S1936879821003988>
7. US case reports of cerebral venous sinus thrombosis with thrombocytopenia after vaccination with Ad26.COV2.S (against covid-19), March 2 to April 21, 2020: <https://pubmed.ncbi.nlm.nih.gov/33929487/>
8. Portal vein thrombosis associated with ChAdOx1 nCov-19 vaccine: <https://www.thelancet.com/journals/langas/article/PIIS2468-1253(21)00197-7/>
9. Management of cerebral and splanchnic vein thrombosis associated with thrombocytopenia in subjects previously vaccinated with Vaxzevria (AstraZeneca): position statement of the Italian Society for the Study of Hemostasis and Thrombosis (SISET): <https://pubmed.ncbi.nlm.nih.gov/33871350/>
10. Vaccine-induced immune immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis after vaccination with COVID-19; a systematic review: <https://www.sciencedirect.com/science/article/pii/S0022510X21003014>
11. Thrombosis with thrombocytopenia syndrome associated with COVID-19 vaccines: <https://www.sciencedirect.com/science/article/abs/pii/S0735675721004381>
12. Covid-19 vaccine-induced thrombosis and thrombocytopenia: a commentary on an important and practical clinical dilemma: <https://www.sciencedirect.com/science/article/abs/pii/S0033062021000505>
13. Thrombosis with thrombocytopenia syndrome associated with COVID-19 viral vector vaccines: <https://www.sciencedirect.com/science/article/abs/pii/S0953620521001904>
14. COVID-19 vaccine-induced immune-immune thrombotic thrombocytopenia: an emerging cause of splanchnic vein thrombosis: <https://www.sciencedirect.com/science/article/pii/S1665268121000557>
15. The roles of platelets in COVID-19-associated coagulopathy and vaccine-induced immune thrombotic immune thrombocytopenia (covid): <https://www.sciencedirect.com/science/article/pii/S1050173821000967>
16. Roots of autoimmunity of thrombotic events after COVID-19 vaccination: <https://www.sciencedirect.com/science/article/abs/pii/S1568997221002160>
17. Cerebral venous sinus thrombosis after vaccination: the United Kingdom experience: <https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)01788-8/fulltext>
18. Thrombotic immune thrombocytopenia induced by SARS-CoV-2 vaccine: <https://www.nejm.org/doi/full/10.1056/nejme2106315>
19. Myocarditis after immunization with COVID-19 mRNA vaccines in members of the US military. This article reports that in “23 male patients, including 22 previously healthy military members, myocarditis was identified within 4 days after receipt of the vaccine”: <https://jamanetwork.com/journals/jamacardiology/fullarticle/2781601>
20. Thrombosis and thrombocytopenia after vaccination with ChAdOx1 nCoV-19: <https://www.nejm.org/doi/full/10.1056/NEJMoa2104882?query=recirc_curatedRelated_article>
21. Association of myocarditis with the BNT162b2 messenger RNA COVID-19 vaccine in a case series of children: <https://pubmed.ncbi.nlm.nih.gov/34374740/>
22. Thrombotic thrombocytopenia after vaccination with ChAdOx1 nCov-19: <https://www.nejm.org/doi/full/10.1056/NEJMoa2104840?query=recirc_curatedRelated_article>
23. Post-mortem findings in vaccine-induced thrombotic thrombocytopenia (covid-19): <https://haematologica.org/article/view/haematol.2021.279075>
24. Thrombocytopenia, including immune thrombocytopenia after receiving COVID-19 mRNA vaccines reported to the Vaccine Adverse Event Reporting System (VAERS): <https://www.sciencedirect.com/science/article/pii/S0264410X21005247>
25. Acute symptomatic myocarditis in seven adolescents after Pfizer-BioNTech COVID-19 vaccination: <https://pediatrics.aappublications.org/content/early/2021/06/04/peds.2021-052478>
26. Aphasia seven days after the second dose of an mRNA-based SARS-CoV-2 vaccine. Brain MRI revealed an intracerebral hemorrhage (ICBH) in the left temporal lobe in a 52-year-old man. <https://www.sciencedirect.com/science/article/pii/S2589238X21000292#f0005>
27. Comparison of vaccine-induced thrombotic episodes between ChAdOx1 nCoV-19 and Ad26.COV.2.S vaccines: <https://www.sciencedirect.com/science/article/abs/pii/S0896841121000895>
28. Hypothesis behind the very rare cases of thrombosis with thrombocytopenia syndrome after SARS-CoV-2 vaccination: <https://www.sciencedirect.com/science/article/abs/pii/S0049384821003315>
29. Blood clots and bleeding episodes after BNT162b2 and ChAdOx1 nCoV-19 vaccination: analysis of European data: <https://www.sciencedirect.com/science/article/pii/S0896841121000937>
30. Cerebral venous thrombosis after BNT162b2 mRNA SARS-CoV-2 vaccine: <https://www.sciencedirect.com/science/article/abs/pii/S1052305721003098>
31. Primary adrenal insufficiency associated with thrombotic immune thrombocytopenia induced by the Oxford-AstraZeneca ChAdOx1 nCoV-19 vaccine (VITT): <https://www.sciencedirect.com/science/article/pii/S0953620521002363>
32. Myocarditis and pericarditis after vaccination with COVID-19 mRNA: practical considerations for care providers: <https://www.sciencedirect.com/science/article/pii/S0828282X21006243>
33. “Portal vein thrombosis occurring after the first dose of SARS-CoV-2 mRNA vaccine in a patient with antiphospholipid syndrome”: <https://www.sciencedirect.com/science/article/pii/S2666572721000389>
34. Early results of bivalirudin treatment for thrombotic thrombocytopenia and cerebral venous sinus thrombosis after vaccination with Ad26.COV2.S: <https://www.sciencedirect.com/science/article/pii/S0196064421003425>
35. Myocarditis, pericarditis and cardiomyopathy after COVID-19 vaccination: <https://www.sciencedirect.com/science/article/pii/S1443950621011562>
36. Mechanisms of immunothrombosis in vaccine-induced thrombotic thrombocytopenia (VITT) compared to natural SARS-CoV-2 infection: <https://www.sciencedirect.com/science/article/abs/pii/S0896841121000706>
37. Prothrombotic immune thrombocytopenia after COVID-19 vaccination: <https://www.sciencedirect.com/science/article/pii/S0006497121009411>
38. Vaccine-induced thrombotic thrombocytopenia: the dark chapter of a success story: <https://www.sciencedirect.com/science/article/pii/S2589936821000256>
39. Cerebral venous sinus thrombosis negative for anti-PF4 antibody without thrombocytopenia after immunization with COVID-19 vaccine in a non-comorbid elderly Indian male treated with conventional heparin-warfarin based anticoagulation: <https://www.sciencedirect.com/science/article/pii/S1871402121002046>
40. Thrombosis after COVID-19 vaccination: possible link to ACE pathways: <https://www.sciencedirect.com/science/article/pii/S0049384821004369>
41. Cerebral venous sinus thrombosis in the U.S. population after SARS-CoV-2 vaccination with adenovirus and after COVID-19: <https://www.sciencedirect.com/science/article/pii/S0735109721051949>
42. A rare case of a middle-aged Asian male with cerebral venous thrombosis after AstraZeneca COVID-19 vaccination: <https://www.sciencedirect.com/science/article/pii/S0735675721005714>
43. Cerebral venous sinus thrombosis and thrombocytopenia after COVID-19 vaccination: report of two cases in the United Kingdom: <https://www.sciencedirect.com/science/article/abs/pii/S088915912100163X>
44. Immune thrombocytopenic purpura after vaccination with COVID-19 vaccine (ChAdOx1 nCov-19): <https://www.sciencedirect.com/science/article/abs/pii/S0006497121013963>.
45. Antiphospholipid antibodies and risk of thrombophilia after COVID-19 vaccination: the straw that breaks the camel’s back?: <https://docs.google.com/document/d/1XzajasO8VMMnC3CdxSBKks1o7kiOLXFQ>
46. Vaccine-induced thrombotic thrombocytopenia, a rare but severe case of friendly fire in the battle against the COVID-19 pandemic: What pathogenesis?: <https://www.sciencedirect.com/science/article/pii/S0953620521002314>
47. Diagnostic-therapeutic recommendations of the ad-hoc FACME expert working group on the management of cerebral venous thrombosis related to COVID-19 vaccination: <https://www.sciencedirect.com/science/article/pii/S0213485321000839>
48. Thrombocytopenia and intracranial venous sinus thrombosis after exposure to the “AstraZeneca COVID-19 vaccine”: <https://pubmed.ncbi.nlm.nih.gov/33918932/>
49. Thrombocytopenia following Pfizer and Moderna SARS-CoV-2 vaccination: <https://pubmed.ncbi.nlm.nih.gov/33606296/>
50. Severe and refractory immune thrombocytopenia occurring after SARS-CoV-2 vaccination: <https://pubmed.ncbi.nlm.nih.gov/33854395/>
51. Purpuric rash and thrombocytopenia after mRNA-1273 (Modern) COVID-19 vaccine: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7996471/>
52. COVID-19 vaccination: information on the occurrence of arterial and venous thrombosis using data from VigiBase: <https://pubmed.ncbi.nlm.nih.gov/33863748/>
53. Cerebral venous thrombosis associated with the covid-19 vaccine in Germany: <https://onlinelibrary.wiley.com/doi/10.1002/ana.26172>
54. Cerebral venous thrombosis following BNT162b2 mRNA vaccination of BNT162b2 against SARS-CoV-2: a black swan event: <https://pubmed.ncbi.nlm.nih.gov/34133027/>
55. The importance of recognizing cerebral venous thrombosis following anti-COVID-19 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34001390/>
56. Thrombosis with thrombocytopenia after messenger RNA vaccine -1273: <https://pubmed.ncbi.nlm.nih.gov/34181446/>
57. Blood clots and bleeding after BNT162b2 and ChAdOx1 nCoV-19 vaccination: an analysis of European data: <https://pubmed.ncbi.nlm.nih.gov/34174723/>
58. First dose of ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic, and hemorrhagic events in Scotland: <https://www.nature.com/articles/s41591-021-01408-4>
59. Exacerbation of immune thrombocytopenia after COVID-19 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34075578/>
60. First report of a de novo iTTP episode associated with a COVID-19 mRNA-based anti-COVID-19 vaccine: <https://pubmed.ncbi.nlm.nih.gov/34105244/>
61. PF4 immunoassays in vaccine-induced thrombotic thrombocytopenia: <https://www.nejm.org/doi/full/10.1056/NEJMc2106383>
62. Antibody epitopes in vaccine-induced immune immune thrombotic thrombocytopenia: <https://www.nature.com/articles/s41586-021-03744-4>
63. Myocarditis with COVID-19 mRNA vaccines: <https://www.ahajournals.org/doi/pdf/10.1161/CIRCULATIONAHA.121.056135>
64. Myocarditis and pericarditis after COVID-19 vaccination: <https://jamanetwork.com/journals/jama/fullarticle/2782900>
65. Myocarditis temporally associated with COVID-19 vaccination: <https://www.ahajournals.org/doi/pdf/10.1161/CIRCULATIONAHA.121.055891>.
66. COVID-19 Vaccination Associated with Myocarditis in Adolescents: <https://pediatrics.aappublications.org/content/pediatrics/early/2021/08/12/peds.2021-053427.full.pdf>
67. Acute myocarditis after administration of BNT162b2 vaccine against COVID-19: <https://pubmed.ncbi.nlm.nih.gov/33994339/>
68. Temporal association between COVID-19 vaccine Ad26.COV2.S and acute myocarditis: case report and review of the literature: <https://www.sciencedirect.com/science/article/pii/S1553838921005789>
69. COVID-19 vaccine-induced myocarditis: a case report with review of the literature: <https://www.sciencedirect.com/science/article/pii/S1871402121002253>
70. Potential association between COVID-19 vaccine and myocarditis: clinical and CMR findings: <https://www.sciencedirect.com/science/article/pii/S1936878X2100485X>
71. Recurrence of acute myocarditis temporally associated with receipt of coronavirus mRNA disease vaccine 2019 (COVID-19) in a male adolescent: <https://www.sciencedirect.com/science/article/pii/S002234762100617X>
72. Fulminant myocarditis and systemic hyper inflammation temporally associated with BNT162b2 COVID-19 mRNA vaccination in two patients: <https://www.sciencedirect.com/science/article/pii/S0167527321012286>.
73. Acute myocarditis after administration of BNT162b2 vaccine: <https://www.sciencedirect.com/science/article/pii/S2214250921001530>
74. Lymphohistocytic myocarditis after vaccination with COVID-19 Ad26.COV2.S viral vector: <https://www.sciencedirect.com/science/article/pii/S2352906721001573>
75. Myocarditis following vaccination with BNT162b2 in a healthy male: <https://www.sciencedirect.com/science/article/pii/S0735675721005362>
76. Acute myocarditis after Comirnaty (Pfizer) vaccination in a healthy male with previous SARS-CoV-2 infection: <https://www.sciencedirect.com/science/article/pii/S1930043321005549>
77. Myopericarditis after Pfizer mRNA COVID-19 vaccination in adolescents: <https://www.sciencedirect.com/science/article/pii/S002234762100665X>
78. Pericarditis after administration of BNT162b2 mRNA COVID-19 mRNA vaccine: <https://www.sciencedirect.com/science/article/pii/S1885585721002218>
79. Acute myocarditis after vaccination with SARS-CoV-2 mRNA-1273 mRNA: <https://www.sciencedirect.com/science/article/pii/S2589790X21001931>
80. Temporal relationship between the second dose of BNT162b2 mRNA Covid-19 vaccine and cardiac involvement in a patient with previous SARS-COV-2 infection: <https://www.sciencedirect.com/science/article/pii/S2352906721000622>
81. Myopericarditis after vaccination with COVID-19 mRNA in adolescents 12 to 18 years of age: <https://www.sciencedirect.com/science/article/pii/S0022347621007368>
82. Acute myocarditis after SARS-CoV-2 vaccination in a 24-year-old man: <https://www.sciencedirect.com/science/article/pii/S0870255121003243>
83. Important information on myopericarditis after vaccination with Pfizer COVID-19 mRNA in adolescents: <https://www.sciencedirect.com/science/article/pii/S0022347621007496>
84. A series of patients with myocarditis after vaccination against SARS-CoV-2 with mRNA-1279 and BNT162b2: <https://www.sciencedirect.com/science/article/pii/S1936878X21004861>
85. Takotsubo cardiomyopathy after vaccination with mRNA COVID-19: <https://www.sciencedirect.com/science/article/pii/S1443950621011331>
86. COVID-19 mRNA vaccination and myocarditis: <https://pubmed.ncbi.nlm.nih.gov/34268277/>
87. COVID-19 vaccine and myocarditis: <https://pubmed.ncbi.nlm.nih.gov/34399967/>
88. Epidemiology and clinical features of myocarditis/pericarditis before the introduction of COVID-19 mRNA vaccine in Korean children: a multicenter study [https://search.bvsalud.org/global-literature-on-novel-coronavirus-2019-ncov/resourc e/en/covidwho-1360706](https://search.bvsalud.org/global-literature-on-novel-coronavirus-2019-ncov/resourc%20e/en/covidwho-1360706).
89. COVID-19 vaccines and myocarditis: <https://pubmed.ncbi.nlm.nih.gov/34246566/>
90. Myocarditis and other cardiovascular complications of COVID-19 mRNA-based COVID-19 vaccines https://www.cureus.com/articles/61030-myocarditis-and-other-cardiovascular-comp lications-of-the-mrna-based-covid-19-vaccines <https://www.cureus.com/articles/61030-myocarditis-and-other-cardiovascular-complications-of-the-mrna-based-covid-19-vaccines>
91. Myocarditis, pericarditis, and cardiomyopathy after COVID-19 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34340927/>
92. Myocarditis with covid-19 mRNA vaccines: <https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.121.056135>
93. Association of myocarditis with COVID-19 mRNA vaccine in children: [https://media.jamanetwork.com/news-item/association-of-myocarditis-with-mrna-co vid-19-vaccine-in-children/](https://media.jamanetwork.com/news-item/association-of-myocarditis-with-mrna-co%20vid-19-vaccine-in-children/)
94. Association of myocarditis with COVID-19 messenger RNA vaccine BNT162b2 in a case series of children: <https://jamanetwork.com/journals/jamacardiology/fullarticle/2783052>
95. Myocarditis after immunization with COVID-19 mRNA vaccines in members of the U.S. military: <https://jamanetwork.com/journals/jamacardiology/fullarticle/2781601%5C>
96. Myocarditis occurring after immunization with COVID-19 mRNA-based COVID-19 vaccines: <https://jamanetwork.com/journals/jamacardiology/fullarticle/2781600>
97. Myocarditis following immunization with Covid-19 mRNA: <https://www.nejm.org/doi/full/10.1056/NEJMc2109975>
98. Patients with acute myocarditis after vaccination withCOVID-19 mRNA: <https://jamanetwork.com/journals/jamacardiology/fullarticle/2781602>
99. Myocarditis associated with vaccination with COVID-19 mRNA: <https://pubs.rsna.org/doi/10.1148/radiol.2021211430>
100. Symptomatic Acute Myocarditis in 7 Adolescents after Pfizer-BioNTech COVID-19 Vaccination: <https://pediatrics.aappublications.org/content/148/3/e2021052478>
101. Cardiovascular magnetic resonance imaging findings in young adult patients with acute myocarditis after COVID-19 mRNA vaccination: a case series: <https://jcmr-online.biomedcentral.com/articles/10.1186/s12968-021-00795-4>
102. Clinical Guidance for Young People with Myocarditis and Pericarditis after Vaccination with COVID-19 mRNA: <https://www.cps.ca/en/documents/position/clinical-guidance-for-youth-with-myocarditis-and-pericarditis>
103. Cardiac imaging of acute myocarditis after vaccination with COVID-19 mRNA: <https://pubmed.ncbi.nlm.nih.gov/34402228/>
104. Case report: acute myocarditis after second dose of mRNA-1273 SARS-CoV-2 mRNA vaccine: <https://academic.oup.com/ehjcr/article/5/8/ytab319/6339567>
105. Myocarditis / pericarditis associated with COVID-19 vaccine: <https://science.gc.ca/eic/site/063.nsf/eng/h_98291.html>
106. Transient cardiac injury in adolescents receiving the BNT162b2 mRNA COVID-19 vaccine: [https://journals.lww.com/pidj/Abstract/9000/Transient\_Cardiac\_Injury\_in\_Adolesce nts\_Receiving.95800.aspx](https://journals.lww.com/pidj/Abstract/9000/Transient_Cardiac_Injury_in_Adolesce%20nts_Receiving.95800.aspx)
107. Perimyocarditis in adolescents after Pfizer-BioNTech COVID-19 vaccine: <https://academic.oup.com/jpids/advance-article/doi/10.1093/jpids/piab060/6329543>
108. The new COVID-19 mRNA vaccine platform and myocarditis: clues to the possible underlying mechanism: <https://pubmed.ncbi.nlm.nih.gov/34312010/>
109. Acute myocardial injury after COVID-19 vaccination: a case report and review of current evidence from the Vaccine Adverse Event Reporting System database: <https://pubmed.ncbi.nlm.nih.gov/34219532/>
110. Be alert to the risk of adverse cardiovascular events after COVID-19 vaccination: <https://www.xiahepublishing.com/m/2472-0712/ERHM-2021-00033>
111. Myocarditis associated with COVID-19 vaccination: echocardiographic, cardiac tomography, and magnetic resonance imaging findings: <https://www.ahajournals.org/doi/10.1161/CIRCIMAGING.121.013236>
112. In-depth evaluation of a case of presumed myocarditis after the second dose of COVID-19 mRNA vaccine: <https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.121.056038>
113. Occurrence of acute infarct-like myocarditis after COVID-19 vaccination: just an accidental coincidence or rather a vaccination-associated autoimmune myocarditis?: <https://pubmed.ncbi.nlm.nih.gov/34333695/>
114. Recurrence of acute myocarditis temporally associated with receipt of coronavirus mRNA disease vaccine 2019 (COVID-19) in a male adolescent: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8216855/>
115. Myocarditis after SARS-CoV-2 vaccination: a vaccine-induced reaction?: <https://pubmed.ncbi.nlm.nih.gov/34118375/>
116. Self-limited myocarditis presenting with chest pain and ST-segment elevation in adolescents after vaccination with the BNT162b2 mRNA vaccine: <https://pubmed.ncbi.nlm.nih.gov/34180390/>
117. Myopericarditis in a previously healthy adolescent male after COVID-19 vaccination: Case report: <https://pubmed.ncbi.nlm.nih.gov/34133825/>
118. Biopsy-proven lymphocytic myocarditis after first COVID-19 mRNA vaccination in a 40-year-old man: case report: <https://pubmed.ncbi.nlm.nih.gov/34487236/>
119. Insights from a murine model of COVID-19 mRNA vaccine-induced myopericarditis: could accidental intravenous injection of a vaccine induce myopericarditis <https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciab741/6359059>
120. Unusual presentation of acute perimyocarditis after modern SARS-COV-2 mRNA-1237 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34447639/>
121. Perimyocarditis after the first dose of mRNA-1273 SARS-CoV-2 (Modern) mRNA-1273 vaccine in a young healthy male: case report: <https://bmccardiovascdisord.biomedcentral.com/articles/10.1186/s12872-021-02183>
122. Acute myocarditis after the second dose of SARS-CoV-2 vaccine: serendipity or causal relationship: <https://pubmed.ncbi.nlm.nih.gov/34236331/>
123. Rhabdomyolysis and fasciitis induced by the COVID-19 mRNA vaccine: <https://pubmed.ncbi.nlm.nih.gov/34435250/>
124. COVID-19 vaccine-induced rhabdomyolysis: case report with literature review: <https://pubmed.ncbi.nlm.nih.gov/34186348/>.
125. GM1 ganglioside antibody and COVID-19-related Guillain Barre syndrome: case report, systemic review, and implications for vaccine development: <https://www.sciencedirect.com/science/article/pii/S2666354621000065>
126. Guillain-Barré syndrome after AstraZeneca COVID-19 vaccination: causal or casual association: <https://www.sciencedirect.com/science/article/pii/S0303846721004169>
127. Sensory Guillain-Barré syndrome after ChAdOx1 nCov-19 vaccine: report of two cases and review of the literature: <https://www.sciencedirect.com/science/article/pii/S0165572821002186>
128. Guillain-Barré syndrome after the first dose of SARS-CoV-2 vaccine: a temporary occurrence, not a causal association: <https://www.sciencedirect.com/science/article/pii/S2214250921000998>.
129. Guillain-Barré syndrome presenting as facial diplegia after vaccination with COVID-19: a case report: <https://www.sciencedirect.com/science/article/pii/S0736467921006442>
130. Guillain-Barré syndrome after the first injection of ChAdOx1 nCoV-19 vaccine: first report: <https://www.sciencedirect.com/science/article/pii/S0035378721005853>.
131. SARS-CoV-2 vaccines are not safe for those with Guillain-Barre syndrome following vaccination: <https://www.sciencedirect.com/science/article/pii/S2049080121005343>
132. Acute hyperactive encephalopathy following COVID-19 vaccination with dramatic response to methylprednisolone: a case report: <https://www.sciencedirect.com/science/article/pii/S2049080121007536>
133. Facial nerve palsy following administration of COVID-19 mRNA vaccines: analysis of self-report database: <https://www.sciencedirect.com/science/article/pii/S1201971221007049>
134. Neurological symptoms and neuroimaging alterations related to COVID-19 vaccine: cause or coincidence: <https://www.sciencedirect.com/science/article/pii/S0899707121003557>.
135. New-onset refractory status epilepticus after ChAdOx1 nCoV-19 vaccination: <https://www.sciencedirect.com/science/article/pii/S0165572821001569>
136. Acute myelitis and ChAdOx1 nCoV-19 vaccine: coincidental or causal association: <https://www.sciencedirect.com/science/article/pii/S0165572821002137>
137. Bell’s palsy and SARS-CoV-2 vaccines: an unfolding story: <https://www.sciencedirect.com/science/article/pii/S1473309921002735>
138. Bell’s palsy after the second dose of the Pfizer COVID-19 vaccine in a patient with a history of recurrent Bell’s palsy: <https://www.sciencedirect.com/science/article/pii/S266635462100020X>
139. Acute-onset central serous retinopathy after immunization with COVID-19 mRNA vaccine:. <https://www.sciencedirect.com/science/article/pii/S2451993621001456>.
140. Bell’s palsy after COVID-19 vaccination: case report: <https://www.sciencedirect.com/science/article/pii/S217358082100122X>.
141. An academic hospital experience assessing the risk of COVID-19 mRNA vaccine using patient’s allergy history: <https://www.sciencedirect.com/science/article/pii/S2213219821007972>
142. COVID-19 vaccine-induced axillary and pectoral lymphadenopathy in PET: <https://www.sciencedirect.com/science/article/pii/S1930043321002612>
143. ANCA-associated vasculitis after Pfizer-BioNTech COVID-19 vaccine: <https://www.sciencedirect.com/science/article/pii/S0272638621007423>
144. Late cutaneous reactions after administration of COVID-19 mRNA vaccines: <https://www.sciencedirect.com/science/article/pii/S2213219821007996>
145. COVID-19 vaccine-induced rhabdomyolysis: case report with review of the literature: <https://www.sciencedirect.com/science/article/pii/S1871402121001880>
146. Clinical and pathologic correlates of skin reactions to COVID-19 vaccine, including V-REPP: a registry-based study: <https://www.sciencedirect.com/science/article/pii/S0190962221024427>
147. Thrombosis with thrombocytopenia syndrome associated with COVID-19 vaccines:. <https://www.sciencedirect.com/science/article/abs/pii/S0735675721004381>.
148. COVID-19 vaccine-associated anaphylaxis: a statement from the Anaphylaxis Committee of the World Allergy Organization:. <https://www.sciencedirect.com/science/article/pii/S1939455121000119>.
149. Cerebral venous sinus thrombosis negative for anti-PF4 antibody without thrombocytopenia after immunization with COVID-19 vaccine in an elderly, non-comorbid Indian male treated with conventional heparin-warfarin-based anticoagulation:. <https://www.sciencedirect.com/science/article/pii/S1871402121002046>.
150. Acute myocarditis after administration of BNT162b2 vaccine against COVID-19:. <https://www.sciencedirect.com/science/article/abs/pii/S188558572100133X>
151. Blood clots and bleeding after BNT162b2 and ChAdOx1 nCoV-19 vaccine: an analysis of European data:. <https://www.sciencedirect.com/science/article/pii/S0896841121000937>.
152. immune thrombocytopenia associated with Pfizer-BioNTech’s COVID-19 BNT162b2 mRNA vaccine:. <https://www.sciencedirect.com/science/article/pii/S2214250921002018>.
153. Bullous drug eruption after the second dose of COVID-19 mRNA-1273 (Moderna) vaccine: Case report: <https://www.sciencedirect.com/science/article/pii/S1876034121001878>.
154. COVID-19 RNA-based vaccines and the risk of prion disease: https://scivisionpub.com/pdfs/covid19rna-based-vaccines-and-the-risk-of-prion-dis ease-1503.pdf
155. This study notes that 115 pregnant women lost their babies, out of 827 who participated in a study on the safety of covid-19 vaccines: <https://www.nejm.org/doi/full/10.1056/NEJMoa2104983>.
156. Process-related impurities in the ChAdOx1 nCov-19 vaccine: <https://www.researchsquare.com/article/rs-477964/v1>
157. COVID-19 mRNA vaccine causing CNS inflammation: a case series: <https://link.springer.com/article/10.1007/s00415-021-10780-7>
158. Allergic reactions, including anaphylaxis, after receiving the first dose of the Pfizer-BioNTech COVID-19 vaccine: <https://pubmed.ncbi.nlm.nih.gov/33475702/>
159. Allergic reactions to the first COVID-19 vaccine: a potential role of polyethylene glycol: <https://pubmed.ncbi.nlm.nih.gov/33320974/>
160. Pfizer Vaccine Raises Allergy Concerns: <https://pubmed.ncbi.nlm.nih.gov/33384356/>
161. Allergic reactions, including anaphylaxis, after receiving the first dose of Pfizer-BioNTech COVID-19 vaccine – United States, December 14-23, 2020: <https://pubmed.ncbi.nlm.nih.gov/33444297/>
162. Allergic reactions, including anaphylaxis, after receiving first dose of Modern COVID-19 vaccine – United States, December 21, 2020-January 10, 2021: <https://pubmed.ncbi.nlm.nih.gov/33507892/>
163. Reports of anaphylaxis after coronavirus disease vaccination 2019, South Korea, February 26-April 30, 2021: <https://pubmed.ncbi.nlm.nih.gov/34414880/>
164. Reports of anaphylaxis after receiving COVID-19 mRNA vaccines in the U.S.-Dec 14, 2020-Jan 18, 2021: <https://pubmed.ncbi.nlm.nih.gov/33576785/>
165. Immunization practices and risk of anaphylaxis: a current, comprehensive update of COVID-19 vaccination data: <https://pubmed.ncbi.nlm.nih.gov/34269740/>
166. Relationship between pre-existing allergies and anaphylactic reactions following administration of COVID-19 mRNA vaccine: <https://pubmed.ncbi.nlm.nih.gov/34215453/>
167. Anaphylaxis Associated with COVID-19 mRNA Vaccines: Approach to Allergy Research: <https://pubmed.ncbi.nlm.nih.gov/33932618/>
168. Severe Allergic Reactions after COVID-19 Vaccination with the Pfizer / BioNTech Vaccine in Great Britain and the USA: Position Statement of the German Allergy Societies: German Medical Association of Allergologists (AeDA), German Society for Allergology and Clinical Immunology (DGAKI) and Society for Pediatric Allergology and Environmental Medicine (GPA): <https://pubmed.ncbi.nlm.nih.gov/33643776/>
169. Allergic reactions and anaphylaxis to LNP-based COVID-19 vaccines: <https://pubmed.ncbi.nlm.nih.gov/33571463/>
170. Reported orofacial adverse effects from COVID-19 vaccines: the known and the unknown: <https://pubmed.ncbi.nlm.nih.gov/33527524/>
171. Cutaneous adverse effects of available COVID-19 vaccines: <https://pubmed.ncbi.nlm.nih.gov/34518015/>
172. Cumulative adverse event report of anaphylaxis following injections of COVID-19 mRNA vaccine (Pfizer-BioNTech) in Japan: the first month report: <https://pubmed.ncbi.nlm.nih.gov/34347278/>
173. COVID-19 vaccines increase the risk of anaphylaxis: <https://pubmed.ncbi.nlm.nih.gov/33685103/>
174. Biphasic anaphylaxis after exposure to the first dose of the Pfizer-BioNTech COVID-19 mRNA vaccine COVID-19: <https://pubmed.ncbi.nlm.nih.gov/34050949/>
175. Allergenic components of the mRNA-1273 vaccine for COVID-19: possible involvement of polyethylene glycol and IgG-mediated complement activation: <https://pubmed.ncbi.nlm.nih.gov/33657648/>
176. Polyethylene glycol (PEG) is a cause of anaphylaxis to Pfizer / BioNTech mRNA COVID-19 vaccine: <https://pubmed.ncbi.nlm.nih.gov/33825239/>
177. Acute allergic reactions to COVID-19 mRNA vaccines: <https://pubmed.ncbi.nlm.nih.gov/33683290/>
178. Polyethylene glycole allergy of the SARS CoV2 vaccine recipient: case report of a young adult recipient and management of future exposure to SARS-CoV2: <https://pubmed.ncbi.nlm.nih.gov/33919151/>
179. Elevated rates of anaphylaxis after vaccination with Pfizer BNT162b2 mRNA vaccine against COVID-19 in Japanese healthcare workers; a secondary analysis of initial post-approval safety data: <https://pubmed.ncbi.nlm.nih.gov/34128049/>
180. Allergic reactions and adverse events associated with administration of mRNA-based vaccines. A health system experience: <https://pubmed.ncbi.nlm.nih.gov/34474708/>
181. Allergic reactions to COVID-19 vaccines: statement of the Belgian Society of Allergy and Clinical Immunology (BelSACI): <https://www.tandfonline.com/doi/abs/10.1080/17843286.2021.1909447>
182. .IgE-mediated allergy to polyethylene glycol (PEG) as a cause of anaphylaxis to COVID-19 mRNA vaccines: <https://pubmed.ncbi.nlm.nih.gov/34318537/>
183. Allergic reactions after COVID-19 vaccination: putting the risk in perspective: <https://pubmed.ncbi.nlm.nih.gov/34463751/>
184. Anaphylactic reactions to COVID-19 mRNA vaccines: a call for further studies: https://pubmed.ncbi.nlm.nih.gov/33846043/ 188.
185. Risk of severe allergic reactions to COVID-19 vaccines among patients with allergic skin disease: practical recommendations. An ETFAD position statement with external experts: <https://pubmed.ncbi.nlm.nih.gov/33752263/>
186. COVID-19 vaccine and death: causality algorithm according to the WHO eligibility diagnosis: <https://pubmed.ncbi.nlm.nih.gov/34073536/>
187. Fatal brain hemorrhage after COVID-19 vaccine: <https://pubmed.ncbi.nlm.nih.gov/33928772/>
188. A case series of skin reactions to COVID-19 vaccine in the Department of Dermatology at Loma Linda University: <https://pubmed.ncbi.nlm.nih.gov/34423106/>
189. Skin reactions reported after Moderna and Pfizer’s COVID-19 vaccination: a study based on a registry of 414 cases: <https://pubmed.ncbi.nlm.nih.gov/33838206/>
190. Clinical and pathologic correlates of skin reactions to COVID-19 vaccine, including V-REPP: a registry-based study: <https://pubmed.ncbi.nlm.nih.gov/34517079/>
191. Skin reactions after vaccination against SARS-COV-2: a nationwide Spanish cross-sectional study of 405 cases: <https://pubmed.ncbi.nlm.nih.gov/34254291/>
192. Varicella zoster virus and herpes simplex virus reactivation after vaccination with COVID-19: review of 40 cases in an international dermatologic registry: <https://pubmed.ncbi.nlm.nih.gov/34487581/>
193. Immune thrombosis and thrombocytopenia (VITT) associated with the COVID-19 vaccine: diagnostic and therapeutic recommendations for a new syndrome: <https://pubmed.ncbi.nlm.nih.gov/33987882/>
194. Laboratory testing for suspicion of COVID-19 vaccine-induced thrombotic (immune) thrombocytopenia: <https://pubmed.ncbi.nlm.nih.gov/34138513/>
195. Intracerebral hemorrhage due to thrombosis with thrombocytopenia syndrome after COVID-19 vaccination: the first fatal case in Korea: <https://pubmed.ncbi.nlm.nih.gov/34402235/>
196. Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and positive SARS-CoV-2 tests: self-controlled case series study: <https://pubmed.ncbi.nlm.nih.gov/34446426/>
197. Vaccine-induced immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis after covid-19 vaccination; a systematic review: <https://pubmed.ncbi.nlm.nih.gov/34365148/>.
198. Nerve and muscle adverse events after vaccination with COVID-19: a systematic review and meta-analysis of clinical trials: <https://pubmed.ncbi.nlm.nih.gov/34452064/>.
199. A rare case of cerebral venous thrombosis and disseminated intravascular coagulation temporally associated with administration of COVID-19 vaccine: <https://pubmed.ncbi.nlm.nih.gov/33917902/>
200. Primary adrenal insufficiency associated with thrombotic immune thrombocytopenia induced by Oxford-AstraZeneca ChAdOx1 nCoV-19 vaccine (VITT): <https://pubmed.ncbi.nlm.nih.gov/34256983/>
201. Acute cerebral venous thrombosis and pulmonary artery embolism associated with the COVID-19 vaccine: <https://pubmed.ncbi.nlm.nih.gov/34247246/>.
202. Thromboaspiration infusion and fibrinolysis for portomesenteric thrombosis after administration of AstraZeneca COVID-19 vaccine: <https://pubmed.ncbi.nlm.nih.gov/34132839/>
203. 59-year-old woman with extensive deep venous thrombosis and pulmonary thromboembolism 7 days after a first dose of Pfizer-BioNTech BNT162b2 mRNA vaccine COVID-19: <https://pubmed.ncbi.nlm.nih.gov/34117206/>
204. Cerebral venous thrombosis and vaccine-induced thrombocytopenia.a. Oxford-AstraZeneca COVID-19: a missed opportunity for a rapid return on experience: <https://pubmed.ncbi.nlm.nih.gov/34033927/>
205. Myocarditis and other cardiovascular complications of mRNA-based COVID-19 vaccines: <https://pubmed.ncbi.nlm.nih.gov/34277198/>
206. Pericarditis after administration of COVID-19 mRNA BNT162b2 vaccine: <https://pubmed.ncbi.nlm.nih.gov/34364831/>
207. Unusual presentation of acute pericarditis after vaccination against SARS-COV-2 mRNA-1237 Modern: <https://pubmed.ncbi.nlm.nih.gov/34447639/>
208. Case report: acute myocarditis after second dose of SARS-CoV-2 mRNA-1273 vaccine mRNA-1273: <https://pubmed.ncbi.nlm.nih.gov/34514306/>
209. Immune-mediated disease outbreaks or recent-onset disease in 27 subjects after mRNA/DNA vaccination against SARS-CoV-2: <https://pubmed.ncbi.nlm.nih.gov/33946748/>
210. Insights from a murine model of myopericarditis induced by COVID-19 mRNA vaccine: could accidental intravenous injection of a vaccine induce myopericarditis: <https://pubmed.ncbi.nlm.nih.gov/34453510/>
211. Immune thrombocytopenia in a 22-year-old post Covid-19 vaccine: <https://pubmed.ncbi.nlm.nih.gov/33476455/>
212. propylthiouracil-induced neutrophil anti-cytoplasmic antibody-associated vasculitis after COVID-19 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34451967/>
213. Secondary immune thrombocytopenia (ITP) associated with ChAdOx1 Covid-19 vaccine: case report: <https://pubmed.ncbi.nlm.nih.gov/34377889/>
214. Thrombosis with thrombocytopenia syndrome (TTS) following AstraZeneca ChAdOx1 nCoV-19 (AZD1222) COVID-19 vaccination: risk-benefit analysis for persons <60 years in Australia: <https://pubmed.ncbi.nlm.nih.gov/34272095/>
215. COVID-19 vaccination association and facial nerve palsy: A case-control study: <https://pubmed.ncbi.nlm.nih.gov/34165512/>
216. The association between COVID-19 vaccination and Bell’s palsy: <https://pubmed.ncbi.nlm.nih.gov/34411533/>
217. Bell’s palsy after COVID-19 vaccination: <https://pubmed.ncbi.nlm.nih.gov/33611630/>
218. Acute transverse myelitis (ATM): clinical review of 43 patients with COVID-19-associated ATM and 3 serious adverse events of post-vaccination ATM with ChAdOx1 nCoV-19 vaccine (AZD1222): <https://pubmed.ncbi.nlm.nih.gov/33981305/>
219. Bell’s palsy after 24 hours of mRNA-1273 SARS-CoV-2 mRNA-1273 vaccine: <https://pubmed.ncbi.nlm.nih.gov/34336436/>
220. Sequential contralateral facial nerve palsy after first and second doses of COVID-19 vaccine: <https://pubmed.ncbi.nlm.nih.gov/34281950/>.
221. Transverse myelitis induced by SARS-CoV-2 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34458035/>
222. Peripheral facial nerve palsy after vaccination with BNT162b2 (COVID-19): <https://pubmed.ncbi.nlm.nih.gov/33734623/>
223. Acute abducens nerve palsy after COVID-19 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34044114/>.
224. Facial nerve palsy after administration of COVID-19 mRNA vaccines: analysis of self-report database: <https://pubmed.ncbi.nlm.nih.gov/34492394/>
225. Transient oculomotor paralysis after administration of RNA-1273 messenger vaccine for SARS-CoV-2 diplopia after COVID-19 vaccine: <https://pubmed.ncbi.nlm.nih.gov/34369471/>
226. Bell’s palsy after Ad26.COV2.S COVID-19 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34014316/>
227. Bell’s palsy after COVID-19 vaccination: case report: <https://pubmed.ncbi.nlm.nih.gov/34330676/>
228. A case of acute demyelinating polyradiculoneuropathy with bilateral facial palsy following ChAdOx1 nCoV-19 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34272622/>
229. Guillian Barré syndrome after vaccination with mRNA-1273 against COVID-19: <https://pubmed.ncbi.nlm.nih.gov/34477091/>
230. Acute facial paralysis as a possible complication of SARS-CoV-2 vaccination: <https://pubmed.ncbi.nlm.nih.gov/33975372/>.
231. Bell’s palsy after COVID-19 vaccination with high antibody response in CSF: <https://pubmed.ncbi.nlm.nih.gov/34322761/>.
232. Parsonage-Turner syndrome associated with SARS-CoV-2 or SARS-CoV-2 vaccination. Comment on: “Neuralgic amyotrophy and COVID-19 infection: 2 cases of accessory spinal nerve palsy” by Coll et al. Articular Spine 2021; 88: 10519: <https://pubmed.ncbi.nlm.nih.gov/34139321/>.
233. Bell’s palsy after a single dose of vaccine mRNA. SARS-CoV-2: case report: <https://pubmed.ncbi.nlm.nih.gov/34032902/>.
234. Autoimmune hepatitis developing after coronavirus disease vaccine 2019 (COVID-19): causality or victim?: <https://pubmed.ncbi.nlm.nih.gov/33862041/>
235. Autoimmune hepatitis triggered by vaccination against SARS-CoV-2: <https://pubmed.ncbi.nlm.nih.gov/34332438/>
236. Acute autoimmune-like hepatitis with atypical antimitochondrial antibody after vaccination with COVID-19 mRNA: a new clinical entity: <https://pubmed.ncbi.nlm.nih.gov/34293683/>.
237. Autoimmune hepatitis after COVID vaccine: <https://pubmed.ncbi.nlm.nih.gov/34225251/>
238. A novel case of bifacial diplegia variant of Guillain-Barré syndrome after vaccination with Janssen COVID-19: <https://pubmed.ncbi.nlm.nih.gov/34449715/>
239. Comparison of vaccine-induced thrombotic events between ChAdOx1 nCoV-19 and Ad26.COV.2.S vaccines: <https://pubmed.ncbi.nlm.nih.gov/34139631/>.
240. Bilateral superior ophthalmic vein thrombosis, ischemic stroke and immune thrombocytopenia after vaccination with ChAdOx1 nCoV-19: <https://pubmed.ncbi.nlm.nih.gov/33864750/>
241. Diagnosis and treatment of cerebral venous sinus thrombosis with vaccine-induced immune-immune thrombotic thrombocytopenia: <https://pubmed.ncbi.nlm.nih.gov/33914590/>
242. Venous sinus thrombosis after vaccination with ChAdOx1 nCov-19: <https://pubmed.ncbi.nlm.nih.gov/34420802/>
243. Cerebral venous sinus thrombosis following vaccination against SARS-CoV-2: an analysis of cases reported to the European Medicines Agency: <https://pubmed.ncbi.nlm.nih.gov/34293217/>
244. Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and positive SARS-CoV-2 tests: self-controlled case series study: <https://pubmed.ncbi.nlm.nih.gov/34446426/>
245. Blood clots and bleeding after BNT162b2 and ChAdOx1 nCoV-19 vaccination: an analysis of European data: <https://pubmed.ncbi.nlm.nih.gov/34174723/>
246. Arterial events, venous thromboembolism, thrombocytopenia and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population-based cohort study: <https://pubmed.ncbi.nlm.nih.gov/33952445/>
247. First dose of ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland: <https://pubmed.ncbi.nlm.nih.gov/34108714/>
248. Cerebral venous thrombosis associated with COVID-19 vaccine in Germany: <https://pubmed.ncbi.nlm.nih.gov/34288044/>
249. Malignant cerebral infarction after vaccination with ChAdOx1 nCov-19: a catastrophic variant of vaccine-induced immune-mediated thrombotic thrombocytopenia: <https://pubmed.ncbi.nlm.nih.gov/34341358/>
250. celiac artery and splenic artery thrombosis complicated by splenic infarction 7 days after the first dose of Oxford vaccine, causal relationship or coincidence: <https://pubmed.ncbi.nlm.nih.gov/34261633/>.
251. Primary adrenal insufficiency associated with Oxford-AstraZeneca ChAdOx1 nCoV-19 (VITT) vaccine-induced immune thrombotic thrombocytopenia: <https://pubmed.ncbi.nlm.nih.gov/34256983/>
252. Thrombocytopenia after COVID-19 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34332437/>.
253. Cerebral venous sinus thrombosis associated with thrombocytopenia after COVID-19 vaccination: <https://pubmed.ncbi.nlm.nih.gov/33845870/>.
254. Thrombosis with thrombocytopenia syndrome after COVID-19 immunization: <https://pubmed.ncbi.nlm.nih.gov/34236343/>
255. Acute myocardial infarction within 24 hours after COVID-19 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34364657/>.
256. Bilateral acute macular neuroretinopathy after SARS-CoV-2 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34287612/>
257. central venous sinus thrombosis with subarachnoid hemorrhage after COVID-19 mRNA vaccination: are these reports merely coincidental: <https://pubmed.ncbi.nlm.nih.gov/34478433/>
258. Intracerebral hemorrhage due to thrombosis with thrombocytopenia syndrome after COVID-19 vaccination: the first fatal case in Korea: <https://pubmed.ncbi.nlm.nih.gov/34402235/>
259. Cerebral venous sinus thrombosis negative for anti-PF4 antibody without thrombocytopenia after immunization with COVID-19 vaccine in a non-comorbid elderly Indian male treated with conventional heparin-warfarin-based anticoagulation: <https://pubmed.ncbi.nlm.nih.gov/34186376/>
260. Cerebral venous sinus thrombosis 2 weeks after first dose of SARS-CoV-2 mRNA vaccine: <https://pubmed.ncbi.nlm.nih.gov/34101024/>
261. A case of multiple thrombocytopenia and thrombosis following vaccination with ChAdOx1 nCoV-19 against SARS-CoV-2: <https://pubmed.ncbi.nlm.nih.gov/34137813/>
262. Vaccine-induced thrombotic thrombocytopenia: the elusive link between thrombosis and adenovirus-based SARS-CoV-2 vaccines: <https://pubmed.ncbi.nlm.nih.gov/34191218/>
263. Acute ischemic stroke revealing immune thrombotic thrombocytopenia induced by ChAdOx1 nCov-19 vaccine: impact on recanalization strategy: <https://pubmed.ncbi.nlm.nih.gov/34175640/>
264. New-onset refractory status epilepticus after ChAdOx1 nCoV-19 vaccine: <https://pubmed.ncbi.nlm.nih.gov/34153802/>
265. Thrombosis with thrombocytopenia syndrome associated with COVID-19 viral vector vaccines: <https://pubmed.ncbi.nlm.nih.gov/34092488/>
266. Pulmonary embolism, transient ischemic attack, and thrombocytopenia after Johnson & Johnson COVID-19 vaccine: <https://pubmed.ncbi.nlm.nih.gov/34261635/>
267. Thromboaspiration infusion and fibrinolysis for portomesenteric thrombosis after administration of the AstraZeneca COVID-19 vaccine: <https://pubmed.ncbi.nlm.nih.gov/34132839/>.
268. Spontaneous HIT syndrome: knee replacement, infection, and parallels with vaccine-induced immune thrombotic thrombocytopenia: <https://pubmed.ncbi.nlm.nih.gov/34144250/>
269. Deep venous thrombosis (DVT) occurring shortly after second dose of SARS-CoV-2 mRNA vaccine: <https://pubmed.ncbi.nlm.nih.gov/33687691/>
270. Procoagulant antibody-mediated procoagulant platelets in immune thrombotic thrombocytopenia associated with SARS-CoV-2 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34011137/>.
271. Vaccine-induced immune thrombotic thrombocytopenia causing a severe form of cerebral venous thrombosis with high mortality rate: a case series: <https://pubmed.ncbi.nlm.nih.gov/34393988/>.
272. Procoagulant microparticles: a possible link between vaccine-induced immune thrombocytopenia (VITT) and cerebral sinus venous thrombosis: <https://pubmed.ncbi.nlm.nih.gov/34129181/>.
273. Atypical thrombosis associated with the vaccine VaxZevria® (AstraZeneca): data from the French network of regional pharmacovigilance centers: <https://pubmed.ncbi.nlm.nih.gov/34083026/>.
274. Acute cerebral venous thrombosis and pulmonary artery embolism associated with the COVID-19 vaccine: <https://pubmed.ncbi.nlm.nih.gov/34247246/>.
275. Vaccine-induced thrombosis and thrombocytopenia with bilateral adrenal haemorrhage: <https://pubmed.ncbi.nlm.nih.gov/34235757/>.
276. Palmar digital vein thrombosis after Oxford-AstraZeneca COVID-19 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34473841/>.
277. Cutaneous thrombosis associated with cutaneous necrosis following Oxford-AstraZeneca COVID-19 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34189756/>
278. Cerebral venous thrombosis following COVID-19 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34045111/>.
279. Lipschütz ulcers after AstraZeneca COVID-19 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34366434/>.
280. Amyotrophic Neuralgia secondary to Vaxzevri vaccine (AstraZeneca) COVID-19: <https://pubmed.ncbi.nlm.nih.gov/34330677/>
281. Thrombosis with thrombocytopenia after Messenger vaccine RNA-1273: <https://pubmed.ncbi.nlm.nih.gov/34181446/>
282. Intracerebral hemorrhage twelve days after vaccination with ChAdOx1 nCoV-19: <https://pubmed.ncbi.nlm.nih.gov/34477089/>
283. Thrombotic thrombocytopenia after vaccination with COVID-19: in search of the underlying mechanism: <https://pubmed.ncbi.nlm.nih.gov/34071883/>
284. Coronavirus (COVID-19) Vaccine-induced immune thrombotic thrombocytopenia (VITT): <https://pubmed.ncbi.nlm.nih.gov/34033367/>
285. Comparison of adverse drug reactions among four COVID-19 vaccines in Europe using the EudraVigilance database: Thrombosis in unusual sites: <https://pubmed.ncbi.nlm.nih.gov/34375510/>
286. Immunoglobulin adjuvant for vaccine-induced immune thrombotic thrombocytopenia: <https://pubmed.ncbi.nlm.nih.gov/34107198/>
287. Severe vaccine-induced thrombotic thrombocytopenia following vaccination with COVID-19: an autopsy case report and review of the literature: <https://pubmed.ncbi.nlm.nih.gov/34355379/>.
288. A case of acute pulmonary embolism after immunization with SARS-CoV-2 mRNA: <https://pubmed.ncbi.nlm.nih.gov/34452028/>
289. Neurosurgical considerations regarding decompressive craniectomy for intracerebral hemorrhage after SARS-CoV-2 vaccination in vaccine-induced thrombotic thrombocytopenia-VITT: <https://pubmed.ncbi.nlm.nih.gov/34202817/>
290. Thrombosis and SARS-CoV-2 vaccines: vaccine-induced immune thrombotic thrombocytopenia: <https://pubmed.ncbi.nlm.nih.gov/34237213/>.
291. Acquired thrombotic thrombocytopenic thrombocytopenic purpura: a rare disease associated with the BNT162b2 vaccine: <https://pubmed.ncbi.nlm.nih.gov/34105247/>.
292. Immune complexes, innate immunity and NETosis in ChAdOx1 vaccine-induced thrombocytopenia: <https://pubmed.ncbi.nlm.nih.gov/34405870/>.
293. Sensory Guillain-Barré syndrome following ChAdOx1 nCov-19 vaccine: report of two cases and review of the literature: <https://pubmed.ncbi.nlm.nih.gov/34416410/>.
294. Vogt-Koyanagi-Harada syndrome after COVID-19 and ChAdOx1 nCoV-19 (AZD1222) vaccination: <https://pubmed.ncbi.nlm.nih.gov/34462013/>.
295. Reactivation of Vogt-Koyanagi-Harada disease under control for more than 6 years, after anti-SARS-CoV-2 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34224024/>.
296. Post-vaccinal encephalitis after ChAdOx1 nCov-19: <https://pubmed.ncbi.nlm.nih.gov/34324214/>
297. Neurological symptoms and neuroimaging alterations related to COVID-19 vaccine: cause or coincidence?: <https://pubmed.ncbi.nlm.nih.gov/34507266/>
298. Fatal systemic capillary leak syndrome after SARS-COV-2 vaccination in a patient with multiple myeloma: <https://pubmed.ncbi.nlm.nih.gov/34459725/>
299. Polyarthralgia and myalgia syndrome after vaccination with ChAdOx1 nCOV-19: <https://pubmed.ncbi.nlm.nih.gov/34463066/>
300. Three cases of subacute thyroiditis after SARS-CoV-2 vaccination: post-vaccination ASIA syndrome: <https://pubmed.ncbi.nlm.nih.gov/34043800/>.
301. Facial diplegia: a rare and atypical variant of Guillain-Barré syndrome and the Ad26.COV2.S vaccine: <https://pubmed.ncbi.nlm.nih.gov/34447646/>
302. Association between ChAdOx1 nCoV-19 vaccination and bleeding episodes: large population-based cohort study: <https://pubmed.ncbi.nlm.nih.gov/34479760/>.
303. fulminant myocarditis and systemic hyperinflammation temporally associated with BNT162b2 COVID-19 mRNA vaccination in two patients: <https://pubmed.ncbi.nlm.nih.gov/34416319/>.
304. Adverse effects reported after COVID-19 vaccination in a tertiary care hospital, centered on cerebral venous sinus thrombosis (CVST): <https://pubmed.ncbi.nlm.nih.gov/34092166/>
305. Induction and exacerbation of subacute cutaneous lupus erythematosus erythematosus after mRNA- or adenoviral vector-based SARS-CoV-2 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34291477/>
306. Petechiae and peeling of fingers after immunization with BTN162b2 messenger RNA (mRNA)-based COVID-19 vaccine: <https://pubmed.ncbi.nlm.nih.gov/34513435/>
307. Hepatitis C virus reactivation after COVID-19 vaccination: a case report: <https://pubmed.ncbi.nlm.nih.gov/34512037/>
308. Bilateral immune-mediated keratolysis after immunization with SARS-CoV-2 recombinant viral vector vaccine: <https://pubmed.ncbi.nlm.nih.gov/34483273/>.
309. Immune-mediated thrombocytopenic purpura after Pfizer-BioNTech COVID-19 vaccine in an elderly woman: <https://pubmed.ncbi.nlm.nih.gov/34513446/>
310. Platelet activation and modulation in thrombosis with thrombocytopenia syndrome associated with the ChAdO × 1 nCov-19 vaccine: <https://pubmed.ncbi.nlm.nih.gov/34474550/>
311. Reactive arthritis after COVID-19 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34033732/>.
312. Two cases of Graves’ disease after SARS-CoV-2 vaccination: an autoimmune / inflammatory syndrome induced by adjuvants: <https://pubmed.ncbi.nlm.nih.gov/33858208/>
313. Acute relapse and impaired immunization after COVID-19 vaccination in a patient with multiple sclerosis treated with rituximab: <https://pubmed.ncbi.nlm.nih.gov/34015240/>
314. Widespread fixed bullous drug eruption after vaccination with ChAdOx1 nCoV-19: <https://pubmed.ncbi.nlm.nih.gov/34482558/>
315. COVID-19 mRNA vaccine causing CNS inflammation: a case series: <https://pubmed.ncbi.nlm.nih.gov/34480607/>
316. Thymic hyperplasia after Covid-19 mRNA-based vaccination with Covid-19: <https://pubmed.ncbi.nlm.nih.gov/34462647/>
317. Acute disseminated encephalomyelitis following vaccination against SARS-CoV-2: <https://pubmed.ncbi.nlm.nih.gov/34325334/>
318. Tolosa-Hunt syndrome occurring after COVID-19 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34513398/>
319. Systemic capillary extravasation syndrome following vaccination with ChAdOx1 nCOV-19 (Oxford-AstraZeneca): <https://pubmed.ncbi.nlm.nih.gov/34362727/>
320. Immune-mediated thrombocytopenia associated with Ad26.COV2.S vaccine (Janssen; Johnson & Johnson): <https://pubmed.ncbi.nlm.nih.gov/34469919/>.
321. Transient thrombocytopenia with glycoprotein-specific platelet autoantibodies after vaccination with Ad26.COV2.S: case report: <https://pubmed.ncbi.nlm.nih.gov/34516272/>.
322. Acute hyperactive encephalopathy following COVID-19 vaccination with dramatic response to methylprednisolone: case report: <https://pubmed.ncbi.nlm.nih.gov/34512961/>
323. Transient cardiac injury in adolescents receiving the BNT162b2 mRNA COVID-19 vaccine: <https://pubmed.ncbi.nlm.nih.gov/34077949/>
324. Autoimmune hepatitis developing after ChAdOx1 nCoV-19 vaccine (Oxford-AstraZeneca): <https://pubmed.ncbi.nlm.nih.gov/34171435/>
325. Severe relapse of multiple sclerosis after COVID-19 vaccination: a case report: <https://pubmed.ncbi.nlm.nih.gov/34447349/>
326. Lymphohistocytic myocarditis after vaccination with the COVID-19 viral vector Ad26.COV2.S: <https://pubmed.ncbi.nlm.nih.gov/34514078/>
327. Hemophagocytic lymphohistiocytosis after vaccination with ChAdOx1 nCov-19: <https://pubmed.ncbi.nlm.nih.gov/34406660/>.
328. IgA vasculitis in adult patient after vaccination with ChadOx1 nCoV-19: <https://pubmed.ncbi.nlm.nih.gov/34509658/>
329. A case of leukocytoclastic vasculitis after vaccination with a SARS-CoV2 vaccine: case report: <https://pubmed.ncbi.nlm.nih.gov/34196469/>.
330. Onset / outbreak of psoriasis after Corona virus ChAdOx1 nCoV-19 vaccine (Oxford-AstraZeneca / Covishield): report of two cases: <https://pubmed.ncbi.nlm.nih.gov/34350668/>
331. Hailey-Hailey disease exacerbation after SARS-CoV-2 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34436620/>
332. Supraclavicular lymphadenopathy after COVID-19 vaccination in Korea: serial follow-up by ultrasonography: <https://pubmed.ncbi.nlm.nih.gov/34116295/>.
333. COVID-19 vaccine, immune thrombotic thrombocytopenia, jaundice, hyperviscosity: concern in cases with underlying hepatic problems: <https://pubmed.ncbi.nlm.nih.gov/34509271/>.
334. Report of the International Cerebral Venous Thrombosis Consortium on cerebral venous thrombosis after SARS-CoV-2 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34462996/>
335. Immune thrombocytopenia after vaccination during the COVID-19 pandemic: <https://pubmed.ncbi.nlm.nih.gov/34435486/>
336. COVID-19: lessons from the Norwegian tragedy should be taken into account in planning for vaccine launch in less developed/developing countries: <https://pubmed.ncbi.nlm.nih.gov/34435142/>
337. Rituximab-induced acute lympholysis and pancytopenia following vaccination with COVID-19: <https://pubmed.ncbi.nlm.nih.gov/34429981/>
338. Exacerbation of plaque psoriasis after COVID-19 inactivated mRNA and BNT162b2 vaccines: report of two cases: <https://pubmed.ncbi.nlm.nih.gov/34427024/>
339. Vaccine-induced interstitial lung disease: a rare reaction to COVID-19 vaccine: <https://pubmed.ncbi.nlm.nih.gov/34510014/>.
340. Vesiculobullous cutaneous reactions induced by COVID-19 mRNA vaccine: report of four cases and review of the literature: <https://pubmed.ncbi.nlm.nih.gov/34236711/>
341. Vaccine-induced thrombocytopenia with severe headache: <https://pubmed.ncbi.nlm.nih.gov/34525282/>
342. Acute perimyocarditis after the first dose of COVID-19 mRNA vaccine: <https://pubmed.ncbi.nlm.nih.gov/34515024/>
343. Rhabdomyolysis and fasciitis induced by COVID-19 mRNA vaccine: <https://pubmed.ncbi.nlm.nih.gov/34435250/>.
344. Rare cutaneous adverse effects of COVID-19 vaccines: a case series and review of the literature: <https://pubmed.ncbi.nlm.nih.gov/34363637/>
345. Immune thrombocytopenia associated with the Pfizer-BioNTech COVID-19 mRNA vaccine BNT162b2: <https://www.sciencedirect.com/science/article/pii/S2214250921002018>
346. Secondary immune thrombocytopenia putatively attributable to COVID-19 vaccination: <https://casereports.bmj.com/content/14/5/e242220.abstract>.
347. Immune thrombocytopenia following Pfizer-BioNTech BNT162b2 mRNA COVID-19 vaccine: <https://pubmed.ncbi.nlm.nih.gov/34155844/>
348. Newly diagnosed idiopathic thrombocytopenia after COVID-19 vaccine administration: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8176657/>.
349. Idiopathic thrombocytopenic purpura and the Modern Covid-19 vaccine: <https://www.annemergmed.com/article/S0196-0644(21)00122-0/fulltext>.
350. Thrombocytopenia after Pfizer and Moderna SARS vaccination – CoV -2: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8014568/>.
351. Immune thrombocytopenic purpura and acute liver injury after COVID-19 vaccination: <https://casereports.bmj.com/content/14/7/e242678>.
352. Collection of complement-mediated and autoimmune-mediated hematologic conditions after SARS-CoV-2 vaccination: <https://ashpublications.org/bloodadvances/article/5/13/2794/476324/Autoimmune-and-complement-mediated-hematologic>
353. Petechial rash associated with CoronaVac vaccination: first report of cutaneous side effects before phase 3 results: <https://ejhp.bmj.com/content/early/2021/05/23/ejhpharm-2021-002794>
354. COVID-19 vaccines induce severe hemolysis in paroxysmal nocturnal hemoglobinuria: <https://ashpublications.org/blood/article/137/26/3670/475905/COVID-19-vaccines-induce-severe-hemolysis-in>
355. Cerebral venous thrombosis associated with COVID-19 vaccine in Germany: <https://pubmed.ncbi.nlm.nih.gov/34288044/>.
356. Cerebral venous sinus thrombosis after COVID-19 vaccination : Neurological and radiological management: <https://pubmed.ncbi.nlm.nih.gov/34327553/>.
357. Cerebral venous thrombosis and thrombocytopenia after COVID-19 vaccination: <https://pubmed.ncbi.nlm.nih.gov/33878469/>.
358. Cerebral venous sinus thrombosis and thrombocytopenia after COVID-19 vaccination: report of two cases in the United Kingdom: <https://pubmed.ncbi.nlm.nih.gov/33857630/>.
359. Cerebral venous thrombosis induced by SARS-CoV-2 vaccine: <https://pubmed.ncbi.nlm.nih.gov/34090750/>.
360. Carotid artery immune thrombosis induced by adenovirus-vectored COVID-19 vaccine: case report: <https://pubmed.ncbi.nlm.nih.gov/34312301/>.
361. Cerebral venous sinus thrombosis associated with vaccine-induced thrombotic thrombocytopenia: <https://pubmed.ncbi.nlm.nih.gov/34333995/>
362. The roles of platelets in COVID-19-associated coagulopathy and vaccine-induced immune-immune thrombotic thrombocytopenia: <https://pubmed.ncbi.nlm.nih.gov/34455073/>
363. Cerebral venous thrombosis after the BNT162b2 mRNA SARS-CoV-2 vaccine: <https://pubmed.ncbi.nlm.nih.gov/34111775/>.
364. Cerebral venous thrombosis after COVID-19 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34045111/>
365. Lethal cerebral venous sinus thrombosis after COVID-19 vaccination: <https://pubmed.ncbi.nlm.nih.gov/33983464/>
366. Cerebral venous sinus thrombosis in the U.S. population, After SARS-CoV-2 vaccination with adenovirus and after COVID-19: <https://pubmed.ncbi.nlm.nih.gov/34116145/>
367. Cerebral venous thrombosis after COVID-19 vaccination: is the risk of thrombosis increased by intravascular administration of the vaccine: <https://pubmed.ncbi.nlm.nih.gov/34286453/>.
368. Central venous sinus thrombosis with subarachnoid hemorrhage after COVID-19 mRNA vaccination: are these reports merely coincidental: <https://pubmed.ncbi.nlm.nih.gov/34478433/>
369. Cerebral venous sinus thrombosis after ChAdOx1 nCov-19 vaccination with a misleading first brain MRI: <https://pubmed.ncbi.nlm.nih.gov/34244448/>
370. Early results of bivalirudin treatment for thrombotic thrombocytopenia and cerebral venous sinus thrombosis after vaccination with Ad26.COV2.S: <https://pubmed.ncbi.nlm.nih.gov/34226070/>
371. Cerebral venous sinus thrombosis associated with post-vaccination thrombocytopenia by COVID-19: <https://pubmed.ncbi.nlm.nih.gov/33845870/>.
372. Cerebral venous sinus thrombosis 2 weeks after the first dose of SARS-CoV-2 mRNA vaccine: <https://pubmed.ncbi.nlm.nih.gov/34101024/>.
373. Vaccine-induced immune thrombotic thrombocytopenia causing a severe form of cerebral venous thrombosis with a high mortality rate: a case series: <https://pubmed.ncbi.nlm.nih.gov/34393988/>.
374. Adenovirus interactions with platelets and coagulation and vaccine-associated autoimmune thrombocytopenia thrombosis syndrome: <https://pubmed.ncbi.nlm.nih.gov/34407607/>.
375. Headache attributed to COVID-19 (SARS-CoV-2 coronavirus) vaccination with the ChAdOx1 nCoV-19 (AZD1222) vaccine: a multicenter observational cohort study: <https://pubmed.ncbi.nlm.nih.gov/34313952/>
376. Adverse effects reported after COVID-19 vaccination in a tertiary care hospital, focus on cerebral venous sinus thrombosis (CVST): <https://pubmed.ncbi.nlm.nih.gov/34092166/>
377. Cerebral venous sinus thrombosis following vaccination against SARS-CoV-2: an analysis of cases reported to the European Medicines Agency: <https://pubmed.ncbi.nlm.nih.gov/34293217/>
378. A rare case of a middle-age Asian male with cerebral venous thrombosis after COVID-19 AstraZeneca vaccination: <https://pubmed.ncbi.nlm.nih.gov/34274191/>
379. Cerebral venous sinus thrombosis negative for anti-PF4 antibody without thrombocytopenia after immunization with COVID-19 vaccine in a non-comorbid elderly Indian male treated with conventional heparin-warfarin-based anticoagulation: <https://pubmed.ncbi.nlm.nih.gov/34186376/>
380. Arterial events, venous thromboembolism, thrombocytopenia and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population-based cohort study: <https://pubmed.ncbi.nlm.nih.gov/33952445/>
381. Procoagulant microparticles: a possible link between vaccine-induced immune thrombocytopenia (VITT) and cerebral sinus venous thrombosis: <https://pubmed.ncbi.nlm.nih.gov/34129181/>
382. S. case reports of cerebral venous sinus thrombosis with thrombocytopenia after vaccination with Ad26.COV2.S, March 2-April 21, 2021: <https://pubmed.ncbi.nlm.nih.gov/33929487/>.
383. Malignant cerebral infarction after vaccination with ChAdOx1 nCov-19: a catastrophic variant of vaccine-induced immune-mediated thrombotic thrombocytopenia: <https://pubmed.ncbi.nlm.nih.gov/34341358/>
384. Acute ischemic stroke revealing immune thrombotic thrombocytopenia induced by ChAdOx1 nCov-19 vaccine: impact on recanalization strategy: <https://pubmed.ncbi.nlm.nih.gov/34175640/>
385. Vaccine-induced immune thrombotic immune thrombocytopenia (VITT): a new clinicopathologic entity with heterogeneous clinical presentations: <https://pubmed.ncbi.nlm.nih.gov/34159588/>.
386. Imaging and hematologic findings in thrombosis and thrombocytopenia after vaccination with ChAdOx1 nCoV-19 (AstraZeneca): <https://pubmed.ncbi.nlm.nih.gov/34402666/>
387. Autoimmunity roots of thrombotic events after vaccination with COVID-19: <https://pubmed.ncbi.nlm.nih.gov/34508917/>
388. Cerebral venous sinus thrombosis after vaccination: the UK experience: <https://pubmed.ncbi.nlm.nih.gov/34370974/>
389. Massive cerebral venous thrombosis and venous basin infarction as late complications of COVID-19: a case report: <https://pubmed.ncbi.nlm.nih.gov/34373991/>
390. Australian and New Zealand approach to the diagnosis and treatment of vaccine-induced immune thrombosis and immune thrombocytopenia: <https://pubmed.ncbi.nlm.nih.gov/34490632/>
391. An observational study to identify the prevalence of thrombocytopenia and anti-PF4 / polyanion antibodies in Norwegian health care workers after COVID-19 vaccination: <https://pubmed.ncbi.nlm.nih.gov/33909350/>
392. Acute transverse myelitis (ATM): clinical review of 43 patients with COVID-19-associated ATM and 3 serious adverse events of post-vaccination ATM with ChAdOx1 nCoV-19 (AZD1222) vaccine: <https://pubmed.ncbi.nlm.nih.gov/33981305/>.
393. A case of acute demyelinating polyradiculoneuropathy with bilateral facial palsy after ChAdOx1 nCoV-19 vaccine:. <https://pubmed.ncbi.nlm.nih.gov/34272622/>
394. Thrombocytopenia with acute ischemic stroke and hemorrhage in a patient recently vaccinated with an adenoviral vector-based COVID-19 vaccine:. <https://pubmed.ncbi.nlm.nih.gov/33877737/>
395. Predicted and observed incidence of thromboembolic events among Koreans vaccinated with the ChAdOx1 nCoV-19 vaccine: <https://pubmed.ncbi.nlm.nih.gov/34254476/>
396. First dose of ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic, and hemorrhagic events in Scotland: <https://pubmed.ncbi.nlm.nih.gov/34108714/>
397. ChAdOx1 nCoV-19 vaccine-associated thrombocytopenia: three cases of immune thrombocytopenia after 107,720 doses of ChAdOx1 vaccination in Thailand: <https://pubmed.ncbi.nlm.nih.gov/34483267/>.
398. Pulmonary embolism, transient ischemic attack, and thrombocytopenia after Johnson & Johnson COVID-19 vaccine: <https://pubmed.ncbi.nlm.nih.gov/34261635/>
399. Neurosurgical considerations with respect to decompressive craniectomy for intracerebral hemorrhage after SARS-CoV-2 vaccination in vaccine-induced thrombotic thrombocytopenia-VITT: <https://pubmed.ncbi.nlm.nih.gov/34202817/>
400. Large hemorrhagic stroke after vaccination against ChAdOx1 nCoV-19: a case report: <https://pubmed.ncbi.nlm.nih.gov/34273119/>
401. Polyarthralgia and myalgia syndrome after vaccination with ChAdOx1 nCOV-19: <https://pubmed.ncbi.nlm.nih.gov/34463066/>
402. A rare case of thrombosis and thrombocytopenia of the superior ophthalmic vein after ChAdOx1 nCoV-19 vaccination against SARS-CoV-2: <https://pubmed.ncbi.nlm.nih.gov/34276917/>
403. Thrombosis and severe acute respiratory syndrome Coronavirus 2 vaccines: vaccine-induced immune thrombotic thrombocytopenia: <https://pubmed.ncbi.nlm.nih.gov/34237213/>.
404. Renal vein thrombosis and pulmonary embolism secondary to vaccine-induced thrombotic immune thrombocytopenia (VITT): <https://pubmed.ncbi.nlm.nih.gov/34268278/>.
405. Limb ischemia and pulmonary artery thrombosis after ChAdOx1 nCoV-19 vaccine (Oxford-AstraZeneca): a case of vaccine-induced immune thrombotic thrombocytopenia: <https://pubmed.ncbi.nlm.nih.gov/33990339/>.
406. Association between ChAdOx1 nCoV-19 vaccination and bleeding episodes: large population-based cohort study: <https://pubmed.ncbi.nlm.nih.gov/34479760/>.
407. Secondary thrombocytopenia after SARS-CoV-2 vaccination: case report of haemorrhage and hematoma after minor oral surgery: <https://pubmed.ncbi.nlm.nih.gov/34314875/>.
408. Venous thromboembolism and mild thrombocytopenia after vaccination with ChAdOx1 nCoV-19: <https://pubmed.ncbi.nlm.nih.gov/34384129/>
409. Fatal exacerbation of ChadOx1-nCoV-19-induced thrombotic thrombocytopenia syndrome after successful initial therapy with intravenous immunoglobulins: a rationale for monitoring immunoglobulin G levels: <https://pubmed.ncbi.nlm.nih.gov/34382387/>
410. A case of ANCA-associated vasculitis after AZD1222 (Oxford-AstraZeneca) SARS-CoV-2 vaccination: victim or causality?: <https://pubmed.ncbi.nlm.nih.gov/34416184/>.
411. Intracerebral hemorrhage associated with vaccine-induced thrombotic thrombocytopenia after ChAdOx1 nCOVID-19 vaccination in a pregnant woman: <https://pubmed.ncbi.nlm.nih.gov/34261297/>
412. Massive cerebral venous thrombosis due to vaccine-induced immune thrombotic thrombocytopenia: <https://pubmed.ncbi.nlm.nih.gov/34261296/>
413. Nephrotic syndrome after ChAdOx1 nCoV-19 vaccine against SARScoV-2: <https://pubmed.ncbi.nlm.nih.gov/34250318/>.
414. A case of vaccine-induced immune-immune thrombotic thrombocytopenia with massive arteriovenous thrombosis: <https://pubmed.ncbi.nlm.nih.gov/34059191/>
415. Cutaneous thrombosis associated with cutaneous necrosis following Oxford-AstraZeneca COVID-19 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34189756/>
416. Thrombocytopenia in an adolescent with sickle cell anemia after COVID-19 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34331506/>
417. Vaccine-induced thrombocytopenia with severe headache: <https://pubmed.ncbi.nlm.nih.gov/34525282/>
418. Myocarditis associated with SARS-CoV-2 mRNA vaccination in children aged 12 to 17 years: stratified analysis of a national database: <https://www.medrxiv.org/content/10.1101/2021.08.30.21262866v1>
419. COVID-19 mRNA vaccination and development of CMR-confirmed myopericarditis: <https://www.medrxiv.org/content/10.1101/2021.09.13.21262182v1.full?s=09>.
420. Severe autoimmune hemolytic anemia after receipt of SARS-CoV-2 mRNA vaccine: <https://onlinelibrary.wiley.com/doi/10.1111/trf.16672>
421. Intravenous injection of coronavirus disease 2019 (COVID-19) mRNA vaccine can induce acute myopericarditis in a mouse model: <https://t.co/j0IEM8cMXI>
422. A report of myocarditis adverse events in the U.S. Vaccine Adverse Event Reporting System. (VAERS) in association with COVID-19 injectable biologics: <https://pubmed.ncbi.nlm.nih.gov/34601006/>
423. This study concludes that: “The vaccine was associated with an excess risk of myocarditis (1 to 5 events per 100,000 persons). The risk of this potentially serious adverse event and of many other serious adverse events increased substantially after SARS-CoV-2 infection”: <https://www.nejm.org/doi/full/10.1056/NEJMoa2110475>
424. Bilateral uveitis after inoculation with COVID-19 vaccine: a case report: <https://www.sciencedirect.com/science/article/pii/S1201971221007797>
425. Myocarditis associated with SARS-CoV-2 mRNA vaccination in children aged 12 to 17 years: stratified analysis of a national database: <https://www.medrxiv.org/content/10.1101/2021.08.30.21262866v1>.
426. Immune-mediated hepatitis with the Moderna vaccine is no longer a coincidence but confirmed: <https://www.sciencedirect.com/science/article/pii/S0168827821020936>
427. Extensive investigations revealed consistent pathophysiologic alterations after vaccination with COVID-19 vaccines: <https://www.nature.com/articles/s41421-021-00329-3>
428. Lobar hemorrhage with ventricular rupture shortly after the first dose of an mRNA-based SARS-CoV-2 vaccine: <https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8553377/>
429. Mrna COVID vaccines dramatically increase endothelial inflammatory markers and risk of Acute Coronary Syndrome as measured by PULS cardiac testing: a caution: <https://www.ahajournals.org/doi/10.1161/circ.144.suppl_1.10712>
430. ChAdOx1 interacts with CAR and PF4 with implications for thrombosis with thrombocytopenia syndrome:https://www.science.org/doi/10.1126/sciadv.abl8213
431. Lethal vaccine-induced immune thrombotic immune thrombocytopenia (VITT) following announcement 26.COV2.S: first documented case outside the U.S.: <https://pubmed.ncbi.nlm.nih.gov/34626338/>
432. A prothrombotic thrombocytopenic disorder resembling heparin-induced thrombocytopenia after coronavirus-19 vaccination: [https://europepmc.org/article/PPR/PPR304469 435](https://europepmc.org/article/PPR/PPR304469%20435).
433. VITT (vaccine-induced immune thrombotic thrombocytopenia) after vaccination with ChAdOx1 nCoV-19: <https://pubmed.ncbi.nlm.nih.gov/34731555/>
434. Vaccine-induced immune thrombotic thrombocytopenia (VITT): a new clinicopathologic entity with heterogeneous clinical presentations: <https://pubmed.ncbi.nlm.nih.gov/34159588/>
435. Treatment of acute ischemic stroke associated with ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia: <https://pubmed.ncbi.nlm.nih.gov/34461442/>
436. Spectrum of neurological complications after COVID-19 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34719776/>.
437. Cerebral venous sinus thrombosis after vaccination: the UK experience: <https://pubmed.ncbi.nlm.nih.gov/34370974/>
438. Cerebral venous vein/venous sinus thrombosis with thrombocytopenia syndrome after COVID-19 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34373413/>
439. Portal vein thrombosis due to vaccine-induced immune thrombotic immune thrombocytopenia (VITT) after Covid vaccination with ChAdOx1 nCoV-19: <https://pubmed.ncbi.nlm.nih.gov/34598301/>
440. Hematuria, a generalized petechial rash and headaches after Oxford AstraZeneca ChAdOx1 nCoV-19 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34620638/>
441. Myocardial infarction and azygos vein thrombosis after vaccination with ChAdOx1 nCoV-19 in a hemodialysis patient: <https://pubmed.ncbi.nlm.nih.gov/34650896/>
442. Takotsubo (stress) cardiomyopathy after vaccination with ChAdOx1 nCoV-19: <https://pubmed.ncbi.nlm.nih.gov/34625447/>
443. Humoral response induced by Prime-Boost vaccination with ChAdOx1 nCoV-19 and BNT162b2 mRNA vaccines in a patient with multiple sclerosis treated with teriflunomide: <https://pubmed.ncbi.nlm.nih.gov/34696248/>
444. Guillain-Barré syndrome after ChAdOx1 nCoV-19 COVID-19 vaccination: a case series: <https://pubmed.ncbi.nlm.nih.gov/34548920/>
445. Refractory vaccine-induced immune thrombotic thrombocytopenia (VITT) treated with delayed therapeutic plasma exchange (TPE): <https://pubmed.ncbi.nlm.nih.gov/34672380/>.
446. Rare case of COVID-19 vaccine-associated intracranial hemorrhage with venous sinus thrombosis: <https://pubmed.ncbi.nlm.nih.gov/34556531/>.
447. Delayed headache after COVID-19 vaccination: a warning sign for vaccine-induced cerebral venous thrombosis: <https://pubmed.ncbi.nlm.nih.gov/34535076/>.
448. Clinical features of vaccine-induced thrombocytopenia and immune thrombosis: <https://pubmed.ncbi.nlm.nih.gov/34379914/>.
449. Predictors of mortality in thrombotic thrombocytopenia after adenoviral COVID-19 vaccination: the FAPIC score: <https://pubmed.ncbi.nlm.nih.gov/34545400/>
450. Ischemic stroke as a presenting feature of immune thrombotic thrombocytopenia induced by ChAdOx1-nCoV-19 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34035134/>
451. In-hospital observational study of neurological disorders in patients recently vaccinated with COVID-19 mRNA vaccines: <https://pubmed.ncbi.nlm.nih.gov/34688190/>
452. Endovascular treatment for vaccine-induced cerebral venous sinus thrombosis and thrombocytopenia after vaccination with ChAdOx1 nCoV-19: report of three cases: <https://pubmed.ncbi.nlm.nih.gov/34782400/>
453. Cardiovascular, neurological, and pulmonary events after vaccination with BNT162b2, ChAdOx1 nCoV-19, and Ad26.COV2.S vaccines: an analysis of European data: <https://pubmed.ncbi.nlm.nih.gov/34710832/>
454. Cerebral venous thrombosis developing after vaccination. COVID-19: VITT, VATT, TTS and more: <https://pubmed.ncbi.nlm.nih.gov/34695859/>
455. Cerebral venous thrombosis and myeloproliferative neoplasms: a three-center study of 74 consecutive cases: <https://pubmed.ncbi.nlm.nih.gov/34453762/>.
456. Possible triggers of thrombocytopenia and/or hemorrhage by BNT162b2 vaccine, Pfizer-BioNTech: <https://pubmed.ncbi.nlm.nih.gov/34660652/>.
457. Multiple sites of arterial thrombosis in a 35-year-old patient after vaccination with ChAdOx1 (AstraZeneca), which required emergency femoral and carotid surgical thrombectomy: <https://pubmed.ncbi.nlm.nih.gov/34644642/>
458. Case series of vaccine-induced thrombotic thrombocytopenia in a London teaching hospital: <https://pubmed.ncbi.nlm.nih.gov/34694650/>
459. Neuro-ophthalmic complications with thrombocytopenia and thrombosis induced by ChAdOx1 nCoV-19 vaccine: <https://pubmed.ncbi.nlm.nih.gov/34726934/>
460. Thrombotic events after COVID-19 vaccination in over 50 years of age: results of a population-based study in Italy: <https://pubmed.ncbi.nlm.nih.gov/34835237/>
461. Intracerebral hemorrhage associated with vaccine-induced thrombotic thrombocytopenia after ChAdOx1 nCOVID-19 vaccination in a pregnant woman: <https://pubmed.ncbi.nlm.nih.gov/34261297/>
462. Age- and sex-specific incidence of cerebral venous sinus thrombosis associated with Ad26.COV2.S COVID-19 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34724036/>.
463. Genital necrosis with cutaneous thrombosis following vaccination with COVID-19 mRNA: <https://pubmed.ncbi.nlm.nih.gov/34839563/>
464. Cerebral venous sinus thrombosis after mRNA-based COVID-19 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34783932/>.
465. COVID-19 vaccine-induced immune thrombosis with thrombocytopenia thrombosis (VITT) and shades of gray in thrombus formation: <https://pubmed.ncbi.nlm.nih.gov/34624910/>
466. Inflammatory myositis after vaccination with ChAdOx1: <https://pubmed.ncbi.nlm.nih.gov/34585145/>
467. Acute ST-segment elevation myocardial infarction secondary to vaccine-induced immune thrombosis with thrombocytopenia (VITT): <https://pubmed.ncbi.nlm.nih.gov/34580132/>.
468. A rare case of COVID-19 vaccine-induced thrombotic thrombocytopenia (VITT) affecting the venosplanchnic and pulmonary arterial circulation from a UK district general hospital: <https://pubmed.ncbi.nlm.nih.gov/34535492/>
469. COVID-19 vaccine-induced thrombotic thrombocytopenia: a case series: <https://pubmed.ncbi.nlm.nih.gov/34527501/>
470. Thrombosis with thrombocytopenia syndrome (TTS) after vaccination with AstraZeneca ChAdOx1 nCoV-19 (AZD1222) COVID-19: a risk-benefit analysis for persons <60% risk-benefit analysis for people <60 years in Australia: <https://pubmed.ncbi.nlm.nih.gov/34272095/>
471. Immune thrombocytopenia after immunization with Vaxzevria ChadOx1-S vaccine (AstraZeneca), Victoria, Australia: <https://pubmed.ncbi.nlm.nih.gov/34756770/>
472. Characteristics and outcomes of patients with cerebral venous sinus thrombosis in thrombotic immune thrombocytopenia induced by SARS-CoV-2 vaccine: <https://jamanetwork.com/journals/jamaneurology/fullarticle/2784622>
473. Case study of thrombosis and thrombocytopenia syndrome after administration of the AstraZeneca COVID-19 vaccine: <https://pubmed.ncbi.nlm.nih.gov/34781321/>
474. Thrombosis with Thrombocytopenia Syndrome Associated with COVID-19 Vaccines: <https://pubmed.ncbi.nlm.nih.gov/34062319/>
475. Cerebral venous sinus thrombosis following vaccination with ChAdOx1: the first case of definite thrombosis with thrombocytopenia syndrome in India: <https://pubmed.ncbi.nlm.nih.gov/34706921/>
476. COVID-19 vaccine-associated thrombosis with thrombocytopenia syndrome (TTS): systematic review and post hoc analysis: <https://pubmed.ncbi.nlm.nih.gov/34698582/>.
477. Case report of immune thrombocytopenia after vaccination with ChAdOx1 nCoV-19: <https://pubmed.ncbi.nlm.nih.gov/34751013/>.
478. Acute transverse myelitis after COVID-19 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34684047/>.
479. Concerns for adverse effects of thrombocytopenia and thrombosis after adenovirus-vectored COVID-19 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34541935/>
480. Major hemorrhagic stroke after ChAdOx1 nCoV-19 vaccination: a case report: <https://pubmed.ncbi.nlm.nih.gov/34273119/>
481. Cerebral venous sinus thrombosis after COVID-19 vaccination: neurologic and radiologic management: <https://pubmed.ncbi.nlm.nih.gov/34327553/>.
482. Thrombocytopenia with acute ischemic stroke and hemorrhage in a patient recently vaccinated with an adenoviral vector-based COVID-19 vaccine: <https://pubmed.ncbi.nlm.nih.gov/33877737/>
483. Intracerebral hemorrhage and thrombocytopenia after AstraZeneca COVID-19 vaccine: clinical and diagnostic challenges of vaccine-induced thrombotic thrombocytopenia: <https://pubmed.ncbi.nlm.nih.gov/34646685/>
484. Minimal change disease with severe acute kidney injury after Oxford-AstraZeneca COVID-19 vaccine: case report: <https://pubmed.ncbi.nlm.nih.gov/34242687/>.
485. Case report: cerebral sinus vein thrombosis in two patients with AstraZeneca SARS-CoV-2 vaccine: <https://pubmed.ncbi.nlm.nih.gov/34609603/>
486. Case report: Pityriasis rosea-like rash after vaccination with COVID-19: <https://pubmed.ncbi.nlm.nih.gov/34557507/>
487. Extensive longitudinal transverse myelitis after ChAdOx1 nCOV-19 vaccine: case report: <https://pubmed.ncbi.nlm.nih.gov/34641797/>.
488. Acute eosinophilic pneumonia associated with anti-COVID-19 vaccine AZD1222: <https://pubmed.ncbi.nlm.nih.gov/34812326/>.
489. Thrombocytopenia, including immune thrombocytopenia after receiving COVID-19 mRNA vaccines reported to the Vaccine Adverse Event Reporting System (VAERS): <https://pubmed.ncbi.nlm.nih.gov/34006408/>
490. A case of ANCA-associated vasculitis after AZD1222 (Oxford-AstraZeneca) SARS-CoV-2 vaccination: victim or causality?: <https://pubmed.ncbi.nlm.nih.gov/34416184/>
491. Vaccine-induced immune thrombosis and thrombocytopenia syndrome after adenovirus-vectored severe acute respiratory syndrome coronavirus 2 vaccination: a new hypothesis on mechanisms and implications for future vaccine development: <https://pubmed.ncbi.nlm.nih.gov/34664303/>.
492. Thrombosis in peripheral artery disease and thrombotic thrombocytopenia following adenoviral COVID-19 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34649281/>.
493. Newly diagnosed immune thrombocytopenia in a pregnant patient after coronavirus disease 2019 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34420249/>
494. Cerebral venous sinus thrombosis and thrombotic events after vector-based COVID-19 vaccines: systematic review and meta-analysis: <https://pubmed.ncbi.nlm.nih.gov/34610990/>.
495. Sweet’s syndrome after Oxford-AstraZeneca COVID-19 vaccine (AZD1222) in an elderly woman: <https://pubmed.ncbi.nlm.nih.gov/34590397/>
496. Sudden sensorineural hearing loss after COVID-19 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34670143/>.
497. Prevalence of serious adverse events among health care professionals after receiving the first dose of ChAdOx1 nCoV-19 coronavirus vaccine (Covishield) in Togo, March 2021: <https://pubmed.ncbi.nlm.nih.gov/34819146/>.
498. Acute hemichorea-hemibalismus after COVID-19 (AZD1222) vaccination: <https://pubmed.ncbi.nlm.nih.gov/34581453/>
499. Recurrence of alopecia areata after covid-19 vaccination: a report of three cases in Italy: <https://pubmed.ncbi.nlm.nih.gov/34741583/>
500. Shingles-like skin lesion after vaccination with AstraZeneca for COVID-19: a case report: <https://pubmed.ncbi.nlm.nih.gov/34631069/>
501. Thrombosis after COVID-19 vaccination: possible link to ACE pathways: <https://pubmed.ncbi.nlm.nih.gov/34479129/>
502. Thrombocytopenia in an adolescent with sickle cell anemia after COVID-19 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34331506/>
503. Leukocytoclastic vasculitis as a cutaneous manifestation of ChAdOx1 corona virus vaccine nCoV-19 (recombinant): <https://pubmed.ncbi.nlm.nih.gov/34546608/>
504. Abdominal pain and bilateral adrenal hemorrhage from immune thrombotic thrombocytopenia induced by COVID-19 vaccine: <https://pubmed.ncbi.nlm.nih.gov/34546343/>
505. Longitudinally extensive cervical myelitis after vaccination with inactivated virus based COVID-19 vaccine: <https://pubmed.ncbi.nlm.nih.gov/34849183/>
506. Induction of cutaneous leukocytoclastic vasculitis after ChAdOx1 nCoV-19 vaccine: <https://pubmed.ncbi.nlm.nih.gov/34853744/>.
507. A case of toxic epidermal necrolysis after vaccination with ChAdOx1 nCoV-19 (AZD1222): <https://pubmed.ncbi.nlm.nih.gov/34751429/>.
508. Ocular adverse events following COVID-19 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34559576/>
509. Depression after ChAdOx1-S / nCoV-19 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34608345/>.
510. Venous thromboembolism and mild thrombocytopenia after ChAdOx1 nCoV-19 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34384129/>.
511. Recurrent ANCA-associated vasculitis after Oxford AstraZeneca ChAdOx1-S COVID-19 vaccination: a case series of two patients: <https://pubmed.ncbi.nlm.nih.gov/34755433/>
512. Major artery thrombosis and vaccination against ChAdOx1 nCov-19: <https://pubmed.ncbi.nlm.nih.gov/34839830/>
513. Rare case of contralateral supraclavicular lymphadenopathy after vaccination with COVID-19: computed tomography and ultrasound findings: <https://pubmed.ncbi.nlm.nih.gov/34667486/>
514. Cutaneous lymphocytic vasculitis after administration of the second dose of AZD1222 (Oxford-AstraZeneca) Severe acute respiratory syndrome Coronavirus 2 vaccine: chance or causality: <https://pubmed.ncbi.nlm.nih.gov/34726187/>.
515. Pancreas allograft rejection after ChAdOx1 nCoV-19 vaccine: <https://pubmed.ncbi.nlm.nih.gov/34781027/>
516. Understanding the risk of thrombosis with thrombocytopenia syndrome following Ad26.COV2.S vaccination: <https://pubmed.ncbi.nlm.nih.gov/34595694/>
517. Cutaneous adverse reactions of 35,229 doses of COVID-19 Sinovac and AstraZeneca vaccine COVID-19: a prospective cohort study in health care workers: <https://pubmed.ncbi.nlm.nih.gov/34661934/>
518. Comments on thrombosis after vaccination: spike protein leader sequence could be responsible for thrombosis and antibody-mediated thrombocytopenia: <https://pubmed.ncbi.nlm.nih.gov/34788138>
519. Eosinophilic dermatosis after AstraZeneca COVID-19 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34753210/>.
520. Severe immune thrombocytopenia following COVID-19 vaccination: report of four cases and review of the literature: <https://pubmed.ncbi.nlm.nih.gov/34653943/>.
521. Relapse of immune thrombocytopenia after COVID-19 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34591991/>
522. Thrombosis in pre- and post-vaccination phase of COVID-19; <https://pubmed.ncbi.nlm.nih.gov/34650382/>
523. A look at the role of postmortem immunohistochemistry in understanding the inflammatory pathophysiology of COVID-19 disease and vaccine-related thrombotic adverse events: a narrative review: <https://pubmed.ncbi.nlm.nih.gov/34769454/>
524. COVID-19 vaccine in patients with hypercoagulability disorders: a clinical perspective: <https://pubmed.ncbi.nlm.nih.gov/34786893/>
525. Vaccine-associated thrombocytopenia and thrombosis: venous endotheliopathy leading to combined venous micro-macrothrombosis: <https://pubmed.ncbi.nlm.nih.gov/34833382/>
526. Thrombosis and thrombocytopenia syndrome causing isolated symptomatic carotid occlusion after COVID-19 Ad26.COV2.S vaccine (Janssen): <https://pubmed.ncbi.nlm.nih.gov/34670287/>
527. An unusual presentation of acute deep vein thrombosis after Modern COVID-19 vaccine: case report: <https://pubmed.ncbi.nlm.nih.gov/34790811/>
528. Immediate high-dose intravenous immunoglobulins followed by direct treatment with thrombin inhibitors is crucial for survival in vaccine-induced immune thrombotic thrombocytopenia Sars-Covid-19-vector adenoviral VITT with venous thrombosis of the cerebral sinus and portal vein: <https://pubmed.ncbi.nlm.nih.gov/34023956/>.
529. Thrombosis formation after COVID-19 vaccination immunologic aspects: review article: <https://pubmed.ncbi.nlm.nih.gov/34629931/>
530. Imaging and hematologic findings in thrombosis and thrombocytopenia after vaccination with ChAdOx1 nCoV-19 (AstraZeneca): <https://pubmed.ncbi.nlm.nih.gov/34402666/>
531. Spectrum of neuroimaging findings in post-CoVID-19 vaccination: a case series and review of the literature: <https://pubmed.ncbi.nlm.nih.gov/34842783/>
532. Cerebral venous sinus thrombosis, pulmonary embolism, and thrombocytopenia after COVID-19 vaccination in a Taiwanese man: a case report and review of the literature: <https://pubmed.ncbi.nlm.nih.gov/34630307/>
533. Fatal cerebral venous sinus thrombosis after COVID-19 vaccination: <https://pubmed.ncbi.nlm.nih.gov/33983464/>
534. Autoimmune roots of thrombotic events after COVID-19 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34508917/>.
535. New portal vein thrombosis in cirrhosis: is thrombophilia exacerbated by vaccine or COVID-19: <https://www.jcehepatology.com/article/S0973-6883(21)00545-4/fulltext>.
536. Images of immune thrombotic thrombocytopenia induced by Oxford / AstraZeneca® COVID-19 vaccine: <https://pubmed.ncbi.nlm.nih.gov/33962903/>.
537. Cerebral venous sinus thrombosis after vaccination with COVID-19 mRNA of BNT162b2: <https://pubmed.ncbi.nlm.nih.gov/34796065/>.
538. Increased risk of urticaria/angioedema after BNT162b2 mRNA COVID-19 vaccination in health care workers taking ACE inhibitors: <https://pubmed.ncbi.nlm.nih.gov/34579248/>
539. A case of unusual mild clinical presentation of COVID-19 vaccine-induced immune thrombotic thrombocytopenia with splanchnic vein thrombosis: <https://pubmed.ncbi.nlm.nih.gov/34843991/>
540. Cerebral venous sinus thrombosis following vaccination with Pfizer-BioNTech COVID-19 (BNT162b2): <https://pubmed.ncbi.nlm.nih.gov/34595867/>
541. A case of idiopathic thrombocytopenic purpura after a booster dose of COVID-19 BNT162b2 vaccine (Pfizer-Biontech): <https://pubmed.ncbi.nlm.nih.gov/34820240/>
542. Vaccine-induced immune thrombotic immune thrombocytopenia (VITT): targeting pathologic mechanisms with Bruton’s tyrosine kinase inhibitors: <https://pubmed.ncbi.nlm.nih.gov/33851389/>
543. Thrombotic thrombocytopenic purpura after vaccination with Ad26.COV2-S: <https://pubmed.ncbi.nlm.nih.gov/33980419/>
544. Thromboembolic events in younger females exposed to Pfizer-BioNTech or Moderna COVID-19 vaccines: <https://pubmed.ncbi.nlm.nih.gov/34264151/>
545. Potential risk of thrombotic events after COVID-19 vaccination with Oxford-AstraZeneca in women receiving estrogen: <https://pubmed.ncbi.nlm.nih.gov/34734086/>
546. Thrombosis after adenovirus-vectored COVID-19 vaccination: a concern for underlying disease: <https://pubmed.ncbi.nlm.nih.gov/34755555/>
547. Adenovirus interactions with platelets and coagulation and vaccine-induced immune thrombotic thrombocytopenia syndrome: <https://pubmed.ncbi.nlm.nih.gov/34407607/>
548. Thrombotic thrombocytopenic purpura: a new threat after COVID bnt162b2 vaccine: <https://pubmed.ncbi.nlm.nih.gov/34264514/>.
549. Unusual site of deep vein thrombosis after vaccination against coronavirus mRNA-2019 coronavirus disease (COVID-19): <https://pubmed.ncbi.nlm.nih.gov/34840204/>
550. Neurological side effects of SARS-CoV-2 vaccines: <https://pubmed.ncbi.nlm.nih.gov/34750810/>
551. Coagulopathies after SARS-CoV-2 vaccination may derive from a combined effect of SARS-CoV-2 spike protein and adenovirus vector-activated signaling pathways: <https://pubmed.ncbi.nlm.nih.gov/34639132/>
552. Isolated pulmonary embolism after COVID vaccination: 2 case reports and a review of acute pulmonary embolism complications and follow-up: <https://pubmed.ncbi.nlm.nih.gov/34804412/>
553. Central retinal vein occlusion after vaccination with SARS-CoV-2 mRNA: case report: <https://pubmed.ncbi.nlm.nih.gov/34571653/>.
554. Complicated case report of long-term vaccine-induced thrombotic immune thrombocytopenia A: <https://pubmed.ncbi.nlm.nih.gov/34835275/>.
555. Deep venous thrombosis after vaccination with Ad26.COV2.S in adult males: <https://pubmed.ncbi.nlm.nih.gov/34659839/>.
556. Neurological autoimmune diseases after SARS-CoV-2 vaccination: a case series: <https://pubmed.ncbi.nlm.nih.gov/34668274/>.
557. Severe autoimmune hemolytic autoimmune anemia after receiving SARS-CoV-2 mRNA vaccine: <https://pubmed.ncbi.nlm.nih.gov/34549821/>
558. Occurrence of COVID-19 variants among recipients of ChAdOx1 nCoV-19 vaccine (recombinant): <https://pubmed.ncbi.nlm.nih.gov/34528522/>
559. Prevalence of thrombocytopenia, anti-platelet factor 4 antibodies, and elevated D-dimer in Thais after vaccination with ChAdOx1 nCoV-19: <https://pubmed.ncbi.nlm.nih.gov/34568726/>
560. Epidemiology of acute myocarditis/pericarditis in Hong Kong adolescents after co-vaccination: [https://academic.oup.com/cid/advance-article-abstract/doi/10.1093/cid/ciab989/644 5179](https://academic.oup.com/cid/advance-article-abstract/doi/10.1093/cid/ciab989/644%205179).
561. Myocarditis after 2019 coronavirus disease mRNA vaccine: a case series and determination of incidence rate: <https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciab926/6420408>
562. Myocarditis and pericarditis after COVID-19 vaccination: inequalities in age and vaccine types: <https://www.mdpi.com/2075-4426/11/11/1106>
563. Epidemiology and clinical features of myocarditis/pericarditis before the introduction of COVID-19 mRNA vaccine in Korean children: a multicenter study: <https://pubmed.ncbi.nlm.nih.gov/34402230/>
564. Shedding light on post-vaccination myocarditis and pericarditis in COVID-19 and non-COVID-19 vaccine recipients: <https://pubmed.ncbi.nlm.nih.gov/34696294/>
565. Myocarditis Following mRNA COVID-19 Vaccine: [https://journals.lww.com/pec-online/Abstract/2021/11000/Myocarditis\_Following\_ mRNA\_COVID\_19\_Vaccine.9.aspx](https://journals.lww.com/pec-online/Abstract/2021/11000/Myocarditis_Following_%20mRNA_COVID_19_Vaccine.9.aspx).
566. Myocarditis following BNT162b2 mRNA Covid-19 mRNA vaccine in Israel: <https://pubmed.ncbi.nlm.nih.gov/34614328/>.
567. Myocarditis, pericarditis, and cardiomyopathy following COVID-19 vaccination: <https://www.heartlungcirc.org/article/S1443-9506(21)01156-2/fulltext>
568. Myocarditis and other cardiovascular complications of COVID-19 mRNA-based COVID-19 vaccines: <https://pubmed.ncbi.nlm.nih.gov/34277198/>
569. Possible Association Between COVID-19 Vaccine and Myocarditis: Clinical and CMR Findings: <https://pubmed.ncbi.nlm.nih.gov/34246586/>
570. Hypersensitivity Myocarditis and COVID-19 Vaccines: <https://pubmed.ncbi.nlm.nih.gov/34856634/>.
571. Severe myocarditis associated with COVID-19 vaccine: zebra or unicorn?: <https://www.internationaljournalofcardiology.com/article/S0167-5273(21)01477-7/fulltext>.
572. Acute myocardial infarction and myocarditis after COVID-19 vaccination: <https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8522388/>
573. Myocarditis after Covid-19 vaccination in a large healthcare organization: <https://www.nejm.org/doi/10.1056/NEJMoa2110737>
574. Association of myocarditis with COVID-19 messenger RNA BNT162b2 vaccine in a case series of children: <https://jamanetwork.com/journals/jamacardiology/fullarticle/2783052>
575. Clinical suspicion of myocarditis temporally related to COVID-19 vaccination in adolescents and young adults: <https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.121.056583?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed>
576. STEMI mimicry: focal myocarditis in an adolescent patient after COVID-19 mRNA vaccination:. <https://pubmed.ncbi.nlm.nih.gov/34756746/>
577. Myocarditis and pericarditis in association with COVID-19 mRNA vaccination: cases from a regional pharmacovigilance center: <https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8587334/>
578. Myocarditis after COVID-19 mRNA vaccines: <https://pubmed.ncbi.nlm.nih.gov/34546329/>.
579. Patients with acute myocarditis after COVID-19 mRNA vaccination:. <https://jamanetwork.com/journals/jamacardiology/fullarticle/2781602>.
580. Myocarditis after COVID-19 vaccination: a case series: <https://www.sciencedirect.com/science/article/pii/S0264410X21011725?via%3Dihub>.
581. Myocarditis associated with COVID-19 vaccination in adolescents: <https://publications.aap.org/pediatrics/article/148/5/e2021053427/181357>
582. Myocarditis findings on cardiac magnetic resonance imaging after vaccination with COVID-19 mRNA in adolescents:. <https://pubmed.ncbi.nlm.nih.gov/34704459/>
583. Myocarditis after COVID-19 vaccination: magnetic resonance imaging study: [https://academic.oup.com/ehjcimaging/advance-article/doi/10.1093/ehjci/jeab230/6 421640](https://academic.oup.com/ehjcimaging/advance-article/doi/10.1093/ehjci/jeab230/6%20421640).
584. Acute myocarditis after administration of the second dose of BNT162b2 COVID-19 vaccine: <https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8599115/>
585. Myocarditis after COVID-19 vaccination: <https://www.sciencedirect.com/science/article/pii/S2352906721001603>
586. Case report: probable myocarditis after Covid-19 mRNA vaccine in a patient with arrhythmogenic left ventricular cardiomyopathy: <https://pubmed.ncbi.nlm.nih.gov/34712717/>.
587. Acute myocarditis after administration of BNT162b2 vaccine against COVID-19: <https://www.revespcardiol.org/en-linkresolver-acute-myocarditis-after-administration-bnt162b2-S188558572100133X>.
588. Myocarditis associated with COVID-19 mRNA vaccination: <https://pubs.rsna.org/doi/10.1148/radiol.2021211430>
589. Acute myocarditis after COVID-19 vaccination: a case report: <https://www.sciencedirect.com/science/article/pii/S0248866321007098>
590. Acute myopericarditis after COVID-19 vaccination in adolescents:. <https://pubmed.ncbi.nlm.nih.gov/34589238/>.
591. Perimyocarditis in adolescents after Pfizer-BioNTech COVID-19 vaccination: <https://academic.oup.com/jpids/article/10/10/962/6329543>.
592. Acute myocarditis associated with anti-COVID-19 vaccination: <https://ecevr.org/DOIx.php?id=10.7774/cevr.2021.10.2.196>.
593. Myocarditis associated with COVID-19 vaccination: echocardiographic, cardiac CT, and MRI findings:. <https://pubmed.ncbi.nlm.nih.gov/34428917/>.
594. Acute symptomatic myocarditis in 7 adolescents after Pfizer-BioNTech COVID-19 vaccination:. <https://pubmed.ncbi.nlm.nih.gov/34088762/>.
595. Myocarditis and pericarditis in adolescents after first and second doses of COVID-19 mRNA vaccines:. https://academic.oup.com/ehjqcco/advance-article/doi/10.1093/ehjqcco/qcab090/64 42104.
596. COVID 19 vaccine for adolescents. Concern for myocarditis and pericarditis: <https://www.mdpi.com/2036-7503/13/3/61>.
597. Cardiac imaging of acute myocarditis after vaccination with COVID-19 mRNA: <https://pubmed.ncbi.nlm.nih.gov/34402228/>
598. Myocarditis temporally associated with COVID-19 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34133885/>
599. Acute myocardial injury after COVID-19 vaccination: a case report and review of current evidence from the vaccine adverse event reporting system database: <https://pubmed.ncbi.nlm.nih.gov/34219532/>
600. Acute myocarditis associated with COVID-19 vaccination: report of a case: <https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8639400/>
601. Myocarditis following vaccination with COVID-19 messenger RNA: a Japanese case series: <https://pubmed.ncbi.nlm.nih.gov/34840235/>.
602. Myocarditis in the setting of a recent COVID-19 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34712497/>.
603. Acute myocarditis after a second dose of COVID-19 mRNA vaccine: report of two cases: <https://www.clinicalimaging.org/article/S0899-7071(21)00265-5/fulltext>.
604. Prevalence of thrombocytopenia, antiplatelet factor 4 antibodies, and elevated D-dimer in Thais after vaccination with ChAdOx1 nCoV-19: <https://pubmed.ncbi.nlm.nih.gov/34568726/>
605. Epidemiology of acute myocarditis/pericarditis in Hong Kong adolescents after co-vaccination: <https://academic.oup.com/cid/advance-article-abstract/doi/10.1093/cid/ciab989/6445179>
606. Myocarditis after 2019 coronavirus disease mRNA vaccine: a case series and incidence rate determination: <https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciab926/6420408>.
607. Myocarditis and pericarditis after COVID-19 vaccination: inequalities in age and vaccine types: <https://www.mdpi.com/2075-4426/11/11/1106>
608. Epidemiology and clinical features of myocarditis/pericarditis before the introduction of COVID-19 mRNA vaccine in Korean children: a multicenter study: <https://pubmed.ncbi.nlm.nih.gov/34402230/>
609. Shedding light on post-vaccination myocarditis and pericarditis in COVID-19 and non-COVID-19 vaccine recipients: <https://pubmed.ncbi.nlm.nih.gov/34696294/>
610. Diffuse prothrombotic syndrome after administration of ChAdOx1 nCoV-19 vaccine: case report: <https://pubmed.ncbi.nlm.nih.gov/34615534/>
611. Three cases of acute venous thromboembolism in women after coronavirus 2019 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34352418/>
612. Clinical and biological features of cerebral venous sinus thrombosis after vaccination with ChAdOx1 nCov-19; <https://jnnp.bmj.com/content/early/2021/09/29/jnnp-2021-327340>.
613. COV2-S vaccination may reveal hereditary thrombophilia: massive cerebral venous sinus thrombosis in a young man with normal platelet count: <https://pubmed.ncbi.nlm.nih.gov/34632750/>
614. Post-mortem findings in vaccine-induced thrombotic thrombocytopenia: <https://haematologica.org/article/view/haematol.2021.279075>
615. COVID-19 vaccine-induced thrombosis: <https://pubmed.ncbi.nlm.nih.gov/34802488/>.
616. Inflammation and platelet activation after COVID-19 vaccines: possible mechanisms behind vaccine-induced immune thrombocytopenia and thrombosis: <https://pubmed.ncbi.nlm.nih.gov/34887867/>.
617. Anaphylactoid reaction and coronary thrombosis related to COVID-19 mRNA vaccine: <https://pubmed.ncbi.nlm.nih.gov/34863404/>.
618. Vaccine-induced cerebral venous thrombosis and thrombocytopenia. Oxford-AstraZeneca COVID-19: a missed opportunity for rapid return on experience: <https://www.sciencedirect.com/science/article/pii/S235255682100093X>
619. Occurrence of splenic infarction due to arterial thrombosis after vaccination with COVID-19: <https://pubmed.ncbi.nlm.nih.gov/34876440/>
620. Deep venous thrombosis more than two weeks after COVID-19 vaccination: <https://pubmed.ncbi.nlm.nih.gov/33928773/>
621. Case report: Take a second look: Cerebral venous thrombosis related to Covid-19 vaccination and thrombotic thrombocytopenia syndrome: <https://pubmed.ncbi.nlm.nih.gov/34880826/>
622. Information on ChAdOx1 nCoV-19 vaccine-induced immune-mediated thrombotic thrombocytopenia: <https://pubmed.ncbi.nlm.nih.gov/34587242/>
623. Change in blood viscosity after COVID-19 vaccination: estimation for persons with underlying metabolic syndrome: <https://pubmed.ncbi.nlm.nih.gov/34868465/>
624. Management of a patient with a rare congenital limb malformation syndrome after SARS-CoV-2 vaccine-induced thrombosis and thrombocytopenia (VITT): <https://pubmed.ncbi.nlm.nih.gov/34097311/>
625. Bilateral thalamic stroke: a case of COVID-19 (VITT) vaccine-induced immune thrombotic thrombocytopenia or a coincidence due to underlying risk factors: <https://pubmed.ncbi.nlm.nih.gov/34820232/>.
626. Thrombocytopenia and splanchnic thrombosis after vaccination with Ad26.COV2.S successfully treated with transjugular intrahepatic intrahepatic portosystemic shunt and thrombectomy: <https://onlinelibrary.wiley.com/doi/10.1002/ajh.26258>
627. Incidence of acute ischemic stroke after coronavirus vaccination in Indonesia: case series: <https://pubmed.ncbi.nlm.nih.gov/34579636/>
628. Successful treatment of vaccine-induced immune immune thrombotic thrombocytopenia in a 26-year-old female patient: <https://pubmed.ncbi.nlm.nih.gov/34614491/>
629. Case report: vaccine-induced immune immune thrombotic thrombocytopenia in a patient with pancreatic cancer after vaccination with messenger RNA-1273: <https://pubmed.ncbi.nlm.nih.gov/34790684/>
630. Idiopathic idiopathic external jugular vein thrombophlebitis after coronavirus disease vaccination (COVID-19): <https://pubmed.ncbi.nlm.nih.gov/33624509/>.
631. Squamous cell carcinoma of the lung with hemoptysis following vaccination with tozinameran (BNT162b2, Pfizer-BioNTech): <https://pubmed.ncbi.nlm.nih.gov/34612003/>
632. Vaccine-induced thrombotic thrombocytopenia after Ad26.COV2.S vaccination in a man presenting as acute venous thromboembolism: <https://pubmed.ncbi.nlm.nih.gov/34096082/>
633. Myocarditis associated with COVID-19 vaccination in three adolescent boys: <https://pubmed.ncbi.nlm.nih.gov/34851078/>.
634. Cardiovascular magnetic resonance findings in young adult patients with acute myocarditis after COVID-19 mRNA vaccination: a case series: <https://pubmed.ncbi.nlm.nih.gov/34496880/>
635. Perimyocarditis after vaccination with COVID-19: <https://pubmed.ncbi.nlm.nih.gov/34866957/>
636. Epidemiology of acute myocarditis/pericarditis in Hong Kong adolescents after co-vaccination: <https://pubmed.ncbi.nlm.nih.gov/34849657/>.
637. Myocarditis-induced sudden death after BNT162b2 COVID-19 mRNA vaccination in Korea: case report focusing on histopathological findings: <https://pubmed.ncbi.nlm.nih.gov/34664804/>
638. Acute myocarditis after vaccination with COVID-19 mRNA in adults aged 18 years or older: <https://pubmed.ncbi.nlm.nih.gov/34605853/>
639. Recurrence of acute myocarditis temporally associated with receipt of the 2019 coronavirus mRNA disease vaccine (COVID-19) in an adolescent male: <https://pubmed.ncbi.nlm.nih.gov/34166671/>
640. Young male with myocarditis after mRNA-1273 coronavirus disease-2019 (COVID-19) mRNA vaccination: <https://pubmed.ncbi.nlm.nih.gov/34744118/>
641. Acute myocarditis after SARS-CoV-2 vaccination in a 24-year-old male: <https://pubmed.ncbi.nlm.nih.gov/34334935/>.
642. Ga-DOTATOC digital PET images of inflammatory cell infiltrates in myocarditis after vaccination with COVID-19: <https://pubmed.ncbi.nlm.nih.gov/34746968/>
643. Occurrence of acute infarct-like myocarditis after vaccination with COVID-19: just an accidental coincidence or rather a vaccination-associated autoimmune myocarditis?”: <https://pubmed.ncbi.nlm.nih.gov/34333695/>.
644. Self-limited myocarditis presenting with chest pain and ST-segment elevation in adolescents after vaccination with BNT162b2 mRNA vaccine: <https://pubmed.ncbi.nlm.nih.gov/34180390/>
645. Myocarditis Following Immunization with COVID-19 mRNA Vaccines in Members of the U.S. Military: <https://pubmed.ncbi.nlm.nih.gov/34185045/>
646. Myocarditis after BNT162b2 vaccination in a healthy male: <https://pubmed.ncbi.nlm.nih.gov/34229940/>
647. Myopericarditis in a previously healthy adolescent male after COVID-19 vaccination: Case report: <https://pubmed.ncbi.nlm.nih.gov/34133825/>
648. Acute myocarditis after SARS-CoV-2 mRNA-1273 mRNA vaccination: <https://pubmed.ncbi.nlm.nih.gov/34308326/>.
649. Chest pain with abnormal electrocardiogram redevelopment after injection of COVID-19 vaccine manufactured by Moderna: <https://pubmed.ncbi.nlm.nih.gov/34866106/>
650. Biopsy-proven lymphocytic myocarditis after first vaccination with COVID-19 mRNA in a 40-year-old man: case report: <https://pubmed.ncbi.nlm.nih.gov/34487236/>
651. Multimodality imaging and histopathology in a young man presenting with fulminant lymphocytic myocarditis and cardiogenic shock after vaccination with mRNA-1273: <https://pubmed.ncbi.nlm.nih.gov/34848416/>
652. Report of a case of myopericarditis after vaccination with BNT162b2 COVID-19 mRNA in a young Korean male: <https://pubmed.ncbi.nlm.nih.gov/34636504/>
653. Acute myocarditis after Comirnaty vaccination in a healthy male with previous SARS-CoV-2 infection: <https://pubmed.ncbi.nlm.nih.gov/34367386/>
654. Acute myocarditis in a young adult two days after vaccination with Pfizer: <https://pubmed.ncbi.nlm.nih.gov/34709227/>
655. Case report: acute fulminant myocarditis and cardiogenic shock after messenger RNA coronavirus vaccination in 2019 requiring extracorporeal cardiopulmonary resuscitation: <https://pubmed.ncbi.nlm.nih.gov/34778411/>
656. Acute myocarditis after 2019 coronavirus disease vaccination: <https://pubmed.ncbi.nlm.nih.gov/34734821/>
657. A series of patients with myocarditis after vaccination against SARS-CoV-2 with mRNA-1279 and BNT162b2: <https://pubmed.ncbi.nlm.nih.gov/34246585/>
658. Myopericarditis after Pfizer messenger ribonucleic acid coronavirus coronavirus disease vaccine in adolescents: <https://pubmed.ncbi.nlm.nih.gov/34228985/>
659. Post-vaccination multisystem inflammatory syndrome in adults without evidence of prior SARS-CoV-2 infection: <https://pubmed.ncbi.nlm.nih.gov/34852213/>
660. Acute myocarditis defined after vaccination with 2019 mRNA of coronavirus disease: <https://pubmed.ncbi.nlm.nih.gov/34866122/>
661. Biventricular systolic dysfunction in acute myocarditis after SARS-CoV-2 mRNA-1273 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34601566/>
662. Myocarditis following COVID-19 vaccination: MRI study: <https://pubmed.ncbi.nlm.nih.gov/34739045/>.
663. Acute myocarditis after COVID-19 vaccination: case report: <https://docs.google.com/document/d/1Hc4bh_qNbZ7UVm5BLxkRdMPnnI9zcCsl/e>
664. Association of myocarditis with COVID-19 messenger RNA BNT162b2 vaccine COVID-19 in a case series of children: <https://pubmed.ncbi.nlm.nih.gov/34374740/>
665. Clinical suspicion of myocarditis temporally related to COVID-19 vaccination in adolescents and young adults: <https://pubmed.ncbi.nlm.nih.gov/34865500/>
666. Myocarditis following vaccination with Covid-19 in a large healthcare organization: <https://pubmed.ncbi.nlm.nih.gov/34614329/>
667. AstraZeneca COVID-19 vaccine and Guillain-Barré syndrome in Tasmania: a causal link: <https://pubmed.ncbi.nlm.nih.gov/34560365/>
668. COVID-19, Guillain-Barré and vaccineA dangerous mix: <https://pubmed.ncbi.nlm.nih.gov/34108736/>.
669. Guillain-Barré syndrome after the first dose of Pfizer-BioNTech COVID-19 vaccine: case report and review of reported cases: <https://pubmed.ncbi.nlm.nih.gov/34796417/>.
670. Guillain-Barre syndrome after BNT162b2 COVID-19 vaccine: <https://link.springer.com/article/10.1007%2Fs10072-021-05523-5>.
671. COVID-19 adenovirus vaccines and Guillain-Barré syndrome with facial palsy: <https://onlinelibrary.wiley.com/doi/10.1002/ana.26258>.
672. Association of receipt association of Ad26.COV2.S COVID-19 vaccine with presumed Guillain-Barre syndrome, February-July 2021: <https://jamanetwork.com/journals/jama/fullarticle/2785009>
673. A case of Guillain-Barré syndrome after Pfizer COVID-19 vaccine: <https://pubmed.ncbi.nlm.nih.gov/34567447/>
674. Guillain-Barré syndrome associated with COVID-19 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34648420/>.
675. Rate of recurrent Guillain-Barré syndrome after COVID-19 BNT162b2 mRNA vaccine: <https://jamanetwork.com/journals/jamaneurology/fullarticle/2783708>
676. Guillain-Barre syndrome after COVID-19 vaccination in an adolescent: <https://www.pedneur.com/article/S0887-8994(21)00221-6/fulltext>.
677. Guillain-Barre syndrome after ChAdOx1-S / nCoV-19 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34114256/>.
678. Guillain-Barre syndrome after COVID-19 mRNA-1273 vaccine: case report: <https://pubmed.ncbi.nlm.nih.gov/34767184/>.
679. Guillain-Barre syndrome following SARS-CoV-2 vaccination in 19 patients: <https://pubmed.ncbi.nlm.nih.gov/34644738/>.
680. Guillain-Barre syndrome presenting with facial diplegia following vaccination with COVID-19 in two patients: <https://pubmed.ncbi.nlm.nih.gov/34649856/>
681. A rare case of Guillain-Barré syndrome after COVID-19 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34671572/>
682. Neurological complications of COVID-19: Guillain-Barre syndrome after Pfizer COVID-19 vaccine: <https://pubmed.ncbi.nlm.nih.gov/33758714/>
683. COVID-19 vaccine causing Guillain-Barre syndrome, an uncommon potential side effect: <https://pubmed.ncbi.nlm.nih.gov/34484780/>
684. Guillain-Barre syndrome after the first dose of COVID-19 vaccination: case report; <https://pubmed.ncbi.nlm.nih.gov/34779385/>.
685. Miller Fisher syndrome after Pfizer COVID-19 vaccine: <https://pubmed.ncbi.nlm.nih.gov/34817727/>.
686. Miller Fisher syndrome after 2019 BNT162b2 mRNA coronavirus vaccination: <https://pubmed.ncbi.nlm.nih.gov/34789193/>.
687. Bilateral facial weakness with a variant of paresthesia of Guillain-Barre syndrome after Vaxzevria COVID-19 vaccine: <https://pubmed.ncbi.nlm.nih.gov/34261746/>
688. Guillain-Barre syndrome after the first injection of ChAdOx1 nCoV-19 vaccine: first report: <https://pubmed.ncbi.nlm.nih.gov/34217513/>.
689. A case of sensory ataxic Guillain-Barre syndrome with immunoglobulin G anti-GM1 antibodies after first dose of COVID-19 BNT162b2 mRNA vaccine (Pfizer): <https://pubmed.ncbi.nlm.nih.gov/34871447/>
690. Reporting of acute inflammatory neuropathies with COVID-19 vaccines: subgroup disproportionality analysis in VigiBase: <https://pubmed.ncbi.nlm.nih.gov/34579259/>
691. A variant of Guillain-Barré syndrome after SARS-CoV-2 vaccination: AMSAN: <https://pubmed.ncbi.nlm.nih.gov/34370408/>.
692. A rare variant of Guillain-Barré syndrome after vaccination with Ad26.COV2.S: <https://pubmed.ncbi.nlm.nih.gov/34703690/>.
693. Guillain-Barré syndrome after SARS-CoV-2 vaccination in a patient with previous vaccine-associated Guillain-Barré syndrome: <https://pubmed.ncbi.nlm.nih.gov/34810163/>
694. Guillain-Barré syndrome in an Australian state using mRNA and adenovirus-vector SARS-CoV-2 vaccines: <https://onlinelibrary.wiley.com/doi/10.1002/ana.26218>.
695. Acute transverse myelitis after SARS-CoV-2 vaccination: case report and review of the literature: <https://pubmed.ncbi.nlm.nih.gov/34482455/>.
696. Variant Guillain-Barré syndrome occurring after SARS-CoV-2 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34114269/>.
697. Guillian-Barre syndrome with axonal variant temporally associated with Modern SARS-CoV-2 mRNA-based vaccine: <https://pubmed.ncbi.nlm.nih.gov/34722067/>
698. Guillain-Barre syndrome after the first dose of SARS-CoV-2 vaccine: a temporary occurrence, not a causal association: <https://pubmed.ncbi.nlm.nih.gov/33968610/>
699. SARS-CoV-2 vaccines can be complicated not only by Guillain-Barré syndrome but also by distal small fiber neuropathy: <https://pubmed.ncbi.nlm.nih.gov/34525410/>
700. Clinical variant of Guillain-Barré syndrome with prominent facial diplegia after AstraZeneca 2019 coronavirus disease vaccine: <https://pubmed.ncbi.nlm.nih.gov/34808658/>
701. Adverse event reporting and risk of Bell’s palsy after COVID-19 vaccination: <https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(21)00646-0/fulltext>.
702. Bilateral facial nerve palsy and COVID-19 vaccination: causality or coincidence: <https://pubmed.ncbi.nlm.nih.gov/34522557/>
703. Left Bell’s palsy after the first dose of mRNA-1273 SARS-CoV-2 vaccine: case report: <https://pubmed.ncbi.nlm.nih.gov/34763263/>.
704. Bell’s palsy after inactivated vaccination with COVID-19 in a patient with a history of recurrent Bell’s palsy: case report: <https://pubmed.ncbi.nlm.nih.gov/34621891/>
705. Neurological complications after the first dose of COVID-19 vaccines and SARS-CoV-2 infection: <https://pubmed.ncbi.nlm.nih.gov/34697502/>
706. Type I interferons as a potential mechanism linking COVID-19 mRNA vaccines with Bell’s palsy: <https://pubmed.ncbi.nlm.nih.gov/33858693/>
707. Acute transverse myelitis following inactivated COVID-19 vaccine: <https://pubmed.ncbi.nlm.nih.gov/34370410/>
708. Acute transverse myelitis after COVID-19 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34579245/>.
709. A case of longitudinally extensive transverse myelitis following Covid-19 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34182207/>
710. Post COVID-19 transverse myelitis; a case report with review of the literature: <https://pubmed.ncbi.nlm.nih.gov/34457267/>.
711. Beware of neuromyelitis optica spectrum disorder after vaccination with inactivated virus for COVID-19: <https://pubmed.ncbi.nlm.nih.gov/34189662/>
712. Neuromyelitis optica in a healthy woman after vaccination against severe acute respiratory syndrome coronavirus 2 mRNA-1273: <https://pubmed.ncbi.nlm.nih.gov/34660149/>
713. Acute bilateral bilateral optic neuritis/chiasm with longitudinal extensive transverse myelitis in long-standing stable multiple sclerosis after vector-based vaccination against SARS-CoV-2: <https://pubmed.ncbi.nlm.nih.gov/34131771/>
714. A case series of acute pericarditis after vaccination with COVID-19 in the context of recent reports from Europe and the United States: <https://pubmed.ncbi.nlm.nih.gov/34635376/>
715. Acute pericarditis and cardiac tamponade after vaccination with Covid-19: <https://pubmed.ncbi.nlm.nih.gov/34749492/>
716. Myocarditis and pericarditis in adolescents after the first and second doses of COVID-19 mRNA vaccines: <https://pubmed.ncbi.nlm.nih.gov/34849667/>
717. Perimyocarditis in adolescents after Pfizer-BioNTech COVID-19 vaccine: <https://pubmed.ncbi.nlm.nih.gov/34319393/>
718. Acute myopericarditis after COVID-19 vaccine in adolescents: <https://pubmed.ncbi.nlm.nih.gov/34589238/>
719. Pericarditis after administration of the BNT162b2 mRNA vaccine COVID-19: <https://pubmed.ncbi.nlm.nih.gov/34149145/>
720. Case report: symptomatic pericarditis post COVID-19 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34693198/>.
721. An outbreak of Still’s disease after COVID-19 vaccination in a 34-year-old patient: <https://pubmed.ncbi.nlm.nih.gov/34797392/>
722. Hemophagocytic lymphohistiocytosis following COVID-19 vaccination (ChAdOx1 nCoV-19): <https://pubmed.ncbi.nlm.nih.gov/34862234/>
723. Myocarditis after SARS-CoV-2 mRNA vaccination, a case series: <https://pubmed.ncbi.nlm.nih.gov/34396358/>.
724. Miller-Fisher syndrome and Guillain-Barré syndrome overlap syndrome in a patient after Oxford-AstraZeneca SARS-CoV-2 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34848426/>.
725. Immune-mediated disease outbreaks or new-onset disease in 27 subjects after mRNA/DNA vaccination against SARS-CoV-2: <https://pubmed.ncbi.nlm.nih.gov/33946748/>
726. Post-mortem investigation of deaths after vaccination with COVID-19 vaccines: <https://pubmed.ncbi.nlm.nih.gov/34591186/>
727. Acute kidney injury with macroscopic hematuria and IgA nephropathy after COVID-19 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34352309/>
728. Relapse of immune thrombocytopenia after covid-19 vaccination in young male patient: <https://pubmed.ncbi.nlm.nih.gov/34804803/>.
729. Immune thrombocytopenic purpura associated with COVID-19 mRNA vaccine Pfizer-BioNTech BNT16B2b2: <https://pubmed.ncbi.nlm.nih.gov/34077572/>
730. Retinal hemorrhage after SARS-CoV-2 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34884407/>.
731. Case report: anti-neutrophil cytoplasmic antibody-associated vasculitis with acute renal failure and pulmonary hemorrhage can occur after COVID-19 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34859017/>
732. Intracerebral hemorrhage due to vasculitis following COVID-19 vaccination: case report: <https://pubmed.ncbi.nlm.nih.gov/34783899/>
733. Peduncular, symptomatic cavernous bleeding after immune thrombocytopenia-induced SARS-CoV-2 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34549178/>.
734. Brain death in a vaccinated patient with COVID-19 infection: <https://pubmed.ncbi.nlm.nih.gov/34656887/>
735. Generalized purpura annularis telangiectodes after SARS-CoV-2 mRNA vaccination: <https://pubmed.ncbi.nlm.nih.gov/34236717/>.
736. Lobar hemorrhage with ventricular rupture shortly after the first dose of a SARS-CoV-2 mRNA-based SARS-CoV-2 vaccine: <https://pubmed.ncbi.nlm.nih.gov/34729467/>.
737. A case of outbreak of macroscopic hematuria and IgA nephropathy after SARS-CoV-2 vaccination: <https://pubmed.ncbi.nlm.nih.gov/33932458/>
738. Acral hemorrhage after administration of the second dose of SARS-CoV-2 vaccine. A post-vaccination reaction: <https://pubmed.ncbi.nlm.nih.gov/34092400/742>.
739. Severe immune thrombocytopenic purpura after SARS-CoV-2 vaccine: <https://pubmed.ncbi.nlm.nih.gov/34754937/>
740. Gross hematuria after severe acute respiratory syndrome coronavirus 2 vaccination in 2 patients with IgA nephropathy: <https://pubmed.ncbi.nlm.nih.gov/33771584/>
741. Autoimmune encephalitis after ChAdOx1-S SARS-CoV-2 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34846583/>
742. COVID-19 vaccine and death: causality algorithm according to the WHO eligibility diagnosis: <https://pubmed.ncbi.nlm.nih.gov/34073536/>
743. Bell’s palsy after vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines: a case series and a nested case-control study: <https://pubmed.ncbi.nlm.nih.gov/34411532/>
744. Epidemiology of myocarditis and pericarditis following mRNA vaccines in Ontario, Canada: by vaccine product, schedule, and interval: <https://www.medrxiv.org/content/10.1101/2021.12.02.21267156v1>
745. Anaphylaxis following Covid-19 vaccine in a patient with cholinergic urticaria: <https://pubmed.ncbi.nlm.nih.gov/33851711/>
746. Anaphylaxis induced by CoronaVac COVID-19 vaccine: clinical features and results of revaccination: <https://pubmed.ncbi.nlm.nih.gov/34675550/>.
747. Anaphylaxis after Modern COVID-19 vaccine: <https://pubmed.ncbi.nlm.nih.gov/34734159/>.
748. Association of self-reported history of high-risk allergy with allergy symptoms after COVID-19 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34698847/>
749. Sex differences in the incidence of anaphylaxis to LNP-mRNA vaccines COVID-19: <https://pubmed.ncbi.nlm.nih.gov/34020815/>
750. Allergic reactions, including anaphylaxis, after receiving the first dose of Pfizer-BioNTech COVID-19 vaccine – United States, December 14 to 23, 2020: <https://pubmed.ncbi.nlm.nih.gov/33641264/>
751. Allergic reactions, including anaphylaxis, after receiving the first dose of Modern COVID-19 vaccine – United States, December 21, 2020 to January 10, 2021: <https://pubmed.ncbi.nlm.nih.gov/33641268/>
752. Prolonged anaphylaxis to Pfizer 2019 coronavirus disease vaccine: a case report and mechanism of action: <https://pubmed.ncbi.nlm.nih.gov/33834172/>
753. Anaphylaxis reactions to Pfizer BNT162b2 vaccine: report of 3 cases of anaphylaxis following vaccination with Pfizer BNT162b2: <https://pubmed.ncbi.nlm.nih.gov/34579211/>
754. Biphasic anaphylaxis after first dose of 2019 messenger RNA coronavirus disease vaccine with positive polysorbate 80 skin test result: <https://pubmed.ncbi.nlm.nih.gov/34343674/>
755. Acute myocardial infarction and myocarditis after COVID-19 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34586408/>
756. Takotsubo syndrome after COVID-19 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34539938/>.
757. Takotsubo cardiomyopathy after coronavirus 2019 vaccination in patient on maintenance hemodialysis: <https://pubmed.ncbi.nlm.nih.gov/34731486/>.
758. Premature myocardial infarction or side effect of COVID-19 vaccine: <https://pubmed.ncbi.nlm.nih.gov/33824804/>
759. Myocardial infarction, stroke, and pulmonary embolism after BNT162b2 mRNA COVID-19 vaccine in persons aged 75 years or older: <https://pubmed.ncbi.nlm.nih.gov/34807248/>
760. Kounis syndrome type 1 induced by inactivated SARS-COV-2 vaccine: <https://pubmed.ncbi.nlm.nih.gov/34148772/>
761. Acute myocardial infarction within 24 hours after COVID-19 vaccination: is Kounis syndrome the culprit: <https://pubmed.ncbi.nlm.nih.gov/34702550/>
762. Deaths associated with the recently launched SARS-CoV-2 vaccination (Comirnaty®): <https://pubmed.ncbi.nlm.nih.gov/33895650/>
763. Deaths associated with recently launched SARS-CoV-2 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34425384/>
764. A case of acute encephalopathy and non-ST-segment elevation myocardial infarction after vaccination with mRNA-1273: possible adverse effect: <https://pubmed.ncbi.nlm.nih.gov/34703815/>
765. COVID-19 vaccine-induced urticarial vasculitis: <https://pubmed.ncbi.nlm.nih.gov/34369046/>.
766. ANCA-associated vasculitis after Pfizer-BioNTech COVID-19 vaccine: <https://pubmed.ncbi.nlm.nih.gov/34280507/>.
767. New-onset leukocytoclastic vasculitis after COVID-19 vaccine: <https://pubmed.ncbi.nlm.nih.gov/34241833/>
768. Cutaneous small vessel vasculitis after COVID-19 vaccine: <https://pubmed.ncbi.nlm.nih.gov/34529877/>.
769. Outbreak of leukocytoclastic vasculitis after COVID-19 vaccine: <https://pubmed.ncbi.nlm.nih.gov/33928638/>
770. Leukocytoclastic vasculitis after exposure to COVID-19 vaccine: <https://pubmed.ncbi.nlm.nih.gov/34836739/>
771. Vasculitis and bursitis in [ 18 F] FDG-PET/CT after COVID-19 mRNA vaccine: post hoc ergo propter hoc?; <https://pubmed.ncbi.nlm.nih.gov/34495381/>.
772. Cutaneous lymphocytic vasculitis after administration of COVID-19 mRNA vaccine: <https://pubmed.ncbi.nlm.nih.gov/34327795>
773. Cutaneous leukocytoclastic vasculitis induced by Sinovac COVID-19 vaccine: <https://pubmed.ncbi.nlm.nih.gov/34660867/>.
774. Case report: ANCA-associated vasculitis presenting with rhabdomyolysis and crescentic Pauci-Inmune glomerulonephritis after vaccination with Pfizer-BioNTech COVID-19 mRNA: <https://pubmed.ncbi.nlm.nih.gov/34659268/>
775. Reactivation of IgA vasculitis after vaccination with COVID-19: <https://pubmed.ncbi.nlm.nih.gov/34848431/>
776. Varicella-zoster virus-related small-vessel vasculitis after Pfizer-BioNTech COVID-19 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34310759/>.
777. Imaging in vascular medicine: leukocytoclastic vasculitis after COVID-19 vaccine booster: <https://pubmed.ncbi.nlm.nih.gov/34720009/>
778. A rare case of Henoch-Schönlein purpura after a case report of COVID-19 vaccine: <https://pubmed.ncbi.nlm.nih.gov/34518812/>
779. Cutaneous vasculitis following COVID-19 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34611627/>.
780. Possible case of COVID-19 mRNA vaccine-induced small-vessel vasculitis: <https://pubmed.ncbi.nlm.nih.gov/34705320/>.
781. IgA vasculitis following COVID-19 vaccination in an adult: <https://pubmed.ncbi.nlm.nih.gov/34779011/>
782. Propylthiouracil-induced anti-neutrophil cytoplasmic antibody-associated vasculitis following vaccination with COVID-19: <https://pubmed.ncbi.nlm.nih.gov/34451967/>
783. Coronavirus disease vaccine 2019 (COVID-19) in systemic lupus erythematosus and neutrophil anti-cytoplasmic antibody-associated vasculitis: <https://pubmed.ncbi.nlm.nih.gov/33928459/>
784. Reactivation of IgA vasculitis after COVID-19 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34250509/>
785. Clinical and histopathologic spectrum of delayed adverse skin reactions after COVID-19 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34292611/>.
786. First description of immune complex vasculitis after COVID-19 vaccination with BNT162b2: case report: <https://pubmed.ncbi.nlm.nih.gov/34530771/>.
787. Nephrotic syndrome and vasculitis after SARS-CoV-2 vaccine: true association or circumstantial: <https://pubmed.ncbi.nlm.nih.gov/34245294/>.
788. Occurrence of de novo cutaneous vasculitis after vaccination against coronavirus disease (COVID-19): <https://pubmed.ncbi.nlm.nih.gov/34599716/>.
789. Asymmetric cutaneous vasculitis after COVID-19 vaccination with unusual preponderance of eosinophils: <https://pubmed.ncbi.nlm.nih.gov/34115904/>.
790. Henoch-Schönlein purpura occurring after vaccination with COVID-19: <https://pubmed.ncbi.nlm.nih.gov/34247902/>.
791. Henoch-Schönlein purpura following the first dose of COVID-19 viral vector vaccine: case report: <https://pubmed.ncbi.nlm.nih.gov/34696186/>.
792. Granulomatous vasculitis after AstraZeneca anti-SARS-CoV-2 vaccine: <https://pubmed.ncbi.nlm.nih.gov/34237323/>.
793. Acute retinal necrosis due to varicella zoster virus reactivation after vaccination with BNT162b2 COVID-19 mRNA: <https://pubmed.ncbi.nlm.nih.gov/34851795/>.
794. A case of generalized Sweet’s syndrome with vasculitis triggered by recent vaccination with COVID-19: <https://pubmed.ncbi.nlm.nih.gov/34849386/>
795. Small-vessel vasculitis following Oxford-AstraZeneca vaccination against SARS-CoV-2: <https://pubmed.ncbi.nlm.nih.gov/34310763/>
796. Relapse of microscopic polyangiitis after COVID-19 vaccination: case report: <https://pubmed.ncbi.nlm.nih.gov/34251683/>.
797. Cutaneous vasculitis after severe acute respiratory syndrome coronavirus 2 vaccine: <https://pubmed.ncbi.nlm.nih.gov/34557622/>.
798. Recurrent herpes zoster after COVID-19 vaccination in patients with chronic urticaria on cyclosporine treatment – A report of 3 cases: <https://pubmed.ncbi.nlm.nih.gov/34510694/>
799. Leukocytoclastic vasculitis after coronavirus disease vaccination 2019: <https://pubmed.ncbi.nlm.nih.gov/34713472/803>
800. Outbreaks of mixed cryoglobulinemia vasculitis after vaccination against SARS-CoV-2: <https://pubmed.ncbi.nlm.nih.gov/34819272/>
801. Cutaneous small-vessel vasculitis after vaccination with a single dose of Janssen Ad26.COV2.S: <https://pubmed.ncbi.nlm.nih.gov/34337124/>
802. Case of immunoglobulin A vasculitis after vaccination against coronavirus disease 2019: <https://pubmed.ncbi.nlm.nih.gov/34535924/>
803. Rapid progression of angioimmunoblastic T-cell lymphoma after BNT162b2 mRNA booster vaccination: case report: <https://www.frontiersin.org/articles/10.3389/fmed.2021.798095/>
804. COVID-19 mRNA vaccination-induced lymphadenopathy mimics lymphoma progression on FDG PET / CT: <https://pubmed.ncbi.nlm.nih.gov/33591026/>
805. Lymphadenopathy in COVID-19 vaccine recipients: diagnostic dilemma in oncology patients: <https://pubmed.ncbi.nlm.nih.gov/33625300/>
806. Hypermetabolic lymphadenopathy after administration of BNT162b2 mRNA vaccine Covid-19: incidence assessed by [ 18 F] FDG PET-CT and relevance for study interpretation: <https://pubmed.ncbi.nlm.nih.gov/33774684/>
807. Lymphadenopathy after COVID-19 vaccination: review of imaging findings: <https://pubmed.ncbi.nlm.nih.gov/33985872/>
808. Evolution of bilateral hypermetabolic axillary hypermetabolic lymphadenopathy on FDG PET/CT after 2-dose COVID-19 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34735411/>
809. Lymphadenopathy associated with COVID-19 vaccination on FDG PET/CT: distinguishing features in adenovirus-vectored vaccine: <https://pubmed.ncbi.nlm.nih.gov/34115709/>.
810. COVID-19 vaccination-induced lymphadenopathy in a specialized breast imaging clinic in Israel: analysis of 163 cases: <https://pubmed.ncbi.nlm.nih.gov/34257025/>.
811. COVID-19 vaccine-related axillary lymphadenopathy in breast cancer patients: case series with literature review: <https://pubmed.ncbi.nlm.nih.gov/34836672/>.
812. Coronavirus disease vaccine 2019 mimics lymph node metastases in patients undergoing skin cancer follow-up: a single-center study: <https://pubmed.ncbi.nlm.nih.gov/34280870/>
813. COVID-19 post-vaccination lymphadenopathy: report of fine-needle aspiration biopsy cytologic findings: <https://pubmed.ncbi.nlm.nih.gov/34432391/>
814. Regional lymphadenopathy after COVID-19 vaccination: review of the literature and considerations for patient management in breast cancer care: <https://pubmed.ncbi.nlm.nih.gov/34731748/>
815. Subclinical axillary lymphadenopathy associated with COVID-19 vaccination on screening mammography: <https://pubmed.ncbi.nlm.nih.gov/34906409/>
816. Adverse events of COVID injection that may occur in children.Acute-onset supraclavicular lymphadenopathy coincident with intramuscular mRNA vaccination against COVID-19 may be related to the injection technique of the vaccine, Spain, January and February 2021: <https://pubmed.ncbi.nlm.nih.gov/33706861/>
817. Supraclavicular lymphadenopathy after COVID-19 vaccination in Korea: serial follow-up by ultrasonography: <https://pubmed.ncbi.nlm.nih.gov/34116295/>
818. Oxford-AstraZeneca COVID-19 vaccination induced lymphadenopathy on [18F] choline PET / CT, not just an FDG finding: <https://pubmed.ncbi.nlm.nih.gov/33661328/>
819. Biphasic anaphylaxis after exposure to the first dose of Pfizer-BioNTech COVID-19 mRNA vaccine COVID-19: <https://pubmed.ncbi.nlm.nih.gov/34050949/>
820. Axillary adenopathy associated with COVID-19 vaccination: imaging findings and follow-up recommendations in 23 women: <https://pubmed.ncbi.nlm.nih.gov/33624520/>
821. A case of cervical lymphadenopathy following COVID-19 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34141500/>
822. Unique imaging findings of neurologic phantosmia after Pfizer-BioNtech COVID-19 vaccination: a case report: <https://pubmed.ncbi.nlm.nih.gov/34096896/>
823. Thrombotic adverse events reported for Moderna, Pfizer, and Oxford-AstraZeneca COVID-19 vaccines: comparison of occurrence and clinical outcomes in the EudraVigilance database: <https://pubmed.ncbi.nlm.nih.gov/34835256/>
824. Unilateral lymphadenopathy after COVID-19 vaccination: a practical management plan for radiologists of all specialties: <https://pubmed.ncbi.nlm.nih.gov/33713605/>
825. Unilateral axillary adenopathy in the setting of COVID-19 vaccination: follow-up: <https://pubmed.ncbi.nlm.nih.gov/34298342/>
826. A systematic review of cases of CNS demyelination following COVID-19 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34839149/>
827. Supraclavicular lymphadenopathy after COVID-19 vaccination: an increasing presentation in the two-week wait neck lump clinic: <https://pubmed.ncbi.nlm.nih.gov/33685772/>
828. COVID-19 vaccine-related axillary and cervical lymphadenopathy in patients with current or previous breast cancer and other malignancies: cross-sectional imaging findings on MRI, CT and PET-CT: <https://pubmed.ncbi.nlm.nih.gov/34719892/>
829. Adenopathy after COVID-19 vaccination: <https://pubmed.ncbi.nlm.nih.gov/33625299/>.
830. Incidence of axillary adenopathy on breast imaging after vaccination with COVID-19: <https://pubmed.ncbi.nlm.nih.gov/34292295/>.
831. COVID-19 vaccination and lower cervical lymphadenopathy in two-week neck lump clinic: a follow-up audit: <https://pubmed.ncbi.nlm.nih.gov/33947605/>.
832. Cervical lymphadenopathy after coronavirus disease vaccination 2019: clinical features and implications for head and neck cancer services: <https://pubmed.ncbi.nlm.nih.gov/34526175/>
833. Lymphadenopathy associated with the COVID-19 vaccine: <https://pubmed.ncbi.nlm.nih.gov/33786231/>
834. Evolution of lymphadenopathy on PET/MRI after COVID-19 vaccination: <https://pubmed.ncbi.nlm.nih.gov/33625301/>.
835. Autoimmune hepatitis triggered by SARS-CoV-2 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34332438/>.
836. New-onset nephrotic syndrome after Janssen COVID-19 vaccination: case report and literature review: <https://pubmed.ncbi.nlm.nih.gov/34342187/>.
837. Massive cervical lymphadenopathy following vaccination with COVID-19: <https://pubmed.ncbi.nlm.nih.gov/34601889/>
838. ANCA glomerulonephritis following Modern COVID-19 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34081948/>
839. Extensive longitudinal transverse myelitis following AstraZeneca COVID-19 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34507942/>.
840. Systemic capillary extravasation syndrome after vaccination with ChAdOx1 nCOV-19 (Oxford-AstraZeneca): <https://pubmed.ncbi.nlm.nih.gov/34362727/>
841. Unilateral axillary lymphadenopathy related to COVID-19 vaccine: pattern on screening breast MRI allowing benign evaluation: <https://pubmed.ncbi.nlm.nih.gov/34325221/>
842. Axillary lymphadenopathy in patients with recent Covid-19 vaccination: a new diagnostic dilemma: <https://pubmed.ncbi.nlm.nih.gov/34825530/>.
843. Minimal change disease and acute kidney injury after Pfizer-BioNTech COVID-19 vaccine: <https://pubmed.ncbi.nlm.nih.gov/34000278/>
844. COVID-19 vaccine-induced unilateral axillary adenopathy: follow-up evaluation in the USA: <https://pubmed.ncbi.nlm.nih.gov/34655312/>.
845. Gastroparesis after Pfizer-BioNTech COVID-19 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34187985/>.
846. Acute-onset supraclavicular lymphadenopathy coincident with intramuscular mRNA vaccination against COVID-19 may be related to the injection technique of the vaccine, Spain, January and February 2021: <https://pubmed.ncbi.nlm.nih.gov/33706861/>
847. Supraclavicular lymphadenopathy after COVID-19 vaccination in Korea: serial follow-up by ultrasonography: <https://pubmed.ncbi.nlm.nih.gov/34116295/>
848. Oxford-AstraZeneca COVID-19 vaccination induced lymphadenopathy on [18F] choline PET / CT, not just an FDG finding: <https://pubmed.ncbi.nlm.nih.gov/33661328/>
849. Biphasic anaphylaxis after exposure to the first dose of Pfizer-BioNTech COVID-19 mRNA vaccine COVID-19: <https://pubmed.ncbi.nlm.nih.gov/34050949/>
850. Axillary adenopathy associated with COVID-19 vaccination: imaging findings and follow-up recommendations in 23 women: <https://pubmed.ncbi.nlm.nih.gov/33624520/>
851. A case of cervical lymphadenopathy following COVID-19 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34141500/>
852. Unique imaging findings of neurologic phantosmia after Pfizer-BioNtech COVID-19 vaccination: a case report: <https://pubmed.ncbi.nlm.nih.gov/34096896/>
853. Thrombotic adverse events reported for Moderna, Pfizer, and Oxford-AstraZeneca COVID-19 vaccines: comparison of occurrence and clinical outcomes in the EudraVigilance database: <https://pubmed.ncbi.nlm.nih.gov/34835256/>
854. Unilateral lymphadenopathy after COVID-19 vaccination: a practical management plan for radiologists of all specialties: <https://pubmed.ncbi.nlm.nih.gov/33713605/>
855. Unilateral axillary adenopathy in the setting of COVID-19 vaccination: follow-up: <https://pubmed.ncbi.nlm.nih.gov/34298342/>
856. A systematic review of cases of CNS demyelination following COVID-19 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34839149/>
857. Supraclavicular lymphadenopathy after COVID-19 vaccination: an increasing presentation in the two-week wait neck lump clinic: <https://pubmed.ncbi.nlm.nih.gov/33685772/>
858. COVID-19 vaccine-related axillary and cervical lymphadenopathy in patients with current or previous breast cancer and other malignancies: cross-sectional imaging findings on MRI, CT and PET-CT: <https://pubmed.ncbi.nlm.nih.gov/34719892/>
859. Adenopathy after COVID-19 vaccination: <https://pubmed.ncbi.nlm.nih.gov/33625299/>.
860. Incidence of axillary adenopathy on breast imaging after vaccination with COVID-19: <https://pubmed.ncbi.nlm.nih.gov/34292295/>.
861. COVID-19 vaccination and lower cervical lymphadenopathy in two-week neck lump clinic: a follow-up audit: <https://pubmed.ncbi.nlm.nih.gov/33947605/>.
862. Cervical lymphadenopathy after coronavirus disease vaccination 2019: clinical features and implications for head and neck cancer services: <https://pubmed.ncbi.nlm.nih.gov/34526175/>
863. Lymphadenopathy associated with the COVID-19 vaccine: <https://pubmed.ncbi.nlm.nih.gov/33786231/>
864. Evolution of lymphadenopathy on PET/MRI after COVID-19 vaccination: <https://pubmed.ncbi.nlm.nih.gov/33625301/>.
865. Autoimmune hepatitis triggered by SARS-CoV-2 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34332438/>.
866. New-onset nephrotic syndrome after Janssen COVID-19 vaccination: case report and literature review: <https://pubmed.ncbi.nlm.nih.gov/34342187/>.
867. Massive cervical lymphadenopathy following vaccination with COVID-19: <https://pubmed.ncbi.nlm.nih.gov/34601889/>
868. ANCA glomerulonephritis following Modern COVID-19 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34081948/>
869. Extensive longitudinal transverse myelitis following AstraZeneca COVID-19 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34507942/>.
870. Systemic capillary extravasation syndrome after vaccination with ChAdOx1 nCOV-19 (Oxford-AstraZeneca): <https://pubmed.ncbi.nlm.nih.gov/34362727/>
871. Unilateral axillary lymphadenopathy related to COVID-19 vaccine: pattern on screening breast MRI allowing benign evaluation: <https://pubmed.ncbi.nlm.nih.gov/34325221/>
872. Axillary lymphadenopathy in patients with recent Covid-19 vaccination: a new diagnostic dilemma: <https://pubmed.ncbi.nlm.nih.gov/34825530/>.
873. Minimal change disease and acute kidney injury after Pfizer-BioNTech COVID-19 vaccine: <https://pubmed.ncbi.nlm.nih.gov/34000278/>
874. COVID-19 vaccine-induced unilateral axillary adenopathy: follow-up evaluation in the USA: <https://pubmed.ncbi.nlm.nih.gov/34655312/>.
875. Gastroparesis after Pfizer-BioNTech COVID-19 vaccination: <https://pubmed.ncbi.nlm.nih.gov/34187985/>.
876. Abbate, A., Gavin, J., Madanchi, N., Kim, C., Shah, P. R., Klein, K., . . . Danielides, S. (2021). Fulminant myocarditis and systemic hyperinflammation temporally associated with BNT162b2 mRNA COVID-19 vaccination in two patients. Int J Cardiol, 340, 119-121. doi:10.1016/j.ijcard.2021.08.018. <https://www.ncbi.nlm.nih.gov/pubmed/34416319>
877. Abu Mouch, S., Roguin, A., Hellou, E., Ishai, A., Shoshan, U., Mahamid, L., . . . Berar Yanay, N. (2021). Myocarditis following COVID-19 mRNA vaccination. Vaccine, 39(29), 3790-3793. doi:10.1016/j.vaccine.2021.05.087. <https://www.ncbi.nlm.nih.gov/pubmed/34092429>
878. Albert, E., Aurigemma, G., Saucedo, J., & Gerson, D. S. (2021). Myocarditis following COVID-19 vaccination. Radiol Case Rep, 16(8), 2142-2145. doi:10.1016/j.radcr.2021.05.033. <https://www.ncbi.nlm.nih.gov/pubmed/34025885>
879. Aye, Y. N., Mai, A. S., Zhang, A., Lim, O. Z. H., Lin, N., Ng, C. H., . . . Chew, N. W. S. (2021). Acute Myocardial Infarction and Myocarditis following COVID-19 Vaccination. QJM. doi:10.1093/qjmed/hcab252. <https://www.ncbi.nlm.nih.gov/pubmed/34586408>
880. Azir, M., Inman, B., Webb, J., & Tannenbaum, L. (2021). STEMI Mimic: Focal Myocarditis in an Adolescent Patient After mRNA COVID-19 Vaccine. J Emerg Med, 61(6), e129-e132. doi:10.1016/j.jemermed.2021.09.017. <https://www.ncbi.nlm.nih.gov/pubmed/34756746>
881. Barda, N., Dagan, N., Ben-Shlomo, Y., Kepten, E., Waxman, J., Ohana, R., . . . Balicer, R. D. (2021). Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting. N Engl J Med, 385(12), 1078-1090. doi:10.1056/NEJMoa2110475. <https://www.ncbi.nlm.nih.gov/pubmed/34432976>
882. Bhandari, M., Pradhan, A., Vishwakarma, P., & Sethi, R. (2021). Coronavirus and cardiovascular manifestations- getting to the heart of the matter. World J Cardiol, 13(10), 556-565. doi:10.4330/wjc.v13.i10.556. <https://www.ncbi.nlm.nih.gov/pubmed/34754400>
883. Bozkurt, B., Kamat, I., & Hotez, P. J. (2021). Myocarditis With COVID-19 mRNA Vaccines. Circulation, 144(6), 471-484. doi:10.1161/CIRCULATIONAHA.121.056135. <https://www.ncbi.nlm.nih.gov/pubmed/34281357>
884. Buchhorn, R., Meyer, C., Schulze-Forster, K., Junker, J., & Heidecke, H. (2021). Autoantibody Release in Children after Corona Virus mRNA Vaccination: A Risk Factor of Multisystem Inflammatory Syndrome? Vaccines (Basel), 9(11). doi:10.3390/vaccines9111353. <https://www.ncbi.nlm.nih.gov/pubmed/34835284>
885. Calcaterra, G., Bassareo, P. P., Barilla, F., Romeo, F., & Mehta, J. L. (2022). Concerning the unexpected prothrombotic state following some coronavirus disease 2019 vaccines. J Cardiovasc Med (Hagerstown), 23(2), 71-74. doi:10.2459/JCM.0000000000001232. <https://www.ncbi.nlm.nih.gov/pubmed/34366403>
886. Calcaterra, G., Mehta, J. L., de Gregorio, C., Butera, G., Neroni, P., Fanos, V., & Bassareo, P. P. (2021). COVID 19 Vaccine for Adolescents. Concern about Myocarditis and Pericarditis. Pediatr Rep, 13(3), 530-533. doi:10.3390/pediatric13030061. <https://www.ncbi.nlm.nih.gov/pubmed/34564344>
887. Chai, Q., Nygaard, U., Schmidt, R. C., Zaremba, T., Moller, A. M., & Thorvig, C. M. (2022). Multisystem inflammatory syndrome in a male adolescent after his second Pfizer-BioNTech COVID-19 vaccine. Acta Paediatr, 111(1), 125-127. doi:10.1111/apa.16141. <https://www.ncbi.nlm.nih.gov/pubmed/34617315>
888. Chamling, B., Vehof, V., Drakos, S., Weil, M., Stalling, P., Vahlhaus, C., . . . Yilmaz, A. (2021). Occurrence of acute infarct-like myocarditis following COVID-19 vaccination: just an accidental co-incidence or rather vaccination-associated autoimmune myocarditis? Clin Res Cardiol, 110(11), 1850-1854. doi:10.1007/s00392-021-01916-w. <https://www.ncbi.nlm.nih.gov/pubmed/34333695>
889. Chang, J. C., & Hawley, H. B. (2021). Vaccine-Associated Thrombocytopenia and Thrombosis: Venous Endotheliopathy Leading to Venous Combined Micro-Macrothrombosis. Medicina (Kaunas), 57(11). doi:10.3390/medicina57111163. <https://www.ncbi.nlm.nih.gov/pubmed/34833382>
890. Chelala, L., Jeudy, J., Hossain, R., Rosenthal, G., Pietris, N., & White, C. (2021). Cardiac MRI Findings of Myocarditis After COVID-19 mRNA Vaccination in Adolescents. AJR Am J Roentgenol. doi:10.2214/AJR.21.26853. <https://www.ncbi.nlm.nih.gov/pubmed/34704459>
891. Choi, S., Lee, S., Seo, J. W., Kim, M. J., Jeon, Y. H., Park, J. H., . . . Yeo, N. S. (2021). Myocarditis-induced Sudden Death after BNT162b2 mRNA COVID-19 Vaccination in Korea: Case Report Focusing on Histopathological Findings. J Korean Med Sci, 36(40), e286. doi:10.3346/jkms.2021.36.e286. <https://www.ncbi.nlm.nih.gov/pubmed/34664804>
892. Chouchana, L., Blet, A., Al-Khalaf, M., Kafil, T. S., Nair, G., Robblee, J., . . . Liu, P. P. (2021). Features of Inflammatory Heart Reactions Following mRNA COVID-19 Vaccination at a Global Level. Clin Pharmacol Ther. doi:10.1002/cpt.2499. <https://www.ncbi.nlm.nih.gov/pubmed/34860360>
893. Chua, G. T., Kwan, M. Y. W., Chui, C. S. L., Smith, R. D., Cheung, E. C., Tian, T., . . . Ip, P. (2021). Epidemiology of Acute Myocarditis/Pericarditis in Hong Kong Adolescents Following Comirnaty Vaccination. Clin Infect Dis. doi:10.1093/cid/ciab989. <https://www.ncbi.nlm.nih.gov/pubmed/34849657>
894. Clarke, R., & Ioannou, A. (2021). Should T2 mapping be used in cases of recurrent myocarditis to differentiate between the acute inflammation and chronic scar? J Pediatr. doi:10.1016/j.jpeds.2021.12.026. <https://www.ncbi.nlm.nih.gov/pubmed/34933012>
895. Colaneri, M., De Filippo, M., Licari, A., Marseglia, A., Maiocchi, L., Ricciardi, A., . . . Bruno, R. (2021). COVID vaccination and asthma exacerbation: might there be a link? Int J Infect Dis, 112, 243-246. doi:10.1016/j.ijid.2021.09.026. <https://www.ncbi.nlm.nih.gov/pubmed/34547487>
896. Das, B. B., Kohli, U., Ramachandran, P., Nguyen, H. H., Greil, G., Hussain, T., . . . Khan, D. (2021). Myopericarditis after messenger RNA Coronavirus Disease 2019 Vaccination in Adolescents 12 to 18 Years of Age. J Pediatr, 238, 26-32 e21. doi:10.1016/j.jpeds.2021.07.044. <https://www.ncbi.nlm.nih.gov/pubmed/34339728>
897. Das, B. B., Moskowitz, W. B., Taylor, M. B., & Palmer, A. (2021). Myocarditis and Pericarditis Following mRNA COVID-19 Vaccination: What Do We Know So Far? Children (Basel), 8(7). doi:10.3390/children8070607. <https://www.ncbi.nlm.nih.gov/pubmed/34356586>
898. Deb, A., Abdelmalek, J., Iwuji, K., & Nugent, K. (2021). Acute Myocardial Injury Following COVID-19 Vaccination: A Case Report and Review of Current Evidence from Vaccine Adverse Events Reporting System Database. J Prim Care Community Health, 12, 21501327211029230. doi:10.1177/21501327211029230. <https://www.ncbi.nlm.nih.gov/pubmed/34219532>
899. Dickey, J. B., Albert, E., Badr, M., Laraja, K. M., Sena, L. M., Gerson, D. S., . . . Aurigemma, G. P. (2021). A Series of Patients With Myocarditis Following SARS-CoV-2 Vaccination With mRNA-1279 and BNT162b2. JACC Cardiovasc Imaging, 14(9), 1862-1863. doi:10.1016/j.jcmg.2021.06.003. <https://www.ncbi.nlm.nih.gov/pubmed/34246585>
900. Dimopoulou, D., Spyridis, N., Vartzelis, G., Tsolia, M. N., & Maritsi, D. N. (2021). Safety and tolerability of the COVID-19 mRNA-vaccine in adolescents with juvenile idiopathic arthritis on treatment with TNF-inhibitors. Arthritis Rheumatol. doi:10.1002/art.41977. <https://www.ncbi.nlm.nih.gov/pubmed/34492161>
901. Dimopoulou, D., Vartzelis, G., Dasoula, F., Tsolia, M., & Maritsi, D. (2021). Immunogenicity of the COVID-19 mRNA vaccine in adolescents with juvenile idiopathic arthritis on treatment with TNF inhibitors. Ann Rheum Dis. doi:10.1136/annrheumdis-2021-221607. <https://www.ncbi.nlm.nih.gov/pubmed/34844930>
902. Ehrlich, P., Klingel, K., Ohlmann-Knafo, S., Huttinger, S., Sood, N., Pickuth, D., & Kindermann, M. (2021). Biopsy-proven lymphocytic myocarditis following first mRNA COVID-19 vaccination in a 40-year-old male: case report. Clin Res Cardiol, 110(11), 1855-1859. doi:10.1007/s00392-021-01936-6. <https://www.ncbi.nlm.nih.gov/pubmed/34487236>

1. El Sahly, H. M., Baden, L. R., Essink, B., Doblecki-Lewis, S., Martin, J. M., Anderson, E. J., . . . Group, C. S. (2021). Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase. N Engl J Med, 385(19), 1774-1785. doi:10.1056/NEJMoa2113017. <https://www.ncbi.nlm.nih.gov/pubmed/34551225>
2. Facetti, S., Giraldi, M., Vecchi, A. L., Rogiani, S., & Nassiacos, D. (2021). [Acute myocarditis in a young adult two days after Pfizer vaccination]. G Ital Cardiol (Rome), 22(11), 891-893. doi:10.1714/3689.36746. <https://www.ncbi.nlm.nih.gov/pubmed/34709227>
3. Fazlollahi, A., Zahmatyar, M., Noori, M., Nejadghaderi, S. A., Sullman, M. J. M., Shekarriz-Foumani, R., . . . Safiri, S. (2021). Cardiac complications following mRNA COVID-19 vaccines: A systematic review of case reports and case series. Rev Med Virol, e2318. doi:10.1002/rmv.2318. <https://www.ncbi.nlm.nih.gov/pubmed/34921468>
4. Fazolo, T., Lima, K., Fontoura, J. C., de Souza, P. O., Hilario, G., Zorzetto, R., . . . Bonorino, C. (2021). Pediatric COVID-19 patients in South Brazil show abundant viral mRNA and strong specific anti-viral responses. Nat Commun, 12(1), 6844. doi:10.1038/s41467-021-27120-y. <https://www.ncbi.nlm.nih.gov/pubmed/34824230>
5. Fikenzer, S., & Laufs, U. (2021). Correction to: Response to Letter to the editors referring to Fikenzer, S., Uhe, T., Lavall, D., Rudolph, U., Falz, R., Busse, M., Hepp, P., & Laufs, U. (2020). Effects of surgical and FFP2/N95 face masks on cardiopulmonary exercise capacity. Clinical research in cardiology: official journal of the German Cardiac Society, 1-9. Advance online publication. https://doi.org/10.1007/s00392-020-01704-y. Clin Res Cardiol, 110(8), 1352. doi:10.1007/s00392-021-01896-x. <https://www.ncbi.nlm.nih.gov/pubmed/34170372>
6. Foltran, D., Delmas, C., Flumian, C., De Paoli, P., Salvo, F., Gautier, S., . . . Montastruc, F. (2021). Myocarditis and Pericarditis in Adolescents after First and Second doses of mRNA COVID-19 Vaccines. Eur Heart J Qual Care Clin Outcomes. doi:10.1093/ehjqcco/qcab090. <https://www.ncbi.nlm.nih.gov/pubmed/34849667>
7. Forgacs, D., Jang, H., Abreu, R. B., Hanley, H. B., Gattiker, J. L., Jefferson, A. M., & Ross, T. M. (2021). SARS-CoV-2 mRNA Vaccines Elicit Different Responses in Immunologically Naive and Pre-Immune Humans. Front Immunol, 12, 728021. doi:10.3389/fimmu.2021.728021. <https://www.ncbi.nlm.nih.gov/pubmed/34646267>
8. Furer, V., Eviatar, T., Zisman, D., Peleg, H., Paran, D., Levartovsky, D., . . . Elkayam, O. (2021). Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study. Ann Rheum Dis, 80(10), 1330-1338. doi:10.1136/annrheumdis-2021-220647. <https://www.ncbi.nlm.nih.gov/pubmed/34127481>
9. Galindo, R., Chow, H., & Rongkavilit, C. (2021). COVID-19 in Children: Clinical Manifestations and Pharmacologic Interventions Including Vaccine Trials. Pediatr Clin North Am, 68(5), 961-976. doi:10.1016/j.pcl.2021.05.004. <https://www.ncbi.nlm.nih.gov/pubmed/34538306>
10. Gargano, J. W., Wallace, M., Hadler, S. C., Langley, G., Su, J. R., Oster, M. E., . . . Oliver, S. E. (2021). Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices – United States, June 2021. MMWR Morb Mortal Wkly Rep, 70(27), 977-982. doi:10.15585/mmwr.mm7027e2. <https://www.ncbi.nlm.nih.gov/pubmed/34237049>
11. Gatti, M., Raschi, E., Moretti, U., Ardizzoni, A., Poluzzi, E., & Diemberger, I. (2021). Influenza Vaccination and Myo-Pericarditis in Patients Receiving Immune Checkpoint Inhibitors: Investigating the Likelihood of Interaction through the Vaccine Adverse Event Reporting System and VigiBase. Vaccines (Basel), 9(1). doi:10.3390/vaccines9010019. <https://www.ncbi.nlm.nih.gov/pubmed/33406694>
12. Gautam, N., Saluja, P., Fudim, M., Jambhekar, K., Pandey, T., & Al’Aref, S. (2021). A Late Presentation of COVID-19 Vaccine-Induced Myocarditis. Cureus, 13(9), e17890. doi:10.7759/cureus.17890. <https://www.ncbi.nlm.nih.gov/pubmed/34660088>
13. Gellad, W. F. (2021). Myocarditis after vaccination against covid-19. BMJ, 375, n3090. doi:10.1136/bmj.n3090. <https://www.ncbi.nlm.nih.gov/pubmed/34916217>
14. Greenhawt, M., Abrams, E. M., Shaker, M., Chu, D. K., Khan, D., Akin, C., . . . Golden, D. B. K. (2021). The Risk of Allergic Reaction to SARS-CoV-2 Vaccines and Recommended Evaluation and Management: A Systematic Review, Meta-Analysis, GRADE Assessment, and International Consensus Approach. J Allergy Clin Immunol Pract, 9(10), 3546-3567. doi:10.1016/j.jaip.2021.06.006. <https://www.ncbi.nlm.nih.gov/pubmed/34153517>
15. Haaf, P., Kuster, G. M., Mueller, C., Berger, C. T., Monney, P., Burger, P., . . . Tanner, F. C. (2021). The very low risk of myocarditis and pericarditis after mRNA COVID-19 vaccination should not discourage vaccination. Swiss Med Wkly, 151, w30087. doi:10.4414/smw.2021.w30087. <https://www.ncbi.nlm.nih.gov/pubmed/34668687>
16. Hasnie, A. A., Hasnie, U. A., Patel, N., Aziz, M. U., Xie, M., Lloyd, S. G., & Prabhu, S. D. (2021). Perimyocarditis following first dose of the mRNA-1273 SARS-CoV-2 (Moderna) vaccine in a healthy young male: a case report. BMC Cardiovasc Disord, 21(1), 375. doi:10.1186/s12872-021-02183-3. <https://www.ncbi.nlm.nih.gov/pubmed/34348657>
17. Hause, A. M., Gee, J., Baggs, J., Abara, W. E., Marquez, P., Thompson, D., . . . Shay, D. K. (2021). COVID-19 Vaccine Safety in Adolescents Aged 12-17 Years – United States, December 14, 2020-July 16, 2021. MMWR Morb Mortal Wkly Rep, 70(31), 1053-1058. doi:10.15585/mmwr.mm7031e1. <https://www.ncbi.nlm.nih.gov/pubmed/34351881>
18. Helms, J. M., Ansteatt, K. T., Roberts, J. C., Kamatam, S., Foong, K. S., Labayog, J. S., & Tarantino, M. D. (2021). Severe, Refractory Immune Thrombocytopenia Occurring After SARS-CoV-2 Vaccine. J Blood Med, 12, 221-224. doi:10.2147/JBM.S307047. <https://www.ncbi.nlm.nih.gov/pubmed/33854395>
19. Hippisley-Cox, J., Patone, M., Mei, X. W., Saatci, D., Dixon, S., Khunti, K., . . . Coupland, C. A. C. (2021). Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and SARS-CoV-2 positive testing: self-controlled case series study. BMJ, 374, n1931. doi:10.1136/bmj.n1931. <https://www.ncbi.nlm.nih.gov/pubmed/34446426>
20. Ho, J. S., Sia, C. H., Ngiam, J. N., Loh, P. H., Chew, N. W., Kong, W. K., & Poh, K. K. (2021). A review of COVID-19 vaccination and the reported cardiac manifestations. Singapore Med J. doi:10.11622/smedj.2021210. <https://www.ncbi.nlm.nih.gov/pubmed/34808708>
21. Iguchi, T., Umeda, H., Kojima, M., Kanno, Y., Tanaka, Y., Kinoshita, N., & Sato, D. (2021). Cumulative Adverse Event Reporting of Anaphylaxis After mRNA COVID-19 Vaccine (Pfizer-BioNTech) Injections in Japan: The First-Month Report. Drug Saf, 44(11), 1209-1214. doi:10.1007/s40264-021-01104-9. <https://www.ncbi.nlm.nih.gov/pubmed/34347278>
22. In brief: Myocarditis with the Pfizer/BioNTech and Moderna COVID-19 vaccines. (2021). Med Lett Drugs Ther, 63(1629), e9. Retrieved from [https://www.ncbi.nlm.nih.gov/pubmed/34544112https://www.ncbi.nlm.nih.gov/pubmed/3454412](https://www.ncbi.nlm.nih.gov/pubmed/34544112https:/www.ncbi.nlm.nih.gov/pubmed/3454412)
23. Ioannou, A. (2021a). Myocarditis should be considered in those with a troponin rise and unobstructed coronary arteries following Pfizer-BioNTech COVID-19 vaccination. QJM. doi:10.1093/qjmed/hcab231. <https://www.ncbi.nlm.nih.gov/pubmed/34463755>
24. Ioannou, A. (2021b). T2 mapping should be utilised in cases of suspected myocarditis to confirm an acute inflammatory process. QJM. doi:10.1093/qjmed/hcab326. <https://www.ncbi.nlm.nih.gov/pubmed/34931681>
25. Isaak, A., Feisst, A., & Luetkens, J. A. (2021). Myocarditis Following COVID-19 Vaccination. Radiology, 301(1), E378-E379. doi:10.1148/radiol.2021211766. <https://www.ncbi.nlm.nih.gov/pubmed/34342500>
26. Istampoulouoglou, I., Dimitriou, G., Spani, S., Christ, A., Zimmermanns, B., Koechlin, S., . . . Leuppi-Taegtmeyer, A. B. (2021). Myocarditis and pericarditis in association with COVID-19 mRNA-vaccination: cases from a regional pharmacovigilance centre. Glob Cardiol Sci Pract, 2021(3), e202118. doi:10.21542/gcsp.2021.18. <https://www.ncbi.nlm.nih.gov/pubmed/34805376>
27. Jaafar, R., Boschi, C., Aherfi, S., Bancod, A., Le Bideau, M., Edouard, S., . . . La Scola, B. (2021). High Individual Heterogeneity of Neutralizing Activities against the Original Strain and Nine Different Variants of SARS-CoV-2. Viruses, 13(11). doi:10.3390/v13112177. <https://www.ncbi.nlm.nih.gov/pubmed/34834983>
28. Jain, S. S., Steele, J. M., Fonseca, B., Huang, S., Shah, S., Maskatia, S. A., . . . Grosse-Wortmann, L. (2021). COVID-19 Vaccination-Associated Myocarditis in Adolescents. Pediatrics, 148(5). doi:10.1542/peds.2021-053427. <https://www.ncbi.nlm.nih.gov/pubmed/34389692>
29. Jhaveri, R., Adler-Shohet, F. C., Blyth, C. C., Chiotos, K., Gerber, J. S., Green, M., . . . Zaoutis, T. (2021). Weighing the Risks of Perimyocarditis With the Benefits of SARS-CoV-2 mRNA Vaccination in Adolescents. J Pediatric Infect Dis Soc, 10(10), 937-939. doi:10.1093/jpids/piab061. <https://www.ncbi.nlm.nih.gov/pubmed/34270752>
30. Kaneta, K., Yokoi, K., Jojima, K., Kotooka, N., & Node, K. (2021). Young Male With Myocarditis Following mRNA-1273 Vaccination Against Coronavirus Disease-2019 (COVID-19). Circ J. doi:10.1253/circj.CJ-21-0818. <https://www.ncbi.nlm.nih.gov/pubmed/34744118>
31. Kaul, R., Sreenivasan, J., Goel, A., Malik, A., Bandyopadhyay, D., Jin, C., . . . Panza, J. A. (2021). Myocarditis following COVID-19 vaccination. Int J Cardiol Heart Vasc, 36, 100872. doi:10.1016/j.ijcha.2021.100872. <https://www.ncbi.nlm.nih.gov/pubmed/34568540>
32. Khogali, F., & Abdelrahman, R. (2021). Unusual Presentation of Acute Perimyocarditis Following SARS-COV-2 mRNA-1237 Moderna Vaccination. Cureus, 13(7), e16590. doi:10.7759/cureus.16590. <https://www.ncbi.nlm.nih.gov/pubmed/34447639>
33. Kim, H. W., Jenista, E. R., Wendell, D. C., Azevedo, C. F., Campbell, M. J., Darty, S. N., . . . Kim, R. J. (2021). Patients With Acute Myocarditis Following mRNA COVID-19 Vaccination. JAMA Cardiol, 6(10), 1196-1201. doi:10.1001/jamacardio.2021.2828. <https://www.ncbi.nlm.nih.gov/pubmed/34185046>
34. Kim, I. C., Kim, H., Lee, H. J., Kim, J. Y., & Kim, J. Y. (2021). Cardiac Imaging of Acute Myocarditis Following COVID-19 mRNA Vaccination. J Korean Med Sci, 36(32), e229. doi:10.3346/jkms.2021.36.e229. <https://www.ncbi.nlm.nih.gov/pubmed/34402228>
35. King, W. W., Petersen, M. R., Matar, R. M., Budweg, J. B., Cuervo Pardo, L., & Petersen, J. W. (2021). Myocarditis following mRNA vaccination against SARS-CoV-2, a case series. Am Heart J Plus, 8, 100042. doi:10.1016/j.ahjo.2021.100042. <https://www.ncbi.nlm.nih.gov/pubmed/34396358>
36. Klein, N. P., Lewis, N., Goddard, K., Fireman, B., Zerbo, O., Hanson, K. E., . . . Weintraub, E. S. (2021). Surveillance for Adverse Events After COVID-19 mRNA Vaccination. JAMA, 326(14), 1390-1399. doi:10.1001/jama.2021.15072. <https://www.ncbi.nlm.nih.gov/pubmed/34477808>
37. Klimek, L., Bergmann, K. C., Brehler, R., Pfutzner, W., Zuberbier, T., Hartmann, K., . . . Worm, M. (2021). Practical handling of allergic reactions to COVID-19 vaccines: A position paper from German and Austrian Allergy Societies AeDA, DGAKI, GPA and OGAI. Allergo J Int, 1-17. doi:10.1007/s40629-021-00165-7. <https://www.ncbi.nlm.nih.gov/pubmed/33898162>
38. Klimek, L., Novak, N., Hamelmann, E., Werfel, T., Wagenmann, M., Taube, C., . . . Worm, M. (2021). Severe allergic reactions after COVID-19 vaccination with the Pfizer/BioNTech vaccine in Great Britain and USA: Position statement of the German Allergy Societies: Medical Association of German Allergologists (AeDA), German Society for Allergology and Clinical Immunology (DGAKI) and Society for Pediatric Allergology and Environmental Medicine (GPA). Allergo J Int, 30(2), 51-55. doi:10.1007/s40629-020-00160-4. <https://www.ncbi.nlm.nih.gov/pubmed/33643776>
39. Kohli, U., Desai, L., Chowdhury, D., Harahsheh, A. S., Yonts, A. B., Ansong, A., . . . Ang, J. Y. (2021). mRNA Coronavirus-19 Vaccine-Associated Myopericarditis in Adolescents: A Survey Study. J Pediatr. doi:10.1016/j.jpeds.2021.12.025. <https://www.ncbi.nlm.nih.gov/pubmed/34952008>
40. Kostoff, R. N., Calina, D., Kanduc, D., Briggs, M. B., Vlachoyiannopoulos, P., Svistunov, A. A., & Tsatsakis, A. (2021a). Erratum to “Why are we vaccinating children against COVID-19?” [Toxicol. Rep. 8C (2021) 1665-1684 / 1193]. Toxicol Rep, 8, 1981. doi:10.1016/j.toxrep.2021.10.003. <https://www.ncbi.nlm.nih.gov/pubmed/34642628>
41. Kostoff, R. N., Calina, D., Kanduc, D., Briggs, M. B., Vlachoyiannopoulos, P., Svistunov, A. A., & Tsatsakis, A. (2021b). Why are we vaccinating children against COVID-19? Toxicol Rep, 8, 1665-1684. doi:10.1016/j.toxrep.2021.08.010. <https://www.ncbi.nlm.nih.gov/pubmed/34540594>
42. Kremsner, P. G., Mann, P., Kroidl, A., Leroux-Roels, I., Schindler, C., Gabor, J. J., . . . Group, C.-N.-S. (2021). Safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2 : A phase 1 randomized clinical trial. Wien Klin Wochenschr, 133(17-18), 931-941. doi:10.1007/s00508-021-01922-y. <https://www.ncbi.nlm.nih.gov/pubmed/34378087>
43. Kustin, T., Harel, N., Finkel, U., Perchik, S., Harari, S., Tahor, M., . . . Stern, A. (2021). Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals. Nat Med, 27(8), 1379-1384. doi:10.1038/s41591-021-01413-7. <https://www.ncbi.nlm.nih.gov/pubmed/34127854>
44. Kwan, M. Y. W., Chua, G. T., Chow, C. B., Tsao, S. S. L., To, K. K. W., Yuen, K. Y., . . . Ip, P. (2021). mRNA COVID vaccine and myocarditis in adolescents. Hong Kong Med J, 27(5), 326-327. doi:10.12809/hkmj215120. <https://www.ncbi.nlm.nih.gov/pubmed/34393110>
45. Lee, E., Chew, N. W. S., Ng, P., & Yeo, T. J. (2021). Reply to “Letter to the editor: Myocarditis should be considered in those with a troponin rise and unobstructed coronary arteries following PfizerBioNTech COVID-19 vaccination”. QJM. doi:10.1093/qjmed/hcab232. <https://www.ncbi.nlm.nih.gov/pubmed/34463770>
46. Lee, E. J., Cines, D. B., Gernsheimer, T., Kessler, C., Michel, M., Tarantino, M. D., . . . Bussel, J. B. (2021). Thrombocytopenia following Pfizer and Moderna SARS-CoV-2 vaccination. Am J Hematol, 96(5), 534-537. doi:10.1002/ajh.26132. <https://www.ncbi.nlm.nih.gov/pubmed/33606296>
47. Levin, D., Shimon, G., Fadlon-Derai, M., Gershovitz, L., Shovali, A., Sebbag, A., . . . Gordon, B. (2021). Myocarditis following COVID-19 vaccination – A case series. Vaccine, 39(42), 6195-6200. doi:10.1016/j.vaccine.2021.09.004. <https://www.ncbi.nlm.nih.gov/pubmed/34535317>
48. Li, J., Hui, A., Zhang, X., Yang, Y., Tang, R., Ye, H., . . . Zhu, F. (2021). Safety and immunogenicity of the SARS-CoV-2 BNT162b1 mRNA vaccine in younger and older Chinese adults: a randomized, placebo-controlled, double-blind phase 1 study. Nat Med, 27(6), 1062-1070. doi:10.1038/s41591-021-01330-9. <https://www.ncbi.nlm.nih.gov/pubmed/33888900>
49. Li, M., Yuan, J., Lv, G., Brown, J., Jiang, X., & Lu, Z. K. (2021). Myocarditis and Pericarditis following COVID-19 Vaccination: Inequalities in Age and Vaccine Types. J Pers Med, 11(11). doi:10.3390/jpm11111106. <https://www.ncbi.nlm.nih.gov/pubmed/34834458>
50. Lim, Y., Kim, M. C., Kim, K. H., Jeong, I. S., Cho, Y. S., Choi, Y. D., & Lee, J. E. (2021). Case Report: Acute Fulminant Myocarditis and Cardiogenic Shock After Messenger RNA Coronavirus Disease 2019 Vaccination Requiring Extracorporeal Cardiopulmonary Resuscitation. Front Cardiovasc Med, 8, 758996. doi:10.3389/fcvm.2021.758996. <https://www.ncbi.nlm.nih.gov/pubmed/34778411>
51. Long, S. S. (2021). Important Insights into Myopericarditis after the Pfizer mRNA COVID-19 Vaccination in Adolescents. J Pediatr, 238, 5. doi:10.1016/j.jpeds.2021.07.057. <https://www.ncbi.nlm.nih.gov/pubmed/34332972>
52. Luk, A., Clarke, B., Dahdah, N., Ducharme, A., Krahn, A., McCrindle, B., . . . McDonald, M. (2021). Myocarditis and Pericarditis After COVID-19 mRNA Vaccination: Practical Considerations for Care Providers. Can J Cardiol, 37(10), 1629-1634. doi:10.1016/j.cjca.2021.08.001. <https://www.ncbi.nlm.nih.gov/pubmed/34375696>
53. Madelon, N., Lauper, K., Breville, G., Sabater Royo, I., Goldstein, R., Andrey, D. O., . . . Eberhardt, C. S. (2021). Robust T cell responses in anti-CD20 treated patients following COVID-19 vaccination: a prospective cohort study. Clin Infect Dis. doi:10.1093/cid/ciab954. <https://www.ncbi.nlm.nih.gov/pubmed/34791081>
54. Mangat, C., & Milosavljevic, N. (2021). BNT162b2 Vaccination during Pregnancy Protects Both the Mother and Infant: Anti-SARS-CoV-2 S Antibodies Persistently Positive in an Infant at 6 Months of Age. Case Rep Pediatr, 2021, 6901131. doi:10.1155/2021/6901131. <https://www.ncbi.nlm.nih.gov/pubmed/34676123>
55. Mark, C., Gupta, S., Punnett, A., Upton, J., Orkin, J., Atkinson, A., . . . Alexander, S. (2021). Safety of administration of BNT162b2 mRNA (Pfizer-BioNTech) COVID-19 vaccine in youths and young adults with a history of acute lymphoblastic leukemia and allergy to PEG-asparaginase. Pediatr Blood Cancer, 68(11), e29295. doi:10.1002/pbc.29295. <https://www.ncbi.nlm.nih.gov/pubmed/34398511>
56. Martins-Filho, P. R., Quintans-Junior, L. J., de Souza Araujo, A. A., Sposato, K. B., Souza Tavares, C. S., Gurgel, R. Q., . . . Santos, V. S. (2021). Socio-economic inequalities and COVID-19 incidence and mortality in Brazilian children: a nationwide register-based study. Public Health, 190, 4-6. doi:10.1016/j.puhe.2020.11.005. <https://www.ncbi.nlm.nih.gov/pubmed/33316478>
57. McLean, K., & Johnson, T. J. (2021). Myopericarditis in a previously healthy adolescent male following COVID-19 vaccination: A case report. Acad Emerg Med, 28(8), 918-921. doi:10.1111/acem.14322. <https://www.ncbi.nlm.nih.gov/pubmed/34133825>
58. Mevorach, D., Anis, E., Cedar, N., Bromberg, M., Haas, E. J., Nadir, E., . . . Alroy-Preis, S. (2021). Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel. N Engl J Med, 385(23), 2140-2149. doi:10.1056/NEJMoa2109730. <https://www.ncbi.nlm.nih.gov/pubmed/34614328>
59. Minocha, P. K., Better, D., Singh, R. K., & Hoque, T. (2021). Recurrence of Acute Myocarditis Temporally Associated with Receipt of the mRNA Coronavirus Disease 2019 (COVID-19) Vaccine in a Male Adolescent. J Pediatr, 238, 321-323. doi:10.1016/j.jpeds.2021.06.035. <https://www.ncbi.nlm.nih.gov/pubmed/34166671>
60. Mizrahi, B., Lotan, R., Kalkstein, N., Peretz, A., Perez, G., Ben-Tov, A., . . . Patalon, T. (2021). Correlation of SARS-CoV-2-breakthrough infections to time-from-vaccine. Nat Commun, 12(1), 6379. doi:10.1038/s41467-021-26672-3. <https://www.ncbi.nlm.nih.gov/pubmed/34737312>
61. Moffitt, K., Cheung, E., Yeung, T., Stamoulis, C., & Malley, R. (2021). Analysis of Staphylococcus aureus Transcriptome in Pediatric Soft Tissue Abscesses and Comparison to Murine Infections. Infect Immun, 89(4). doi:10.1128/IAI.00715-20. <https://www.ncbi.nlm.nih.gov/pubmed/33526560>
62. Mohamed, L., Madsen, A. M. R., Schaltz-Buchholzer, F., Ostenfeld, A., Netea, M. G., Benn, C. S., & Kofoed, P. E. (2021). Reactivation of BCG vaccination scars after vaccination with mRNA-Covid-vaccines: two case reports. BMC Infect Dis, 21(1), 1264. doi:10.1186/s12879-021-06949-0. <https://www.ncbi.nlm.nih.gov/pubmed/34930152>
63. Montgomery, J., Ryan, M., Engler, R., Hoffman, D., McClenathan, B., Collins, L., . . . Cooper, L. T., Jr. (2021). Myocarditis Following Immunization With mRNA COVID-19 Vaccines in Members of the US Military. JAMA Cardiol, 6(10), 1202-1206. doi:10.1001/jamacardio.2021.2833. <https://www.ncbi.nlm.nih.gov/pubmed/34185045>
64. Murakami, Y., Shinohara, M., Oka, Y., Wada, R., Noike, R., Ohara, H., . . . Ikeda, T. (2021). Myocarditis Following a COVID-19 Messenger RNA Vaccination: A Japanese Case Series. Intern Med. doi:10.2169/internalmedicine.8731-21. <https://www.ncbi.nlm.nih.gov/pubmed/34840235>
65. Nagasaka, T., Koitabashi, N., Ishibashi, Y., Aihara, K., Takama, N., Ohyama, Y., . . . Kaneko, Y. (2021). Acute Myocarditis Associated with COVID-19 Vaccination: A Case Report. J Cardiol Cases. doi:10.1016/j.jccase.2021.11.006. <https://www.ncbi.nlm.nih.gov/pubmed/34876937>

1. Ntouros, P. A., Vlachogiannis, N. I., Pappa, M., Nezos, A., Mavragani, C. P., Tektonidou, M. G., . . . Sfikakis, P. P. (2021). Effective DNA damage response after acute but not chronic immune challenge: SARS-CoV-2 vaccine versus Systemic Lupus Erythematosus. Clin Immunol, 229, 108765. doi:10.1016/j.clim.2021.108765. <https://www.ncbi.nlm.nih.gov/pubmed/34089859>
2. Nygaard, U., Holm, M., Bohnstedt, C., Chai, Q., Schmidt, L. S., Hartling, U. B., . . . Stensballe, L. G. (2022). Population-based Incidence of Myopericarditis After COVID-19 Vaccination in Danish Adolescents. Pediatr Infect Dis J, 41(1), e25-e28. doi:10.1097/INF.0000000000003389. <https://www.ncbi.nlm.nih.gov/pubmed/34889875>
3. Oberhardt, V., Luxenburger, H., Kemming, J., Schulien, I., Ciminski, K., Giese, S., . . . Hofmann, M. (2021). Rapid and stable mobilization of CD8(+) T cells by SARS-CoV-2 mRNA vaccine. Nature, 597(7875), 268-273. doi:10.1038/s41586-021-03841-4. <https://www.ncbi.nlm.nih.gov/pubmed/34320609>
4. Park, H., Yun, K. W., Kim, K. R., Song, S. H., Ahn, B., Kim, D. R., . . . Kim, Y. J. (2021). Epidemiology and Clinical Features of Myocarditis/Pericarditis before the Introduction of mRNA COVID-19 Vaccine in Korean Children: a Multicenter Study. J Korean Med Sci, 36(32), e232. doi:10.3346/jkms.2021.36.e232. <https://www.ncbi.nlm.nih.gov/pubmed/34402230>
5. Park, J., Brekke, D. R., & Bratincsak, A. (2021). Self-limited myocarditis presenting with chest pain and ST segment elevation in adolescents after vaccination with the BNT162b2 mRNA vaccine. Cardiol Young, 1-4. doi:10.1017/S1047951121002547. <https://www.ncbi.nlm.nih.gov/pubmed/34180390>
6. Patel, Y. R., Louis, D. W., Atalay, M., Agarwal, S., & Shah, N. R. (2021). Cardiovascular magnetic resonance findings in young adult patients with acute myocarditis following mRNA COVID-19 vaccination: a case series. J Cardiovasc Magn Reson, 23(1), 101. doi:10.1186/s12968-021-00795-4. <https://www.ncbi.nlm.nih.gov/pubmed/34496880>
7. Patone, M., Mei, X. W., Handunnetthi, L., Dixon, S., Zaccardi, F., Shankar-Hari, M., . . . Hippisley-Cox, J. (2021). Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection. Nat Med. doi:10.1038/s41591-021-01630-0. <https://www.ncbi.nlm.nih.gov/pubmed/34907393>
8. Patrignani, A., Schicchi, N., Calcagnoli, F., Falchetti, E., Ciampani, N., Argalia, G., & Mariani, A. (2021). Acute myocarditis following Comirnaty vaccination in a healthy man with previous SARS-CoV-2 infection. Radiol Case Rep, 16(11), 3321-3325. doi:10.1016/j.radcr.2021.07.082. <https://www.ncbi.nlm.nih.gov/pubmed/34367386>
9. Perez, Y., Levy, E. R., Joshi, A. Y., Virk, A., Rodriguez-Porcel, M., Johnson, M., . . . Swift, M. D. (2021). Myocarditis Following COVID-19 mRNA Vaccine: A Case Series and Incidence Rate Determination. Clin Infect Dis. doi:10.1093/cid/ciab926. <https://www.ncbi.nlm.nih.gov/pubmed/34734240>
10. Perrotta, A., Biondi-Zoccai, G., Saade, W., Miraldi, F., Morelli, A., Marullo, A. G., . . . Peruzzi, M. (2021). A snapshot global survey on side effects of COVID-19 vaccines among healthcare professionals and armed forces with a focus on headache. Panminerva Med, 63(3), 324-331. doi:10.23736/S0031-0808.21.04435-9. <https://www.ncbi.nlm.nih.gov/pubmed/34738774>

1. Pinana, J. L., Lopez-Corral, L., Martino, R., Montoro, J., Vazquez, L., Perez, A., . . . Cell Therapy, G. (2022). SARS-CoV-2-reactive antibody detection after SARS-CoV-2 vaccination in hematopoietic stem cell transplant recipients: Prospective survey from the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group. Am J Hematol, 97(1), 30-42. doi:10.1002/ajh.26385. <https://www.ncbi.nlm.nih.gov/pubmed/34695229>
2. Revon-Riviere, G., Ninove, L., Min, V., Rome, A., Coze, C., Verschuur, A., . . . Andre, N. (2021). The BNT162b2 mRNA COVID-19 vaccine in adolescents and young adults with cancer: A monocentric experience. Eur J Cancer, 154, 30-34. doi:10.1016/j.ejca.2021.06.002. <https://www.ncbi.nlm.nih.gov/pubmed/34233234>
3. Sanchez Tijmes, F., Thavendiranathan, P., Udell, J. A., Seidman, M. A., & Hanneman, K. (2021). Cardiac MRI Assessment of Nonischemic Myocardial Inflammation: State of the Art Review and Update on Myocarditis Associated with COVID-19 Vaccination. Radiol Cardiothorac Imaging, 3(6), e210252. doi:10.1148/ryct.210252. <https://www.ncbi.nlm.nih.gov/pubmed/34934954>
4. Schauer, J., Buddhe, S., Colyer, J., Sagiv, E., Law, Y., Mallenahalli Chikkabyrappa, S., & Portman, M. A. (2021). Myopericarditis After the Pfizer Messenger Ribonucleic Acid Coronavirus Disease Vaccine in Adolescents. J Pediatr, 238, 317-320. doi:10.1016/j.jpeds.2021.06.083. <https://www.ncbi.nlm.nih.gov/pubmed/34228985>
5. Schneider, J., Sottmann, L., Greinacher, A., Hagen, M., Kasper, H. U., Kuhnen, C., . . . Schmeling, A. (2021). Postmortem investigation of fatalities following vaccination with COVID-19 vaccines. Int J Legal Med, 135(6), 2335-2345. doi:10.1007/s00414-021-02706-9. <https://www.ncbi.nlm.nih.gov/pubmed/34591186>
6. Schramm, R., Costard-Jackle, A., Rivinius, R., Fischer, B., Muller, B., Boeken, U., . . . Gummert, J. (2021). Poor humoral and T-cell response to two-dose SARS-CoV-2 messenger RNA vaccine BNT162b2 in cardiothoracic transplant recipients. Clin Res Cardiol, 110(8), 1142-1149. doi:10.1007/s00392-021-01880-5. <https://www.ncbi.nlm.nih.gov/pubmed/34241676>
7. Sessa, F., Salerno, M., Esposito, M., Di Nunno, N., Zamboni, P., & Pomara, C. (2021). Autopsy Findings and Causality Relationship between Death and COVID-19 Vaccination: A Systematic Review. J Clin Med, 10(24). doi:10.3390/jcm10245876. <https://www.ncbi.nlm.nih.gov/pubmed/34945172>
8. Sharif, N., Alzahrani, K. J., Ahmed, S. N., & Dey, S. K. (2021). Efficacy, Immunogenicity and Safety of COVID-19 Vaccines: A Systematic Review and Meta-Analysis. Front Immunol, 12, 714170. doi:10.3389/fimmu.2021.714170. <https://www.ncbi.nlm.nih.gov/pubmed/34707602>
9. Shay, D. K., Gee, J., Su, J. R., Myers, T. R., Marquez, P., Liu, R., . . . Shimabukuro, T. T. (2021). Safety Monitoring of the Janssen (Johnson & Johnson) COVID-19 Vaccine – United States, March-April 2021. MMWR Morb Mortal Wkly Rep, 70(18), 680-684. doi:10.15585/mmwr.mm7018e2. <https://www.ncbi.nlm.nih.gov/pubmed/33956784>
10. Shazley, O., & Alshazley, M. (2021). A COVID-Positive 52-Year-Old Man Presented With Venous Thromboembolism and Disseminated Intravascular Coagulation Following Johnson & Johnson Vaccination: A Case-Study. Cureus, 13(7), e16383. doi:10.7759/cureus.16383. <https://www.ncbi.nlm.nih.gov/pubmed/34408937>
11. Shiyovich, A., Witberg, G., Aviv, Y., Eisen, A., Orvin, K., Wiessman, M., . . . Hamdan, A. (2021). Myocarditis following COVID-19 vaccination: magnetic resonance imaging study. Eur Heart J Cardiovasc Imaging. doi:10.1093/ehjci/jeab230. <https://www.ncbi.nlm.nih.gov/pubmed/34739045>
12. Simone, A., Herald, J., Chen, A., Gulati, N., Shen, A. Y., Lewin, B., & Lee, M. S. (2021). Acute Myocarditis Following COVID-19 mRNA Vaccination in Adults Aged 18 Years or Older. JAMA Intern Med, 181(12), 1668-1670. doi:10.1001/jamainternmed.2021.5511. <https://www.ncbi.nlm.nih.gov/pubmed/34605853>
13. Singer, M. E., Taub, I. B., & Kaelber, D. C. (2021). Risk of Myocarditis from COVID-19 Infection in People Under Age 20: A Population-Based Analysis. medRxiv. doi:10.1101/2021.07.23.21260998. <https://www.ncbi.nlm.nih.gov/pubmed/34341797>
14. Smith, C., Odd, D., Harwood, R., Ward, J., Linney, M., Clark, M., . . . Fraser, L. K. (2021). Deaths in children and young people in England after SARS-CoV-2 infection during the first pandemic year. Nat Med. doi:10.1038/s41591-021-01578-1. <https://www.ncbi.nlm.nih.gov/pubmed/34764489>
15. Snapiri, O., Rosenberg Danziger, C., Shirman, N., Weissbach, A., Lowenthal, A., Ayalon, I., . . . Bilavsky, E. (2021). Transient Cardiac Injury in Adolescents Receiving the BNT162b2 mRNA COVID-19 Vaccine. Pediatr Infect Dis J, 40(10), e360-e363. doi:10.1097/INF.0000000000003235. <https://www.ncbi.nlm.nih.gov/pubmed/34077949>
16. Spinner, J. A., Julien, C. L., Olayinka, L., Dreyer, W. J., Bocchini, C. E., Munoz, F. M., & Devaraj, S. (2021). SARS-CoV-2 anti-spike antibodies after vaccination in pediatric heart transplantation: A first report. J Heart Lung Transplant. doi:10.1016/j.healun.2021.11.001. <https://www.ncbi.nlm.nih.gov/pubmed/34911654>
17. Starekova, J., Bluemke, D. A., Bradham, W. S., Grist, T. M., Schiebler, M. L., & Reeder, S. B. (2021). Myocarditis Associated with mRNA COVID-19 Vaccination. Radiology, 301(2), E409-E411. doi:10.1148/radiol.2021211430. <https://www.ncbi.nlm.nih.gov/pubmed/34282971>
18. Sulemankhil, I., Abdelrahman, M., & Negi, S. I. (2021). Temporal association between the COVID-19 Ad26.COV2.S vaccine and acute myocarditis: A case report and literature review. Cardiovasc Revasc Med. doi:10.1016/j.carrev.2021.08.012. <https://www.ncbi.nlm.nih.gov/pubmed/34420869>
19. Tailor, P. D., Feighery, A. M., El-Sabawi, B., & Prasad, A. (2021). Case report: acute myocarditis following the second dose of mRNA-1273 SARS-CoV-2 vaccine. Eur Heart J Case Rep, 5(8), ytab319. doi:10.1093/ehjcr/ytab319. <https://www.ncbi.nlm.nih.gov/pubmed/34514306>
20. Takeda, M., Ishio, N., Shoji, T., Mori, N., Matsumoto, M., & Shikama, N. (2021). Eosinophilic Myocarditis Following Coronavirus Disease 2019 (COVID-19) Vaccination. Circ J. doi:10.1253/circj.CJ-21-0935. <https://www.ncbi.nlm.nih.gov/pubmed/34955479>
21. Team, C. C.-R., Food, & Drug, A. (2021). Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine – United States, December 14-23, 2020. MMWR Morb Mortal Wkly Rep, 70(2), 46-51. doi:10.15585/mmwr.mm7002e1. <https://www.ncbi.nlm.nih.gov/pubmed/33444297>
22. Thompson, M. G., Burgess, J. L., Naleway, A. L., Tyner, H., Yoon, S. K., Meece, J., . . . Gaglani, M. (2021). Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines. N Engl J Med, 385(4), 320-329. doi:10.1056/NEJMoa2107058. <https://www.ncbi.nlm.nih.gov/pubmed/34192428>
23. Tinoco, M., Leite, S., Faria, B., Cardoso, S., Von Hafe, P., Dias, G., . . . Lourenco, A. (2021). Perimyocarditis Following COVID-19 Vaccination. Clin Med Insights Cardiol, 15, 11795468211056634. doi:10.1177/11795468211056634. <https://www.ncbi.nlm.nih.gov/pubmed/34866957>
24. Truong, D. T., Dionne, A., Muniz, J. C., McHugh, K. E., Portman, M. A., Lambert, L. M., . . . Newburger, J. W. (2021). Clinically Suspected Myocarditis Temporally Related to COVID-19 Vaccination in Adolescents and Young Adults. Circulation. doi:10.1161/CIRCULATIONAHA.121.056583. <https://www.ncbi.nlm.nih.gov/pubmed/34865500>
25. Tutor, A., Unis, G., Ruiz, B., Bolaji, O. A., & Bob-Manuel, T. (2021). Spectrum of Suspected Cardiomyopathy Due to COVID-19: A Case Series. Curr Probl Cardiol, 46(10), 100926. doi:10.1016/j.cpcardiol.2021.100926. <https://www.ncbi.nlm.nih.gov/pubmed/34311983>
26. Umei, T. C., Kishino, Y., Shiraishi, Y., Inohara, T., Yuasa, S., & Fukuda, K. (2021). Recurrence of myopericarditis following mRNA COVID-19 vaccination in a male adolescent. CJC Open. doi:10.1016/j.cjco.2021.12.002. <https://www.ncbi.nlm.nih.gov/pubmed/34904134>
27. Vidula, M. K., Ambrose, M., Glassberg, H., Chokshi, N., Chen, T., Ferrari, V. A., & Han, Y. (2021). Myocarditis and Other Cardiovascular Complications of the mRNA-Based COVID-19 Vaccines. Cureus, 13(6), e15576. doi:10.7759/cureus.15576. <https://www.ncbi.nlm.nih.gov/pubmed/34277198>
28. Visclosky, T., Theyyunni, N., Klekowski, N., & Bradin, S. (2021). Myocarditis Following mRNA COVID-19 Vaccine. Pediatr Emerg Care, 37(11), 583-584. doi:10.1097/PEC.0000000000002557. <https://www.ncbi.nlm.nih.gov/pubmed/34731877>
29. Warren, C. M., Snow, T. T., Lee, A. S., Shah, M. M., Heider, A., Blomkalns, A., . . . Nadeau, K. C. (2021). Assessment of Allergic and Anaphylactic Reactions to mRNA COVID-19 Vaccines With Confirmatory Testing in a US Regional Health System. JAMA Netw Open, 4(9), e2125524. doi:10.1001/jamanetworkopen.2021.25524. <https://www.ncbi.nlm.nih.gov/pubmed/34533570>
30. Watkins, K., Griffin, G., Septaric, K., & Simon, E. L. (2021). Myocarditis after BNT162b2 vaccination in a healthy male. Am J Emerg Med, 50, 815 e811-815 e812. doi:10.1016/j.ajem.2021.06.051. <https://www.ncbi.nlm.nih.gov/pubmed/34229940>
31. Weitzman, E. R., Sherman, A. C., & Levy, O. (2021). SARS-CoV-2 mRNA Vaccine Attitudes as Expressed in U.S. FDA Public Commentary: Need for a Public-Private Partnership in a Learning Immunization System. Front Public Health, 9, 695807. doi:10.3389/fpubh.2021.695807. <https://www.ncbi.nlm.nih.gov/pubmed/34336774>
32. Welsh, K. J., Baumblatt, J., Chege, W., Goud, R., & Nair, N. (2021). Thrombocytopenia including immune thrombocytopenia after receipt of mRNA COVID-19 vaccines reported to the Vaccine Adverse Event Reporting System (VAERS). Vaccine, 39(25), 3329-3332. doi:10.1016/j.vaccine.2021.04.054. <https://www.ncbi.nlm.nih.gov/pubmed/34006408>
33. Witberg, G., Barda, N., Hoss, S., Richter, I., Wiessman, M., Aviv, Y., . . . Kornowski, R. (2021). Myocarditis after Covid-19 Vaccination in a Large Health Care Organization. N Engl J Med, 385(23), 2132-2139. doi:10.1056/NEJMoa2110737. <https://www.ncbi.nlm.nih.gov/pubmed/34614329>
34. Zimmermann, P., & Curtis, N. (2020). Why is COVID-19 less severe in children? A review of the proposed mechanisms underlying the age-related difference in severity of SARS-CoV-2 infections. Arch Dis Child. doi:10.1136/archdischild-2020-320338. <https://www.ncbi.nlm.nih.gov/pubmed/33262177>

